Medtronic (MDT) 10-Q 9 Mar 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jan. 29, 2016	Mar. 03, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Medtronic plc
Entity Central Index Key	1,613,103
Document Period End Date	Jan. 29, 2016
Current Fiscal Year End Date	--04-29
Document Type	10-Q
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Ordinary Shares Outstanding		1,401,043,252
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,016

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Income Statement [Abstract]
Net sales	$ 6,934	$ 4,318	$ 21,266	$ 12,957
Costs and expenses:
Cost of products sold	2,141	1,128	6,779	3,375
Research and development expense	546	373	1,649	1,112
Selling, general, and administrative expense	2,317	1,487	7,109	4,500
Special charges	0	(138)	0	(38)
Restructuring charges, net	19	0	159	30
Certain litigation charges	0	0	26	0
Acquisition-related items	63	80	183	182
Amortization of intangible assets	484	89	1,448	265
Other expense, net	9	24	127	138
Operating profit	1,355	1,275	3,786	3,393
Interest income	(99)	(95)	(321)	(274)
Interest expense	275	176	905	368
Interest expense, net	176	81	584	94
Income from operations before income taxes	1,179	1,194	3,202	3,299
Provision for income taxes	84	217	767	623
Net income	$ 1,095	$ 977	$ 2,435	$ 2,676
Basic earnings per share (usd per share)	$ 0.78	$ 0.99	$ 1.72	$ 2.71
Diluted earnings per share (usd per share)	$ 0.77	$ 0.98	$ 1.70	$ 2.68
Basic weighted average shares outstanding (shares)	1,406.6	983.8	1,412.5	986.6
Diluted weighted average shares outstanding (shares)	1,422.2	995.8	1,429.2	998.5
Cash dividends declared per ordinary share (usd per share)	$ 0.380	$ 0.305	$ 1.14	$ 0.915

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 1,095	$ 977	$ 2,435	$ 2,676
Other comprehensive (loss) income, net of tax:
Unrealized loss on available-for-sale securities, net of tax benefit of $(34), $(20), $(149), and $(7), respectively	(61)	(37)	(268)	(17)
Translation adjustment	(1,454)	(203)	(1,513)	(332)
Net change in retirement obligations, net of tax expense of $10, $6, $30, and $18, respectively	27	21	62	63
Unrealized (loss) gain on derivatives, net of tax (benefit) expense of $(3), $36, $(36), and $125, respectively	(6)	64	(62)	222
Other comprehensive loss	(1,494)	(155)	(1,781)	(64)
Comprehensive (loss) income	$ (399)	$ 822	$ 654	$ 2,612

Condensed Consolidated Stateme4

Condensed Consolidated Statements of Comprehensive (Loss) Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Other Comprehensive Income (Loss), Tax
Unrealized (loss) gain on investments, tax (benefit) expense	$ (34)	$ (20)	$ (149)	$ (7)
Net change in retirement obligations, tax expense	10	6	30	18
Unrealized (loss) gain on derivatives, tax (benefit) expense	$ (3)	$ 36	$ (36)	$ 125

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Current assets:
Cash and cash equivalents	$ 2,721	$ 4,843
Investments	14,565	14,637
Accounts receivable, less allowances of $164 and $144, respectively	4,863	5,112
Inventories	3,536	3,463
Tax assets	502	1,335
Prepaid expenses and other current assets	1,382	1,454
Total current assets	27,569	30,844
Property, plant, and equipment	9,346	8,863
Accumulated depreciation	(4,710)	(4,164)
Property, plant, and equipment, net	4,636	4,699
Goodwill	40,376	40,530
Other intangible assets, net	27,316	28,101
Long-term tax assets	1,060	774
Other assets	1,749	1,737
Total assets	102,706	106,685
Current liabilities:
Short-term borrowings	2,153	2,434
Accounts payable	1,437	1,610
Accrued compensation	1,481	1,611
Accrued income taxes	454	935
Deferred tax liabilities	0	119
Other accrued expenses	2,616	2,464
Total current liabilities	8,141	9,173
Long-term debt	33,681	33,752
Long-term accrued compensation and retirement benefits	1,585	1,535
Long-term accrued income taxes	2,822	2,476
Long-term deferred tax liabilities	3,802	4,700
Other long-term liabilities	1,859	1,819
Total liabilities	$ 51,890	$ 53,455
Commitments and contingencies (Notes 3 and 16)
Shareholders’ equity:
Ordinary shares— par value $0.0001	$ 0	$ 0
Retained earnings	53,781	54,414
Accumulated other comprehensive loss	(2,965)	(1,184)
Total shareholders’ equity	50,816	53,230
Total liabilities and shareholders’ equity	$ 102,706	$ 106,685

Condensed Consolidated Balance6

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 164	$ 144
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015
Operating Activities:
Net income	$ 2,435	$ 2,676
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,112	629
Amortization of debt issuance costs	22	69
Acquisition-related items	216	2
Provision for doubtful accounts	43	25
Deferred income taxes	(291)	(20)
Stock-based compensation	291	115
Other, net	(117)	(96)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	86	(60)
Inventories	(388)	(245)
Accounts payable and accrued liabilities	177	702
Other operating assets and liabilities	(399)	(1)
Certain litigation charges	26	0
Certain litigation payments	(321)	(806)
Net cash provided by operating activities	3,892	2,990
Investing Activities:
Acquisitions, net of cash acquired	(1,132)	(611)
Additions to property, plant, and equipment	(693)	(316)
Purchases of marketable securities	(4,509)	(5,327)
Sales and maturities of marketable securities	4,017	4,351
Other investing activities, net	(11)	60
Net cash used in investing activities	(2,328)	(1,843)
Financing Activities:
Acquisition-related contingent consideration	(21)	(5)
Change in short-term borrowings, net	1,223	7
Repayment of short-term borrowings (maturities greater than 90 days)	(48)	(150)
Proceeds from short-term borrowings (maturities greater than 90 days)	139	150
Issuance of long-term debt	0	16,918
Payments on long-term debt	(1,612)	(13)
Dividends to shareholders	(1,608)	(902)
Issuance of ordinary shares	360	477
Repurchase of ordinary shares	(2,170)	(1,620)
Other financing activities, net	60	(64)
Net cash used in financing activities	(3,677)	14,798
Effect of exchange rate changes on cash and cash equivalents	(9)	(117)
Net change in cash and cash equivalents	(2,122)	15,828
Cash and cash equivalents at beginning of period	4,843	1,403
Cash and cash equivalents at end of period	2,721	17,231
Supplemental Cash Flow Information
Cash paid for income taxes	1,236	446
Cash paid for interest	$ 707	$ 221

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jan. 29, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic or the Company) for the periods presented. Medtronic plc is the successor registrant to Medtronic, Inc. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended 2015 . The Company’s fiscal years 2016 , 2015 , and 2014 will end or ended on April 29, 2016 , April 24, 2015 , and April 25, 2014 , respectively. Fiscal year 2016 is a 53-week year, and the extra week occurred during the first quarter.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Jan. 29, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted In April 2014, the Financial Accounting Standards Board (FASB) issued amended guidance for reporting discontinued operations. The amended guidance changes the criteria for determining when the results of operations are to be reported as discontinued operations and expands the related disclosure requirements. The guidance defines a discontinued operation as a component or group of components that is disposed of or classified as held for sale, which is a strategic shift that has, or will have, a major effect on financial position and results of operations. The Company prospectively adopted this accounting guidance in the first quarter of fiscal year 2016. Its adoption did not have a material impact on the Company's condensed consolidated financial statements. In September 2015, the FASB issued accounting guidance which eliminates the requirement for an acquirer in a business combination to restate prior period financial statements for measurement period adjustments. An acquirer in a business combination is required to report provisional amounts when measurements are incomplete at the end of the reporting period covering the business combination. Prior to the issuance of the new guidance, an acquirer was required to adjust such provisional amounts by restating prior period financial statements. Under the new guidance, the acquirer will recognize the measurement-period adjustment in the period the adjustment is determined. The Company prospectively adopted this accounting guidance in the third quarter of fiscal year 2016. Its adoption did not have a material impact on the Company's condensed consolidated financial statements. In November 2015, the FASB issued accounting guidance that requires all deferred tax assets and liabilities, along with any related valuation allowance, to be classified as noncurrent on the Condensed Consolidated Balance Sheets. Current guidance requires the deferred taxes for each jurisdiction to be presented as a net current asset or liability and net noncurrent asset or liability. As a result of the new guidance, each jurisdiction will now only have one net noncurrent deferred tax asset or liability. The new guidance does not change the existing requirement that only permits offsetting deferred tax assets and liabilities within a single jurisdiction. Entities have the option to apply the new guidance prospectively or retrospectively. This accounting guidance is effective for financial statements issued for annual periods beginning after December 15, 2016, with early adoption permitted. The Company prospectively adopted this accounting guidance in the third quarter of fiscal year 2016. Prior periods have not been retrospectively adjusted for adoption of this statement. Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s condensed consolidated financial statements.

Acquisitions and Acquisition-Re

Acquisitions and Acquisition-Related Items	9 Months Ended
	Jan. 29, 2016
Business Combinations [Abstract]
Acquisitions and Acquisition-Related Items	Acquisitions and Acquisition-Related Items The Company had various acquisitions and other acquisition-related activity during the first three quarters of fiscal years 2016 and 2015 . Certain acquisitions were accounted for as business combinations as noted below. In accordance with authoritative guidance on business combination accounting, the assets and liabilities of the companies acquired were recorded and consolidated as of the acquisition date at their respective fair values. Unless otherwise disclosed, the pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the results of the Company for the three and nine months ended January 29, 2016 or January 23, 2015 . The results of operations related to each company acquired have been included in the Company's condensed consolidated statements of income since the date each company was acquired. Acquisition of Covidien public limited company On January 26, 2015 (Acquisition Date), pursuant to the transaction agreement, dated as of June 15, 2014 (the Transaction Agreement), the Company acquired Covidien plc (Covidien), and Covidien and Medtronic, Inc. became subsidiaries of Medtronic (collectively, the Transactions). In connection with the consummation of the Transactions, Medtronic re-registered as a public limited company organized under the laws of Ireland. On January 26, 2015, (a) each Covidien ordinary share was converted into the right to receive $35.19 in cash and 0.956 of a newly issued Medtronic plc ordinary share (the Arrangement Consideration) in exchange for each Covidien share held by such shareholders, and (b) each share of Medtronic, Inc. common stock was converted into the right to receive one Medtronic plc ordinary share. Total consideration was approximately $50 billion , consisting of $16 billion cash and $34 billion of non-cash consideration. Based on the number of outstanding shares of Medtronic, Inc. and Covidien as of January 23, 2015 (the last business day prior to the close of the transaction), former Medtronic, Inc. and Covidien shareholders held approximately 69 percent and 31 percent , respectively, of the Company's ordinary shares after giving effect to the acquisition. Covidien was a global leader in the development, manufacture, and sale of healthcare products for use in clinical and home settings. The operating results for Covidien are included in the Minimally Invasive Therapies Group, Cardiac and Vascular Group, and Restorative Therapies Group segments. Fair Value of Assets Acquired and Liabilities Assumed The Company accounted for the acquisition of Covidien as a business combination using the acquisition method of accounting. The assets acquired and liabilities assumed were recorded at their respective fair values as of the Acquisition Date. The fair value of assets acquired and liabilities assumed was finalized during the third quarter of fiscal year 2016. During the measurement period, which ended January 26, 2016, adjustments were made to finalize Covidien's preliminary fair value estimates related primarily to other current assets, intangible assets, goodwill, certain property value, contingent liabilities and the related deferred tax impacts. Based upon the acquisition valuation, the Company acquired $18.3 billion of customer-related intangible assets, $7.1 billion of technology-based intangible assets, $0.4 billion of tradenames, with weighted average estimated useful lives of 18 , 16 , and 6 years, respectively, $0.4 billion of in-process research and development (IPR&D), and $30.0 billion of goodwill. The fair values of the assets acquired and liabilities assumed in connection with the Transactions are as follows: (estimated in millions) January 26, 2015 (as previously reported) Adjustments January 26, 2015 (as adjusted) Accounts receivable $ 1,349 $ — $ 1,349 Inventories 2,222 (3 ) 2,219 Other current assets 2,949 232 3,181 Property, plant, and equipment 2,354 (61 ) 2,293 Goodwill 29,586 393 29,979 Intangible assets 26,265 (55 ) 26,210 Other assets 747 14 761 Total assets acquired 65,472 520 65,992 Short-term borrowings 1,011 — 1,011 Other current liabilities 2,331 103 2,434 Long-term debt 4,623 — 4,623 Long-term deferred tax liabilities 4,736 9 4,745 Other long-term liabilities 2,783 408 3,191 Total liabilities assumed 15,484 520 16,004 Net assets acquired $ 49,988 $ — $ 49,988 Contingent liabilities assumed as part of the Transactions total $2.7 billion and are included within accrued income taxes , other accrued expenses , long-term accrued income taxes , and other long-term liabilities in the condensed consolidated balance sheet. These contingent liabilities include $1.5 billion related to income taxes (including uncertain tax positions and guarantee commitments) and $1.2 billion related to legal claims (including product liability and environmental matters). Contingent liabilities are recorded at their estimated fair values, aside from those pertaining to uncertainty in income taxes which are an exception to the fair value basis of accounting. See Note 16 to the condensed consolidated financial statements for additional background on contingent liabilities. For additional information related to the Transactions, see Note 2 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 . Fiscal Year 2016 The fair values of the assets acquired and liabilities assumed during the nine months ended January 29, 2016 are as follows: (in millions) Twelve, Inc. RF Surgical Systems, Inc. Medina Medical All Other Total Other current assets $ 60 $ 43 $ 11 $ 40 $ 154 Property, plant, and equipment — 3 — 5 8 IPR&D 192 — 122 143 457 Other intangible assets — 115 — 184 299 Goodwill 301 132 126 238 797 Other assets — 2 — 15 17 Total assets acquired 553 295 259 625 1,732 Current liabilities 37 28 6 21 92 Long-term deferred tax liabilities, net 44 27 34 56 161 Other liabilities — — — 2 2 Total liabilities assumed 81 55 40 79 255 Net assets acquired $ 472 $ 240 $ 219 $ 546 $ 1,477 Twelve, Inc. On October 2, 2015, the Company's Coronary & Structural Heart division acquired Twelve, Inc. (Twelve), a privately-held medical device company focused on the development of a transcatheter mitral valve replacement device. Total consideration for the transaction was approximately $472 million , which included an upfront payment of $428 million and the estimated fair value of product development-based contingent consideration of $44 million . Based upon a preliminary acquisition valuation, the Company acquired $192 million of IPR&D and $301 million of goodwill. The acquired goodwill is not deductible for tax purposes. RF Surgical Systems, Inc. On August 11, 2015, the Company's Surgical Solutions division acquired RF Surgical Systems, Inc. (RF Surgical), a medical device company focused on the detection and prevention of retained surgical sponges. Total consideration for the transaction was approximately $240 million . Based upon a preliminary acquisition valuation, the Company acquired $68 million of technology-based intangible assets, $47 million of customer-related intangible assets, with estimated useful lives of 18 and 16 years, respectively, and $132 million of goodwill. The acquired goodwill is not deductible for tax purposes. Medina Medical On August 31, 2015, the Company's Neurovascular division acquired Medina Medical (Medina), a privately-held medical device company focused on commercializing treatments for vascular abnormalities of the brain, including cerebral aneurysms. Total consideration for the transaction was approximately $219 million , which includes an upfront payment of $155 million and the estimated fair value of revenue-based and product development-based contingent consideration of $64 million . Medtronic had previously invested in Medina and held an 11 percent ownership position. Net of this ownership position, the transaction value was approximately $195 million . Based upon a preliminary acquisition valuation, the Company acquired $122 million of IPR&D and $126 million of goodwill. The acquired goodwill is not deductible for tax purposes. The Company accounted for the acquisitions of Twelve, RF Surgical, and Medina and all other acquisitions as business combinations using the acquisition method of accounting. Acquisition-Related Items During the three and nine months ended January 29, 2016 , the Company recorded acquisition-related items of $63 million and $183 million , respectively, primarily due to integration related costs incurred in connection with the Covidien acquisition, partially offset by income related to the change in fair value of contingent consideration associated with acquisitions subsequent to April 29, 2009. Fiscal Year 2015 The fair values of the assets acquired and liabilities assumed from acquisitions during fiscal year 2015, other than the Covidien acquisition, are as follows: (in millions) NGC Medical S.p.A. Sapiens Steering Brain Stimulation All Other Total Other current assets $ 55 $ 3 $ 12 $ 70 Property, plant, and equipment 15 1 2 18 IPR&D — 30 39 69 Other intangible assets 159 — 157 316 Goodwill 197 170 108 475 Other assets 3 3 49 55 Total assets acquired 429 207 367 1,003 Current liabilities 34 4 6 44 Long-term deferred tax liabilities, net 51 — 66 117 Other liabilities 4 — — 4 Total liabilities assumed 89 4 72 165 Net assets acquired $ 340 $ 203 $ 295 $ 838 The Company accounted for the acquisitions above as business combinations using the acquisition method of accounting. Other Acquisitions and Acquisition-Related Items During the three and nine months ended January 23, 2015 , the Company recorded acquisition-related items of $80 million and $182 million , respectively, primarily due to costs incurred in connection with the Covidien acquisition. Contingent Consideration Certain of the Company’s business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. For business combinations subsequent to April 24, 2009, a liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. For business combinations or purchases of intellectual property prior to April 24, 2009, the estimated maximum amount of undiscounted future contingent consideration payments that the Company expected to make was approximately $177 million at January 29, 2016 . The Company estimates the milestones or other conditions associated with the contingent consideration will be reached in fiscal year 2016 and thereafter. The fair value of the contingent consideration is remeasured at each reporting period and the change in fair value recognized as income or expense within acquisition-related items in the condensed consolidated statements of income. The Company measures the liability on a recurring basis using Level 3 inputs. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. Increases (decreases) in projected revenues, probabilities of payment, discount rates, or projected payment dates may result in a higher (lower) fair value measurement. The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at ($ in millions) January 29, 2016 Valuation Technique Unobservable Input Range Discount rate 11% - 27.2% Revenue-based payments $191 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2016 - 2025 Discount rate 0.3% - 5.5% Product development-based payments $180 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2016 - 2025 The fair value of contingent consideration associated with acquisitions subsequent to April 24, 2009, as of January 29, 2016 and April 24, 2015 , was $371 million and $264 million , respectively. As of January 29, 2016 , $311 million was reflected in other long-term liabilities and $60 million was reflected in other accrued expenses in the condensed consolidated balance sheets. As of April 24, 2015 , $242 million was reflected in other long-term liabilities and $22 million was reflected in other accrued expenses in the condensed consolidated balance sheets. The portion of the contingent consideration paid related to the acquisition date fair value is reported as financing activities in the condensed consolidated statements of cash flows. Amounts paid in excess of the original acquisition date fair value are reported as operating activities in the condensed consolidated statements of cash flows. The following table provides a reconciliation of the beginning and ending balances of contingent consideration associated with acquisitions subsequent to April 24, 2009: Three months ended Nine months ended (in millions) January 29, 2016 January 23, 2015 January 29, 2016 January 23, 2015 Beginning Balance $ 368 $ 91 $ 264 $ 68 Purchase price contingent consideration 14 6 149 29 Contingent consideration payments (2 ) — (22 ) (5 ) Change in fair value of contingent consideration (9 ) (4 ) (20 ) 1 Ending Balance $ 371 $ 93 $ 371 $ 93

Special Charges and Certain Lit

Special Charges and Certain Litigation Charges	9 Months Ended
	Jan. 29, 2016
Commitments and Contingencies Disclosure [Abstract]
Special Charges and Certain Litigation Charges	Special Charges and Certain Litigation Charges Special Charges During the three and nine months ended January 29, 2016 , there were no special charges. During the three months ended January 23, 2015 , the Company recognized a $138 million gain, which consisted of a $41 million gain on the sale of a product line in the Surgical Technologies division, and a $97 million gain on the sale of an equity method investment. In addition, during the nine months ended January 23, 2015 , continuing the Company's commitment to improving the health of people and communities throughout the world, the Company made a $100 million charitable cash contribution to meet the multi-year funding needs of the Medtronic Foundation, a related party non-profit organization. Certain Litigation Charges The Company classifies material litigation reserves and gains recognized as certain litigation charges. During the three months ended January 29, 2016 , there were no certain litigation charges. During the nine months ended January 29, 2016 , the Company recorded certain litigation charges of $26 million , which relates to probable and reasonably estimable INFUSE product liability litigation. During the three and nine months ended January 23, 2015 , there were no certain litigation charges.

Restructuring Charges, Net

Restructuring Charges, Net	9 Months Ended
	Jan. 29, 2016
Restructuring and Related Activities [Abstract]
Restructuring Charges, Net	Restructuring Charges, Net Cost Synergies Initiative The cost synergies initiative, initially referred to as the fiscal year 2015 initiative, was the beginning of the Company's restructuring program primarily related to the acquisition of Covidien. This initiative is expected to contribute to the approximately $850 million in cost synergies expected to be achieved as a result of the Covidien acquisition through fiscal year 2018, including administrative office optimization, manufacturing and supply chain infrastructure, certain program cancellations, and certain general and administrative savings. Restructuring charges are expected to be incurred on a quarterly basis throughout fiscal year 2017 and in future fiscal years as cost synergy strategies are finalized. Restructuring accruals resulting from quarterly restructuring charges are scheduled to be substantially complete within one year from the quarter the restructuring charge was initially incurred. A summary of the activity related to the cost synergies initiative is presented below: (in millions) Employee Termination Costs Asset Write-downs Other Costs Total Balance as of April 24, 2015 $ 136 $ — $ 7 $ 143 Restructuring charges 52 — 15 67 Payments/write-downs (76 ) — (7 ) (83 ) Balance as of July 31, 2015 $ 112 $ — $ 15 $ 127 Restructuring charges 64 10 12 86 Payments/write-downs (28 ) (10 ) (6 ) (44 ) Reversal of excess accrual (13 ) — — (13 ) Balance as of October 30, 2015 $ 135 $ — $ 21 $ 156 Restructuring charges 36 12 7 55 Payments/write-downs (30 ) (12 ) (8 ) (50 ) Reversal of excess accrual (17 ) — (2 ) (19 ) Balance as of January 29, 2016 $ 124 $ — $ 18 $ 142 As a result of certain employees identified for elimination finding other positions within the Company and revisions to severance provisions, the Company recorded a $19 million and a $32 million reversal of excess restructuring reserves for the three and nine months ended January 29, 2016 , respectively. As part of the cost synergies initiative, the company recorded $12 million and $22 million of asset write-downs for the three and nine months ended January 29, 2016 , respectively. For the three and nine months ended January 29, 2016 , asset write-downs included $9 million related to inventory write-offs of discontinued product lines, and therefore, was recorded within cost of products sold in the consolidated statements of income. For the three and nine months ended January 29, 2016, asset write-downs included $3 million and $13 million related to property, plant, and equipment impairments, respectively. The Company did not record any significant impairments during the three months ended January 23, 2015 . The Company recorded $10 million related to inventory write-offs of discontinued product lines and production-related asset impairments for the nine months ended January 23, 2015, and therefore, was recorded within cost of products sold in the condensed consolidated statements of earnings. Covidien Initiative Covidien's pre-acquisition restructuring program is designed to improve legacy Covidien's cost structure. The program consists of reducing corporate expenses, expanding shared services, consolidating manufacturing locations, and optimizing distribution centers. The Covidien restructuring initiative is scheduled to be substantially complete by the end of fiscal year 2018. At the Acquisition Date, the Company reserved $103 million in connection with the Covidien initiative, which consisted of employee termination costs of $76 million and other costs of $27 million . In the fourth quarter of fiscal year 2015, the Company recorded a reversal of excess restructuring reserves related to the Covidien initiative of $5 million . In addition, in the third quarter of fiscal year 2016, the Company recorded a reversal of excess restructuring reserves related to the Covidien initiative of $2 million . The reversals were primarily the result of certain employees identified for elimination finding other positions within the Company and revisions to particular strategies. A summary of the activity related to the Covidien initiative is presented below: (in millions) Employee Termination Costs Other Costs Total Balance as of April 24, 2015 $ 61 $ 17 $ 78 Payments (13 ) (5 ) (18 ) Balance as of July 31, 2015 $ 48 $ 12 $ 60 Payments (8 ) (6 ) (14 ) Balance as of October 30, 2015 $ 40 $ 6 $ 46 Payments (12 ) (2 ) (14 ) Reversal of excess accrual (2 ) — (2 ) Balance as of January 29, 2016 $ 26 $ 4 $ 30

Financial Instruments

Financial Instruments	9 Months Ended
	Jan. 29, 2016
Investments [Abstract]
Financial Instruments	Financial Instruments The Company holds investments consisting primarily of marketable debt and equity securities. The authoritative guidance is principally applied to financial assets and liabilities such as marketable equity securities and debt and equity securities that are classified and accounted for as trading and available-for-sale and are measured on a recurring basis. Further, we also hold cost or equity method investments which are measured at fair value on a nonrecurring basis. The following table summarizes the Company's investments by significant investment categories and the related condensed consolidated balance sheets presentation at January 29, 2016 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities Level 1: U.S. government and agency securities $ 1,517 $ 14 $ (1 ) $ 1,530 $ 1,530 $ — Marketable equity securities 77 24 (5 ) 96 — 96 Total Level 1 1,594 38 (6 ) 1,626 1,530 96 Level 2: Corporate debt securities 6,568 56 (95 ) 6,529 6,526 3 U.S. government and agency securities 1,683 4 (1 ) 1,686 1,686 — Mortgage-backed securities 1,407 12 (16 ) 1,403 1,403 — Foreign government and agency securities 27 — — 27 27 — Certificates of deposit 28 — — 28 28 — Other asset-backed securities 517 3 — 520 520 — Debt funds 3,148 1 (379 ) 2,770 2,770 — Total Level 2 13,378 76 (491 ) 12,963 12,960 3 Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 109 — (7 ) 102 — 102 Total Level 3 110 — (7 ) 103 — 103 Total available-for-sale securities 15,082 114 (504 ) 14,692 14,490 202 Trading securities: Level 1: Exchange-traded funds 65 12 (2 ) 75 75 — Total Level 1: 65 12 (2 ) 75 75 — Total trading securities 65 12 (2 ) 75 75 — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 524 — — N/A — 524 Total Level 3: 524 — — N/A — 524 Total cost method, equity method, and other investments 524 — — N/A — 524 Total investments $ 15,671 $ 126 $ (506 ) $ 14,767 $ 14,565 $ 726 The following table summarizes the Company's investments by significant investment categories and the related condensed consolidated balance sheets presentation at April 24, 2015 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 1,525 $ 17 $ (1 ) $ 1,541 $ 1,541 $ — Marketable equity securities 64 35 (19 ) 80 — 80 Total Level 1 1,589 52 (20 ) 1,621 1,541 80 Level 2: Corporate debt securities 6,282 105 (10 ) 6,377 6,377 — U.S. government and agency securities 1,597 4 (3 ) 1,598 1,598 — Mortgage-backed securities 1,462 22 (6 ) 1,478 1,478 — Foreign government and agency securities 85 — — 85 85 — Certificates of deposit 44 — — 44 44 — Other asset-backed securities 504 3 — 507 507 — Debt funds 3,061 19 (150 ) 2,930 2,930 — Total Level 2 13,035 153 (169 ) 13,019 13,019 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 109 — (4 ) 105 — 105 Total Level 3 110 — (4 ) 106 — 106 Total available-for-sale securities 14,734 205 (193 ) 14,746 14,560 186 Trading securities: Level 1: Exchange-traded funds 58 19 — 77 77 — Total Level 1 58 19 — 77 77 — Total trading securities 58 19 — 77 77 — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 520 — — N/A — 520 Total Level 3 520 — — N/A — 520 Total cost method, equity method, and other investments 520 — — N/A — 520 Total investments $ 15,312 $ 224 $ (193 ) $ 14,823 $ 14,637 $ 706 Marketable Debt and Equity Securities: The following tables show the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category as of January 29, 2016 and April 24, 2015 : January 29, 2016 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 2,817 $ (80 ) $ 186 $ (16 ) Auction rate securities — — 102 (7 ) Mortgage-backed securities 626 (11 ) 223 (6 ) U.S. government and agency securities 716 (1 ) 103 — Debt funds 1,231 (62 ) 1,538 (317 ) Marketable equity securities 51 (6 ) — — Total $ 5,441 $ (160 ) $ 2,152 $ (346 ) April 24, 2015 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 944 $ (9 ) $ 34 $ (1 ) Auction rate securities — — 105 (4 ) Mortgage-backed securities 346 (3 ) 206 (3 ) U.S. government and agency securities 356 (1 ) 267 (3 ) Debt funds 1,291 (109 ) 559 (41 ) Marketable equity securities 4 (19 ) — — Total $ 2,941 $ (141 ) $ 1,171 $ (52 ) The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 as of January 29, 2016 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6% The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and nine months ended January 29, 2016 or January 23, 2015 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): Three months ended January 29, 2016 (in millions) Total Level 3 Corporate debt Auction rate Balance as of October 30, 2015 $ 103 $ 1 $ 102 Total unrealized gains included in other comprehensive income — — — Balance as of January 29, 2016 $ 103 $ 1 $ 102 Three months ended January 23, 2015 (in millions) Total Level 3 Corporate debt Auction rate Balance as of October 24, 2014 $ 108 $ 9 $ 99 Total unrealized gains included in other comprehensive income — — — Balance as of January 23, 2015 $ 108 $ 9 $ 99 Nine months ended January 29, 2016 (in millions) Total Level 3 Corporate debt Auction rate Balance as of April 24, 2015 $ 106 $ 1 $ 105 Total unrealized losses included in other comprehensive income (3 ) — (3 ) Balance as of January 29, 2016 $ 103 $ 1 $ 102 Nine months ended January 23, 2015 (in millions) Total Level 3 Corporate debt Auction rate Balance as of April 24, 2014 $ 106 $ 9 $ 97 Total unrealized gains included in other comprehensive income 2 — 2 Balance as of January 23, 2015 $ 108 $ 9 $ 99 Activity related to the Company’s investment portfolio is as follows: Three months ended January 29, 2016 January 23, 2015 (in millions) Debt (a) Equity (b) Debt (a) Equity (b) Proceeds from sales $ 1,261 $ 4 $ 1,478 $ 208 Gross realized gains 2 4 10 99 Gross realized losses (9 ) — (4 ) — Impairment losses recognized — (2 ) — (1 ) Nine months ended January 29, 2016 January 23, 2015 (in millions) Debt (a) Equity (b) (c) Debt (a) Equity (b) (d) Proceeds from sales $ 3,979 $ 38 $ 4,114 $ 237 Gross realized gains 11 36 26 157 Gross realized losses (21 ) — (9 ) — Impairment losses recognized — (43 ) — (22 ) (a) Includes available-for-sale debt securities. (b) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments. (c) As a result of certain acquisitions that occurred during the nine months ended January 29, 2016 , the Company recognized a non-cash realized gain of $9 million on its previously-held minority investment included in other expense, net on the condensed consolidated statement of income. (d) As a result of certain acquisitions that occurred during the nine months ended January 23, 2015 , the Company recognized a non-cash realized gain of $41 million on its previously-held minority investments included in other expense, net on the condensed consolidated statement of income. Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which invested, the Company believes it has recorded all necessary other-than-temporary impairments as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. As of January 29, 2016 and April 24, 2015 , the credit loss portion of other-than temporary impairments on debt securities were not significant. The total reductions for available-for-sale debt securities sold during the three and nine months ended January 29, 2016 and January 23, 2015 were not significant. The total other-than-temporary impairment losses on available-for-sale debt securities for the three and nine months ended January 29, 2016 and January 23, 2015 were not significant. The January 29, 2016 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) January 29, 2016 Due in one year or less $ 2,197 Due after one year through five years 6,294 Due after five years through ten years 3,050 Due after ten years 285 Total $ 11,826 The Company holds investments in marketable equity securities, which are classified as other assets in the condensed consolidated balance sheets. The aggregate carrying amount of these investments was $96 million and $80 million as of January 29, 2016 and April 24, 2015 , respectively. The Company did not record any significant impairment charges related to marketable equity securities during the three months ended January 29, 2016 . During the nine months ended January 29, 2016 , the Company determined that the fair value of certain marketable equity securities were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $20 million in impairment charges for the nine months ended January 29, 2016 , which were recorded within other expense, net in the condensed consolidated statements of income. During the nine months ended January 23, 2015 , the Company determined that the fair value of certain marketable equity securities were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $7 million in impairment charges for the nine months ended January 23, 2015 , which were recorded in other expense, net in the condensed consolidated statements of income. Cost method, equity method, and other investments The Company holds investments in equity and other securities that are accounted for using the cost or equity method, which are classified as other assets in the condensed consolidated balance sheets. As of January 29, 2016 and April 24, 2015 , the aggregate carrying amount of equity and other securities without a quoted market price and accounted for using the cost or equity method was $524 million and $520 million , respectively. These cost or equity method investments are measured at fair value on a nonrecurring basis. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment. During the three and nine months ended January 29, 2016 , the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $2 million and $23 million in impairment charges during the three and nine months ended January 29, 2016 , respectively, which were recorded in other expense, net in the condensed consolidated statements of income. During the three and nine months ended January 23, 2015 , the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $1 million and $14 million in impairment charges during the three and nine months ended January 23, 2015 , which were recorded in other expense, net in the condensed consolidated statements of income. These investments fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value, as the investments are privately-held entities without quoted market prices. To determine the fair value of these investments, the Company used all pertinent financial information available related to the entities, including financial statements and market participant valuations from recent and proposed equity offerings.

Financing Arrangements

Financing Arrangements	9 Months Ended
	Jan. 29, 2016
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.500 billion in commercial paper outstanding, with maturities up to 364 days from the date of issuance. Commercial paper amounts outstanding as of January 29, 2016 totaled $1.293 billion . No amounts were outstanding as of April 24, 2015 . During the three and nine months ended January 29, 2016 , the weighted average original maturity of the commercial paper outstanding was approximately 53 days and 48 days, respectively, and the weighted average interest rate was 0.56 percent and 0.48 percent, respectively. The issuance of commercial paper proportionately reduced the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.500 billion five year credit facility (Credit Facility) which provides back up funding for the commercial paper program described above. As of January 29, 2016 and April 24, 2015 , no amounts were outstanding. Interest rates are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreement also contains customary covenants, all of which the Company remained in compliance with as of January 29, 2016 . Long-Term Debt Long-term debt consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year Payable as of January 29, 2016 Payable as of April 24, 2015 Floating rate three-year 2014 senior notes 2017 $ 250 $ 250 0.875 percent three-year 2014 senior notes 2017 250 250 6.000 percent ten-year 2008 CIFSA senior notes 2018 1,150 1,150 1.500 percent three-year 2015 senior notes 2018 1,000 1,000 1.375 percent five-year 2013 senior notes 2018 1,000 1,000 5.600 percent ten-year 2009 senior notes 2019 400 400 4.450 percent ten-year 2010 senior notes 2020 1,250 1,250 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 1,250 1,250 2.950 percent ten-year 2013 CIFSA senior notes 2024 750 750 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 4.375 percent twenty-year 2015 senior notes 2035 2,500 2,500 6.550 percent thirty-year 2008 CIFSA senior notes 2038 850 850 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 750 750 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,000 4,000 Three-year term loan 2018 3,000 3,000 Interest rate swaps (Note 8) 2017 - 2022 87 79 Deferred gains from interest rate swap terminations, net - — 3 Capital lease obligations 2017 - 2025 117 129 Bank borrowings 2021 31 17 Debt premium 2017 - 2045 421 499 Total Long-Term Debt $ 33,681 $ 33,752 Senior Notes The Company has outstanding unsecured senior obligations including those indicated as senior notes in the long-term debt table above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remains in compliance with as of January 29, 2016 . The Company used the net proceeds from the sale of the Senior Notes primarily for working capital and general corporate uses, which includes the repayment of other indebtedness of the Company, and to fund the acquisition of Covidien in fiscal year 2015. For additional information regarding the terms of these agreements, refer to Note 8 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 . Financial Instruments Not Measured at Fair Value As of January 29, 2016 , the total estimated fair value of the Company’s long-term debt, including the short-term portion, was $31.781 billion compared to a principal value of $30.525 billion ; as of April 24, 2015 , the total estimated fair value was $34.637 billion compared to a principal value of $32.125 billion . The fair value was estimated using quoted market prices for the publicly registered senior notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and derivative/hedging activity.

Derivatives and Foreign Exchang

Derivatives and Foreign Exchange Risk Management	9 Months Ended
	Jan. 29, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Foreign Exchange Risk Management	Derivatives and Foreign Exchange Risk Management The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro and Japanese Yen. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding at January 29, 2016 and April 24, 2015 was $10.739 billion and $9.782 billion , respectively. The aggregate currency exchange rate gains for the three and nine months ended January 29, 2016 were $69 million and $167 million , respectively. The aggregate currency exchange rate gains for the three and nine months ended January 23, 2015 were $27 million and $29 million , respectively. The information that follows explains the various types of derivatives and financial instruments used by the Company, how and why the Company uses such instruments, and how such instruments impact the Company’s condensed consolidated balance sheets, statements of income, and statements of cash flows. Freestanding Derivative Contracts Freestanding derivative contracts are used to offset the Company’s exposure to the change in value of specific foreign currency denominated assets and liabilities and to offset variability of cash flows associated with forecasted transactions denominated in a foreign currency. The gross notional amount of these contracts, not designated as hedging instruments, outstanding at January 29, 2016 and April 24, 2015 , was $4.939 billion and $4.713 billion , respectively. The amount and location of the gains (losses) in the condensed consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and nine months ended January 29, 2016 and January 23, 2015 are as follows: (in millions) Three months ended Derivatives Not Designated as Hedging Instruments Location January 29, 2016 January 23, 2015 Foreign currency exchange rate contracts gains (losses) Other expense, net $ 19 $ 153 (in millions) Nine months ended Derivatives Not Designated as Hedging Instruments Location January 29, 2016 January 23, 2015 Foreign currency exchange rate contracts gains (losses) Other expense, net $ 35 $ 202 Cash Flow Hedges Foreign Currency Exchange Rate Risk Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. No gains or losses relating to ineffectiveness of foreign currency cash flow hedges were recognized in earnings during the three or nine months ended January 29, 2016 or January 23, 2015 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were derecognized or discontinued during the three or nine months ended January 29, 2016 or January 23, 2015 . The gross notional amount of these contracts, designated as cash flow hedges, outstanding at January 29, 2016 and April 24, 2015 , were $5.800 billion and $5.069 billion , respectively, and will mature within the subsequent three -year period. The amount of gains (losses) and location of the gains (losses) in the condensed consolidated statements of income and other comprehensive (loss) income (OCI) related to foreign currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended January 29, 2016 and January 23, 2015 are as follows: Three months ended January 29, 2016 Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 104 Other expense, net $ 111 Cost of products sold (9 ) Total $ 104 $ 102 Three months ended January 23, 2015 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 265 Other expense, net $ 65 Cost of products sold (27 ) Total $ 265 $ 38 Nine months ended January 29, 2016 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 108 Other expense, net $ 295 Cost of products sold (45 ) Total $ 108 $ 250 Nine months ended January 23, 2015 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 556 Other expense, net $ 86 Cost of products sold (28 ) Total $ 556 $ 58 Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. No gains or losses relating to ineffectiveness of forward starting interest rate derivative instruments were recognized in earnings during the three or nine months ended January 29, 2016 or January 23, 2015 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness during the three or nine months ended January 29, 2016 or January 23, 2015 . During the third quarter of fiscal year 2015, the company issued the 2015 Senior Notes for which the Company had previously entered into forward starting interest rate derivatives with a notional amount of $5.850 billion . Upon issuance of the 2015 Senior Notes, these swaps were terminated with no material ineffectiveness on the contracts which were in a net liability position, resulting in cash payment of $79 million . As of January 29, 2016 , the Company had $300 million of fixed pay, forward starting interest rate swaps with a weighted average fixed-rate of 3.10 percent in anticipation of planned debt issuances in fiscal year 2017. For the three and nine months ended January 29, 2016 , the Company reclassified $3 million and $9 million , respectively, of the effective portion of the net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net . For the three and nine months ended January 23, 2015 , the Company reclassified $4 million and $8 million , respectively, of the effective portion of the net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net . The unrealized losses on outstanding forward starting interest rate swap derivative instruments as of January 29, 2016 and April 24, 2015 were $41 million and $71 million , respectively. Unrealized losses on outstanding forward starting interest rate swap derivative instruments were recorded in other long-term liabilities, with the offset recorded in accumulated other comprehensive loss in the condensed consolidated balance sheets. As of January 29, 2016 and April 24, 2015 , the Company had $148 million and $210 million , respectively, in after-tax net unrealized gains associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $174 million of after-tax net unrealized gains as of January 29, 2016 will be reclassified into the condensed consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. As of both January 29, 2016 and April 24, 2015 , the Company had interest rate swaps in gross notional amounts of $1.425 billion and $2.025 billion , respectively, designated as fair value hedges of underlying fixed-rate senior note obligations. For additional information regarding the terms of the Company’s interest rate swap agreements, refer to Note 9 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 . The market value of outstanding interest rate swap agreements was a net $47 million unrealized gain, and the market value of the hedged item was a net $47 million unrealized loss at January 29, 2016 , which were recorded in other assets, prepaid expenses and other current assets, and other long-term liabilities with the offsets recorded in long-term debt and short-term borrowings in the condensed consolidated balance sheets. No hedge ineffectiveness was recorded as a result of these fair value hedges for the three or nine months ended January 29, 2016 or January 23, 2015 . During the three and nine months ended January 29, 2016 and January 23, 2015 , the Company did not have any significant ineffective fair value hedging instruments. In addition, the Company did not recognize any significant gains or losses during the three or nine months ended January 29, 2016 or January 23, 2015 on firm commitments that no longer qualify as fair value hedges. Balance Sheet Presentation The following tables summarize the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets as of January 29, 2016 and April 24, 2015 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories. January 29, 2016 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments Interest rate contracts Prepaid expenses and $ 1 Other accrued expenses $ — Foreign currency exchange rate contracts Prepaid expenses and other current assets 281 Other accrued expenses 13 Interest rate contracts Other assets 87 Other long-term liabilities 41 Foreign currency exchange rate contracts Other assets 85 Other long-term liabilities 8 Total derivatives designated as hedging instruments $ 454 $ 62 Derivatives not designated as hedging instruments Commodity derivatives Prepaid expenses and $ — Other accrued expenses $ 5 Foreign currency exchange rate contracts Prepaid expenses and other current assets 21 Other accrued expenses 19 Cross currency interest rate contracts Other assets 21 Other long-term liabilities 5 Total derivatives not designated as hedging instruments $ 42 $ 29 Total derivatives $ 496 $ 91 April 24, 2015 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments Interest rate contracts Prepaid expenses and $ 10 Other accrued expenses $ — Foreign currency exchange rate contracts Prepaid expenses and other current assets 382 Other accrued expenses 12 Interest rate contracts Other assets 79 Other long-term liabilities 71 Foreign currency exchange rate contracts Other assets 143 Other long-term liabilities 3 Total derivatives designated as hedging instruments $ 614 $ 86 Derivatives not designated as hedging instruments Foreign currency exchange rate contracts Prepaid expenses and other current assets $ 119 Other accrued expenses $ 30 Total derivatives not designated as hedging instruments $ 119 $ 30 Total derivatives $ 733 $ 116 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis as of October 30, 2015 and April 24, 2015: (in millions) January 29, 2016 April 24, 2015 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative Assets $ 387 $ 109 $ — $ 644 $ 89 $ — Derivative Liabilities 40 51 — 45 71 — The Company has elected to present the fair value of derivative assets and liabilities within the condensed consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 387 $ (63 ) $ (197 ) $ 127 Interest rate contracts 88 (6 ) (15 ) 67 Cross currency interest rate contracts 21 — — 21 $ 496 $ (69 ) $ (212 ) $ 215 Derivative Liabilities Foreign currency exchange rate contracts $ (40 ) $ 33 $ — $ (7 ) Interest rate contracts (41 ) 36 — (5 ) Cross currency interest rate contracts (5 ) — — (5 ) Commodity derivatives (5 ) — — (5 ) $ (91 ) $ 69 $ — $ (22 ) Total $ 405 $ — $ (212 ) $ 193 April 24, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 644 $ (61 ) $ (325 ) $ 258 Interest rate contracts 89 (10 ) (13 ) 66 $ 733 $ (71 ) $ (338 ) $ 324 Derivative Liabilities Foreign currency exchange rate contracts $ (45 ) $ 31 $ — $ (14 ) Interest rate contracts (71 ) 40 8 (23 ) $ (116 ) $ 71 $ 8 $ (37 ) Total $ 617 $ — $ (330 ) $ 287

Inventories

Inventories	9 Months Ended
	Jan. 29, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments, or other economic factors. Inventory balances were as follows: (in millions) January 29, 2016 April 24, 2015 Finished goods $ 2,244 $ 2,268 Work in-process 520 509 Raw materials 772 686 Total $ 3,536 $ 3,463

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	9 Months Ended
	Jan. 29, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	Goodwill and Other Intangible Assets, Net The changes in the carrying amount of goodwill for the nine months ended January 29, 2016 are as follows: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total Balance as of April 24, 2015 $ 5,855 $ 23,399 $ 9,424 $ 1,852 $ 40,530 Goodwill as a result of acquisitions 409 196 197 — 802 Purchase accounting adjustments, net 13 346 34 — 393 Currency adjustment, net (95 ) (1,120 ) (135 ) 1 (1,349 ) Balance as of January 29, 2016 $ 6,182 $ 22,821 $ 9,520 $ 1,853 $ 40,376 During the third quarter of fiscal year 2016, in connection with the finalization of the fair values of the assets acquired and liabilities assumed in connection with the Transactions, the Company recorded $1.3 billion impact from foreign currency translation on Covidien goodwill. During the nine months ended January 29, 2016 , the Company recorded $393 million of purchase accounting adjustments, net, primarily related to the Covidien acquisition. See Note 3 to the condensed consolidated financial statements for additional information on purchase accounting adjustments related to the Covidien acquisition. The gross carrying amount and accumulated amortization of intangible assets at January 29, 2016 and April 24, 2015 are as follows: January 29, 2016 April 24, 2015 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortizable: Customer-related $ 18,558 $ (1,066 ) $ 18,492 $ (273 ) Purchased technology and patents 11,305 (2,722 ) 11,118 (2,268 ) Trademarks and tradenames 852 (429 ) 640 (363 ) Other 71 (28 ) 79 (44 ) Total $ 30,786 $ (4,245 ) $ 30,329 $ (2,948 ) Non-Amortizable: IPR&D $ 775 $ 470 Tradenames — 250 Total $ 775 $ 720 Amortization expense for the three and nine months ended January 29, 2016 was $484 million and $1.448 billion , respectively, and for the three and nine months ended January 23, 2015 was $89 million and $265 million , respectively. Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets as of January 29, 2016 , excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows: (in millions) Fiscal Year Estimated Amortization Expense Remaining 2016 $ 484 2017 1,925 2018 1,893 2019 1,799 2020 1,751 2021 1,734 The Company assesses the impairment of goodwill annually in the third quarter at the reporting unit level and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The aggregate carrying amount of goodwill was $40.376 billion and $40.530 billion as of January 29, 2016 and April 24, 2015 , respectively. The Company included the Minimally Invasive Therapies Group as an additional reporting unit in its annual impairment testing performed in the third quarter of fiscal year 2016. No other changes were made to reporting units during fiscal year 2016. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company did not record any goodwill impairment during the three and nine months ended January 29, 2016 or January 23, 2015 . The Company assesses IPR&D for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The aggregate carrying amount of IPR&D was $775 million and $470 million as of January 29, 2016 and April 24, 2015 , respectively. Similar to the goodwill impairment test, the IPR&D impairment test requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of IPR&D asset fair values over their carrying values utilizing a discounted future cash flow analysis. During the three and nine months ended January 29, 2016 and January 23, 2015 , the Company did not record any significant IPR&D impairments. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances or other failures to achieve a commercially viable product, and as a result, may record impairment losses in the future. The Company assesses intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. The aggregate carrying amount of intangible assets, excluding IPR&D and non-amortizable tradenames, was $26.541 billion and $27.381 billion as of January 29, 2016 and April 24, 2015 , respectively. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recorded based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not record any significant intangible asset impairments during the three and nine months ended January 29, 2016 or January 23, 2015 .

Income Taxes

Income Taxes	9 Months Ended
	Jan. 29, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes During the third quarter of fiscal year 2016, the Company recorded a $25 million tax benefit associated with the establishment of a deferred tax asset on the tax basis in excess of book basis of a wholly owned US subsidiary the Company expects to dispose of during the foreseeable future. This benefit was recorded within provision for income taxes in the condensed consolidated statements of income. The Company’s effective tax rates for the three and nine months ended January 29, 2016 were 7.1 percent and 24.0 percent, respectively, compared to 18.2 percent and 18.9 percent for the three and nine months ended January 23, 2015 , respectively. The change in the Company’s effective tax rate for the three and nine months ended January 29, 2016 was primarily due to the permanent extension of the U.S. federal research and development tax credit, certain tax adjustments, the impact of special charges, restructuring charges, net, acquisition-related items, the impact from the acquisition of Covidien, and year over year changes in operational results by jurisdiction. During the nine months ended January 29, 2016 , the Company's gross unrecognized tax benefits decreased from $2.860 billion to $2.647 billion . In addition, the Company has accrued gross interest and penalties of $607 million as of January 29, 2016 . If all of the Company’s unrecognized tax benefits were recognized, approximately $2.070 billion would impact the Company’s effective tax rate. The Company has recorded $11 million of gross unrecognized tax benefits as a current liability and $2.636 billion as a long-term liability. The Company will continue to recognize interest and penalties related to income tax matters within provision for income taxes in the condensed consolidated statements of income and record the liability within accrued income taxes or long-term accrued income taxes in the condensed consolidated balance sheets, as appropriate. See Note 16 to the condensed consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Jan. 29, 2016
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares, issued as part of the Transactions, are considered a participating security. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Three months ended Nine months ended (in millions, except per share data) January 29, January 23, January 29, January 23, Numerator: Net income attributable to ordinary shareholders $ 1,095 $ 977 $ 2,435 $ 2,676 Denominator: Basic – weighted average shares outstanding 1,406.6 983.8 1,412.5 986.6 Effect of dilutive securities: Employee stock options 12.0 8.0 12.5 7.6 Employee restricted stock units 3.5 3.9 4.1 4.2 Other 0.1 0.1 0.1 0.1 Diluted – weighted average shares outstanding 1,422.2 995.8 1,429.2 998.5 Basic earnings per share $ 0.78 $ 0.99 $ 1.72 $ 2.71 Diluted earnings per share $ 0.77 $ 0.98 $ 1.70 $ 2.68 The calculation of weighted average diluted shares outstanding excludes approximately 5 million and 4 million options for the three and nine months ended January 29, 2016 , respectively, and approximately 2 million options for both the three and nine months ended January 23, 2015 , respectively, because their effect would have been anti-dilutive on the Company’s earnings per share. Additionally, the calculation of weighted average diluted shares outstanding excludes approximately 21 million shares for both the three and nine months ended January 29, 2016 , respectively, and approximately 1 million restricted stock units for both the three and nine months ended January 23, 2015 , respectively, because the performance criteria had not yet been met.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Jan. 29, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation Under the fair value recognition provisions of U.S. GAAP for accounting for stock-based compensation, the Company measures stock-based compensation expense at the grant date based on the fair value of the award and recognizes the compensation expense over the requisite service period, which is generally the vesting period. The following table presents the components and classification of stock-based compensation expense recognized for the three and nine months ended January 29, 2016 and January 23, 2015 : Three months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Stock options $ 43 $ 7 $ 162 $ 27 Restricted stock awards 33 24 113 78 Employee stock purchase plan 5 2 15 10 Total stock-based compensation expense $ 81 $ 33 $ 290 $ 115 Cost of products sold $ 12 $ 4 $ 38 $ 12 Research and development expense 8 5 28 20 Selling, general, and administrative expense 47 24 162 83 Restructuring charges, net 2 — 16 — Acquisition-related items 12 — 46 — Total stock-based compensation expense $ 81 $ 33 $ 290 $ 115 Income tax benefits (23 ) (8 ) (86 ) (31 ) Total stock-based compensation expense, net of tax $ 58 $ 25 $ 204 $ 84

Retirement Benefit Plans

Retirement Benefit Plans	9 Months Ended
	Jan. 29, 2016
Compensation and Retirement Disclosure [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and nine months ended January 29, 2016 and January 23, 2015 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) January 29, January 23, January 29, January 23, Service cost $ 30 $ 26 $ 22 $ 15 Interest cost 31 26 9 8 Expected return on plan assets (45 ) (39 ) (13 ) (10 ) Amortization of net actuarial loss 24 16 6 3 Net periodic benefit cost $ 40 $ 29 $ 24 $ 16 U.S. Pension Benefits Non-U.S. Pension Benefits Nine months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Service cost $ 90 $ 78 $ 66 $ 45 Interest cost 93 78 27 24 Expected return on plan assets (135 ) (117 ) (39 ) (30 ) Amortization of net actuarial loss 72 48 18 9 Net periodic benefit cost $ 120 $ 87 $ 72 $ 48

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Jan. 29, 2016
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Changes in AOCI by component are as follows: (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustments (a) Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivatives Total Accumulated Other Comprehensive (Loss) Income Balance as of April 24, 2015, net of tax $ 14 $ (277 ) $ (1,131 ) $ 210 $ (1,184 ) Other comprehensive (loss) income before reclassifications, before tax (399 ) (1,513 ) 2 134 (1,776 ) Tax benefit (expense) 143 — — (50 ) 93 Other comprehensive (loss) income before reclassifications, net of tax (256 ) (1,513 ) 2 84 (1,683 ) Reclassifications, before tax (18 ) — 90 (232 ) (160 ) Tax benefit (expense) 6 — (30 ) 86 62 Reclassifications, net of tax (12 ) (b) — 60 (c) (146 ) (d) (98 ) Other comprehensive (loss) income, net of tax (268 ) (1,513 ) 62 (62 ) (1,781 ) Balance as of January 29, 2016, net of tax $ (254 ) $ (1,790 ) $ (1,069 ) $ 148 $ (2,965 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustments (a) Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivatives Total Accumulated Other Comprehensive (Loss) Income Balance as of April 25, 2014, net of tax $ (6 ) $ 218 $ (765 ) $ (44 ) $ (597 ) Other comprehensive income (loss) before reclassifications, before tax 110 (332 ) 24 397 199 Tax expense (40 ) — — (141 ) (181 ) Other comprehensive income (loss) before reclassifications, net of tax 70 (332 ) 24 256 18 Reclassifications, before tax (134 ) — 57 (50 ) (127 ) Tax benefit (expense) 47 — (18 ) 16 45 Reclassifications, net of tax (87 ) (b) — 39 (c) (34 ) (d) (82 ) Other comprehensive (loss) income, net of tax (17 ) (332 ) 63 222 (64 ) Balance as of January 23, 2015, net of tax $ (23 ) $ (114 ) $ (702 ) $ 178 $ (661 ) (a) Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. (b) Represents net realized gains on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 6 ). (c) Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 14 ). (d) Relates to foreign currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 8 ).

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jan. 29, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, income tax disputes, and other matters. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief (including injunctions barring the sale of products that are the subject of the lawsuit), that could require significant expenditures or result in lost revenues. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery; involve unsubstantiated or indeterminate claims for damages; potentially involve penalties, fines or punitive damages; or could result in a change in business practice. As of January 29, 2016 and April 24, 2015, accrued certain litigation charges involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, and other matters were $1.062 billion and $879 million , respectively. The Company includes accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets. In addition to the litigation contingencies referenced below, the Company also has certain guarantee obligations that may potentially result in future costs. While it is not possible to predict the outcome for most of the matters discussed below, the Company believes it is possible that costs associated with them could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows. Product Liability Matters Sprint Fidelis In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. Pretrial proceedings are underway. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. INFUSE Litigation The Company estimates law firms representing approximately 6,000 claimants have asserted or intend to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of March 1, 2016, the Company has reached agreements to settle approximately 3,900 of these claims. The Company recorded an additional expense of $26 million in the second quarter of fiscal year 2016 related to probable and reasonably estimable damages in connection with this matter. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets as discussed above. Other INFUSE Litigation On June 5, 2014, Humana, Inc. filed a lawsuit for unspecified monetary damages in the U.S. District Court for the Western District of Tennessee, alleging that Medtronic, Inc. violated federal racketeering (RICO) law and various state laws, by conspiring with physicians to promote unapproved uses of INFUSE. On September 25, 2015, the Court granted Medtronic’s motion to dismiss the primary allegations, including the RICO claims, in Humana’s complaint. Plaintiffs have now asked the court for permission to file an amended complaint. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Pelvic Mesh Litigation The Company, through the acquisition of Covidien, is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In July 2015, the Company and Bard agreed that Bard would pay the Company $121 million towards the settlement of 11,000 of these claims. The $121 million settlement was recorded as an opening balance sheet adjustment related to the Covidien acquisition in the first quarter of fiscal year 2016. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 15,800 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of March 1, 2016, the Company has reached agreements to settle approximately 4,200 of these claims. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets as discussed above. Patent Litigation Ethicon Ethicon Endo-Surgery, Inc., et al. v. Covidien, Inc., et al . is a patent infringement action filed on December 14, 2011 in the U.S. District Court for the Southern District of Ohio, Western Division. The complaint alleges that Covidien’s Sonicision product infringes several of Ethicon’s design and utility patents. Ethicon is seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien’s favor, ruling that Covidien does not infringe any of the seven Ethicon patents in dispute and declaring five of Ethicon’s patents invalid. Ethicon appealed the district court’s decision and on August 7, 2015, the Court of Appeals for the Federal Circuit issued a ruling affirming in part, reversing in part, and vacating in part. Specifically, the decision upheld the finding that Sonicision does not infringe any of the four design patents asserted by Ethicon, upheld the claim construction on a patent related to ultrasonic dampening components but remanded to the trial court for further proceedings because of factual issues, and reversed the District Court’s finding that an Ethicon patent directed to ultrasonic shears and methods of sealing blood vessels was invalid. The case was remanded to the U.S. District Court for the Southern District of Ohio, Western Division. The only issues for consideration on remand are infringement and validity with respect to two claims of Ethicon’s ultrasonic damping patent. On November 5, 2015, the case was stayed to allow the parties to pursue mediation on those remaining claims, in addition to six other utility patents that Ethicon more recently alleged to be infringed by the Company’s Sonicision product. On January 21, 2016, after the conclusion of that mediation, the Company filed an action in the U.S. District Court for the Southern District of Ohio, Western Division, seeking a declaration that its Sonicision product does not infringe any of the six additional utility patents subject to the mediation. The stay of Ethicon’s original patent infringement case expired on February 4, 2016, and on February 11, 2016, the court consolidated the Company’s declaratory judgment action with Ethicon’s original patent infringement action for all future purposes. The Company has not accrued for damages in connection with the patent litigation matter. Shareholder Related Matters INFUSE On March 12, 2012, Charlotte Kokocinski (Kokocinski) filed a shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and members of its Board of Directors in the U.S. District Court for the District of Minnesota, setting forth certain allegations, including a claim that defendants violated various purported duties in connection with the INFUSE bone graft product and otherwise. On March 25, 2013, the Court dismissed the case without prejudice, and Kokocinski subsequently filed an amended complaint. On March 30, 2015, the Court granted defendants’ motion to dismiss the amended complaint, dismissing the case with prejudice. Kokocinski sought reconsideration of that decision, and, on September 30, 2015, the Court denied Kokocinski’s request for reconsideration. Kokocinski has appealed the Court’s decision to the U.S. Court of Appeals for the Eighth Circuit. West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. The matters were consolidated in September, 2013, and in the consolidated complaint plaintiffs alleged a class period of September 28, 2010 through August 3, 2011. On September 30, 2015, the Court granted defendants’ motion for summary judgment in the consolidated matters. Plaintiffs have appealed the dismissal to the U.S. Court of Appeals for the Eighth Circuit. Shareholder Related Matters Resulting from the Covidien Acquisition On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstei n and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On December 30, 2014, a hearing was held on plaintiffs’ motion for preliminary injunction and on defendants’ motion to dismiss. On January 2, 2015, the Court denied the plaintiffs’ motion for preliminary injunction and on January 5, 2015 issued its opinion. On March 20, 2015, the Court issued its order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, reversed in part, and remanded the case to the District Court for further proceedings. In February of 2016, the Company petitioned the Minnesota Supreme Court to review the decision of the Minnesota State Court of Appeals. The Company has not recorded an expense related to damages in connection with the shareholder related matters, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. Environmental Proceedings The Company, through the acquisition of Covidien, is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation in December 2008. The compliance order included a directive to remove a significant volume of soils at the site. On December 19, 2008, Covidien filed an appeal with the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order. A hearing before the Maine Board began on January 25, 2010 and concluded on February 4, 2010. On August 19, 2010, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. On April 3, 2014, the Maine Supreme Judicial Court affirmed the Maine Board’s compliance order. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. The Company has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring Covidien to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that Covidien was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study and ordered Covidien to pay costs associated with the study. A report issued by the study panel contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations, and includes preliminary cost estimates for the potential remedial options, which the report describes as “very rough estimates of cost,” ranging from $25 million to $235 million . The report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. In June of 2014, a trial was held to determine if remediation was necessary and feasible, and on September 2, 2015, the District Court issued an order concluding that further engineering study and engineering design work is appropriate to determine the nature and extent of remediation in the Penobscot River and Bay. In January of 2016, the Court appointed an engineering firm to conduct the next phase of the study. The Company's accrued expenses for environmental proceedings are included within accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets as discussed above. Other Matters Medtronic has received subpoenas or document requests from the Attorneys General in Massachusetts, California, Oregon, Illinois, and Washington seeking information regarding sales, marketing, clinical, and other information relating to the INFUSE bone graft product. The Company continues to fully cooperate in connection with these matters. The Company has not recorded an expense related to damages in connection with these matters, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. On May 2, 2011, the U.S. Attorney’s Office for the District of Massachusetts issued a subpoena to ev3, a subsidiary of the Company, requesting production of documents relating to sales and marketing and other issues in connection with several neurovascular products. The matters under investigation relate to activities prior to Covidien's acquisition of ev3 in 2010. ev3 complied as required with the subpoena and cooperated with the investigation. The Company continues to fully cooperate in connection with this matter. In the third quarter of fiscal year 2016, the Company accrued expenses in connection with this matter, which are included within accrued certain litigation charges in other accrued expenses and other long-term liabilities on the condensed consolidated balance sheets as discussed above. On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General and the U.S. Attorney’s Office for the Northern District of California, issued a subpoena requesting production of documents relating to sales and marketing practices associated with certain of ev3’s peripheral vascular products. The Company continues to fully cooperate in connection with this matter. The Company has not accrued expenses related to damages in connection with the issued subpoena. Income Taxes In March 2009, the U.S. Internal Revenue Service (IRS) issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. Medtronic, Inc. filed a Petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency. During October and November 2012, Medtronic, Inc. reached resolution with the IRS on various matters, including the deductibility of a settlement payment. Medtronic, Inc. and the IRS agreed to hold one issue, the calculation of amounts eligible for the one-time repatriation holiday, because such specific issue was being addressed by other taxpayers in litigation with the IRS. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court proceeding with respect to this issue began on February 3, 2015 and ended on March 12, 2015. The Company expects a ruling from the U.S. Tax Court sometime during fiscal year 2017. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. During the first quarter of fiscal year 2016, the Company finalized its agreement with the IRS on the proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon Inc. (Kyphon). The settlement was consistent with the certain tax adjustment recorded during the fourth quarter of fiscal year 2015. The significant issues that remain unresolved for these tax years relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the tax effects of its acquisition structures for Ardian, CoreValve, Inc., and Ablation Frontiers, Inc. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level; however, it will proceed through litigation, if necessary. The IRS continues to audit Medtronic, Inc.'s U.S. federal income tax returns for the fiscal years 2012 through 2014. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for the 2008 and 2009 tax years. The IRS continues to audit Covidien’s U.S. federal income tax returns for the years 2010 through 2012. Open periods for examination also include certain periods during which Covidien was a subsidiary of Tyco International plc (Tyco International). The resolution of these matters is subject to the conditions set forth in the Tyco tax sharing agreement (Tax Sharing Agreement). Tyco International has the right to administer, control and settle all U.S. income tax audits for periods prior to the 2007 separation. The IRS has concluded its field examination of certain of Tyco International’s U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect Covidien’s income tax returns for certain years after 2000. Tyco International has appealed certain of the tax adjustments proposed by the IRS and has resolved all but one of the matters associated with the proposed tax adjustments. The IRS has asserted that substantially all of Tyco International’s intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and has disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on Tyco International’s U.S. income tax returns. The Company disagrees with the IRS’s proposed adjustments, and, on July 22, 2013, Tyco International filed a petition with the U.S. Tax Court contesting the IRS assessment. On January 15, 2016, Tyco International, as the audit managing party under the Tax Sharing Agreement, entered into Stipulations of Settled Issues with the IRS intended to resolve all disputes related to the intercompany debt issues for the tax sharing participants for the 1997 - 2000 audit cycle, currently before the U.S. Tax Court. The Stipulations of Settled Issues are contingent upon the IRS Appeals Division applying the same settlement to all intercompany debt issues on appeal for subsequent audit cycles (2001 - 2007) and the approval of the U.S. Congress Joint Committee on Taxation, if required. If finalized, the tentative resolution would cover all aspects of the controversy before the U.S. Tax Court and the Appeals Division of the IRS, and would result in a total cash payment by the tax sharing participants to the IRS in the range of $475 million to $525 million , which includes all interest and penalties. This payment would be shared among the tax sharing participants according to the formula in the Tax Sharing Agreement, and would be split among the Company, Tyco International, and TE Connectivity Ltd. (TE Connectivity) 42 percent , 27 percent , and 31 percent , respectively. See Note 11 to the condensed consolidated financial statements for additional discussion of income taxes. Guarantees As a result of the acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International, TE Connectivity, and Mallinckrodt plc (Mallinckrodt) which relate to certain contingent tax liabilities. On June 29, 2007, Covidien entered into the Tax Sharing Agreement, under which Covidien shares responsibility for certain of its, Tyco International’s and TE Connectivity’s income tax liabilities for periods prior to Covidien’s 2007 separation from Tyco International (2007 separation). Covidien, Tyco International and TE Connectivity share 42 percent , 27 percent , and 31 percent , respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to Covidien's, Tyco International’s and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to Covidien under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. In connection with the 2007 separation, all tax liabilities associated with Covidien business became Covidien’s tax liabilities. Following Covidien’s spin-off of its Pharmaceuticals business to Covidien shareholders through a distribution of all the outstanding ordinary shares of Mallinkrodt (2013 separation), Mallinckrodt became the primary obligor to the taxing authorities for the tax liabilities attributable to its subsidiaries, a significant portion of which relate to periods prior to the 2007 separation. However, Covidien remains the sole party subject to the Tax Sharing Agreement. Accordingly, Mallinckrodt does not share in Covidien’s liability to Tyco International and TE Connectivity, nor in the receivable that Covidien has from Tyco International and TE Connectivity. If any party to the Tax Sharing Agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tax Sharing Agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of Covidien's, Tyco International’s and TE Connectivity’s tax liabilities. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to certain pre-2007 separation tax liabilities and tax years open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or TE Connectivity legal entities for periods prior to the 2007 separation. In conjunction with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, and Covidien indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to 2013 exceed $200 million , net of certain tax benefits realized. In addition, in connection with the 2013 separation, Covidien entered into certain other guarantee commitments and indemnifications with Mallinckrodt. See Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 for additional information. Except as described above in this note or for certain income tax related matters, the Company has not recorded an expense related to losses in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of them to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of the Company or its affiliates’ products or the negligence of any of their personnel or claims alleging that any of their products infringe third-party patents or other intellectual property. The Company’s maximum exposure under these indemnification provisions cannot be estimated, and the Company has not accrued any liabilities within the condensed consolidated financial statements. Historically, the Company has not experienced significant losses on these types of indemnifications.

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Jan. 29, 2016
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment information The Company’s management evaluates performance and allocates resources based on profit and loss from operations before income taxes and interest expense, net, not including corporate determined charges, as presented in the table below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended April 24, 2015 . Net sales of the Company’s reportable segments include end-customer revenues from the sale of products they each develop and manufacture or distribute. Net sales and income from operations before income taxes by reportable segment are as follows: Three months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Cardiac and Vascular Group $ 2,410 $ 2,224 $ 7,460 $ 6,765 Minimally Invasive Therapies Group 2,291 — 7,103 — Restorative Therapies Group 1,759 1,645 5,335 4,897 Diabetes Group 474 449 1,368 1,295 Total Net Sales $ 6,934 $ 4,318 $ 21,266 $ 12,957 Three months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Cardiac and Vascular Group $ 726 $ 722 $ 2,298 $ 2,148 Minimally Invasive Therapies Group 282 — 963 — Restorative Therapies Group 496 482 1,460 1,318 Diabetes Group 140 144 379 381 Total Reportable Segments’ Income Before Income Taxes 1,644 1,348 5,100 3,847 Special charges — 138 — 38 Impact of inventory step-up — — (226 ) — Restructuring charges, net (19 ) — (159 ) (30 ) Certain litigation charges — — (26 ) — Acquisition-related items (63 ) (80 ) (183 ) (182 ) Interest expense, net (176 ) (81 ) (584 ) (94 ) Corporate (207 ) (131 ) (720 ) (280 ) Total Income From Operations Before Income Taxes $ 1,179 $ 1,194 $ 3,202 $ 3,299 Geographic information Net sales to external customers by geography are as follows: Three months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Americas (a) $ 4,229 $ 2,615 $ 13,064 $ 7,747 EMEA (b) (c) 1,607 1,074 4,843 3,276 Asia-Pacific 729 403 2,235 1,270 Greater China 369 226 1,124 664 Total Net Sales $ 6,934 $ 4,318 $ 21,266 $ 12,957 (a) The U.S., which is included in the Americas, had net sales to external customers of $3.965 billion and $12.205 billion for the three and nine months ended January 29, 2016 , respectively, compared to $2.459 billion and $7.248 billion in the three and nine months ended January 23, 2015 , respectively. (b) EMEA consists of the following regions: Europe, Middle East, and Africa. (c) Sales within Ireland were insignificant during all periods presented. Certain prior period net sales to external customers by geography have been reclassified to conform to the current period classification.

Guarantor Financial Information

Guarantor Financial Information	9 Months Ended
	Jan. 29, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information On January 26, 2015, Medtronic plc (Parent Company Guarantor) and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a subsidiary guarantor, each provided a full and unconditional guarantee of the obligations of Medtronic, Inc. under the Senior Notes (Medtronic Senior Notes). In addition, Medtronic plc and Medtronic Luxco each provided a full and unconditional guarantee of the obligations of Covidien International Finance S.A. (CIFSA), assumed as part of the Covidien acquisition, under the Senior Notes (CIFSA Senior Notes). These guarantees of the CIFSA Senior Notes were in addition to the guarantees of the CIFSA Senior Notes by legacy Covidien holding companies Covidien Ltd. (f/k/a Covidien plc) and Covidien Group Holdings Ltd. (f/k/a Covidien Ltd.), both of which remain guarantors of the CIFSA Senior Notes. A summary of the guarantees is as follows: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Since Medtronic plc and Medtronic Luxco did not exist in the comparable period in the prior fiscal year, the Parent Company Guarantor column and Subsidiary Guarantor column in the consolidating financial information for the guarantee of the Medtronic Senior Notes will appear as zeros for the comparable period in fiscal year 2015. Accordingly, the consolidating financial information presented for the comparable period in the prior year is of the predecessor registrant, Medtronic, Inc. Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. There were no Medtronic plc or Medtronic Luxco guarantees in effect prior to the Acquisition Date, and the CIFSA Senior Notes were assumed as part of the Covidien acquisition. Therefore, no consolidating financial information for the period ended January 23, 2015 is presented related to the guarantee of the CIFSA Senior Notes. The following presents the Company’s Consolidating Statements of Comprehensive Income as of and for the three and nine months ended January 29, 2016 and January 23, 2015 , and Condensed Consolidating Balance Sheets as of January 29, 2016 and April 24, 2015 , and Condensed Consolidating Statements of Cash Flows as of and for the nine months ended January 29, 2016 . The guarantees provided by the Parent Company Guarantor and Subsidiary Guarantor(s) are joint and several. Condensed consolidating financial information for the Parent Company Guarantor, Subsidiary Issuer, and Subsidiary Guarantor(s), on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. During the third quarter of fiscal year 2016, the Company undertook certain steps to reorganize ownership of various subsidiaries. The transactions were entirely among subsidiaries under the common control of Medtronic. This reorganization has been reflected as of the beginning of the earliest period presented. In addition, the Company made a revision to its condensed consolidating balance sheet of the guarantees of the CIFSA Senior Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 24, 2015. The $14.700 billion revision increased the line items Investment in Subsidiaries and Shareholders' Equity in the Subsidiary Issuer (CIFSA) column due to an incorrect presentation primarily related to the investment balance upon acquisition and an intercompany dividend. Additionally, the Company made certain revisions to its condensed consolidating balance sheet of the guarantees of the Medtronic Senior Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 24, 2015. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2015 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. Consolidating Statement of Comprehensive Income Three Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 349 $ — $ 6,934 $ (349 ) $ 6,934 Costs and expenses: Cost of products sold — 242 — 2,261 (362 ) 2,141 Research and development expense — 66 — 480 — 546 Selling, general, and administrative expense 31 79 — 2,207 — 2,317 Restructuring charges, net — — — 19 — 19 Certain litigation charges — — — — — — Acquisition-related items — 36 — 27 — 63 Amortization of intangible assets — 3 — 481 — 484 Other (income) expense, net — (280 ) — 289 — 9 Operating profit (loss) (31 ) 203 — 1,170 13 1,355 Interest income — (58 ) (173 ) (99 ) 231 (99 ) Interest expense 7 408 3 88 (231 ) 275 Interest (income) expense, net 7 350 (170 ) (11 ) — 176 Equity in net (income) loss of subsidiaries (1,130 ) (228 ) (962 ) — 2,320 — Income (loss) from operations before income taxes 1,092 81 1,132 1,181 (2,307 ) 1,179 Provision (benefit) for income taxes (3 ) (16 ) 2 101 — 84 Net income (loss) 1,095 97 1,130 1,080 (2,307 ) 1,095 Other comprehensive income (loss), net of tax (1,494 ) (120 ) (1,615 ) (1,212 ) 2,947 (1,494 ) Total comprehensive income (loss) $ (399 ) $ (23 ) $ (485 ) $ (132 ) $ 640 $ (399 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 1,085 $ — $ 21,266 $ (1,085 ) $ 21,266 Costs and expenses: Cost of products sold — 753 — 7,089 (1,063 ) 6,779 Research and development expense — 348 — 1,301 — 1,649 Selling, general, and administrative expense 93 228 — 6,788 — 7,109 Restructuring charges, net — 4 — 155 — 159 Certain litigation charges — — — 26 — 26 Acquisition-related items — 91 — 92 — 183 Amortization of intangible assets — 9 — 1,439 — 1,448 Other (income) expense, net — (859 ) — 986 — 127 Operating profit (loss) (93 ) 511 — 3,390 (22 ) 3,786 Interest (income) — (179 ) (531 ) (328 ) 717 (321 ) Interest expense 12 1,307 6 297 (717 ) 905 Interest (income) expense, net 12 1,128 (525 ) (31 ) — 584 Equity in net (income) of subsidiaries (2,529 ) 4,729 (2,006 ) — (194 ) — Income (loss) from operations before income taxes 2,424 (5,346 ) 2,531 3,421 172 3,202 Provision (benefit) for income taxes (11 ) (94 ) 2 870 — 767 Net income (loss) 2,435 (5,252 ) 2,529 2,551 172 2,435 Other comprehensive income (loss), net of tax (1,781 ) (367 ) (1,781 ) (1,414 ) 3,562 (1,781 ) Total comprehensive income $ 654 $ (5,619 ) $ 748 $ 1,137 $ 3,734 $ 654 Consolidating Statement of Comprehensive Income Three Months Ended January 23, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 301 $ — $ 4,318 $ (301 ) $ 4,318 Costs and expenses: Cost of products sold — 214 — 1,216 (302 ) 1,128 Research and development expense — 69 — 304 — 373 Selling, general, and administrative expense — 178 — 1,309 — 1,487 Special (gains) charges, net — (98 ) — (40 ) — (138 ) Acquisition-related items — 76 — 4 — 80 Amortization of intangible assets — 3 — 86 — 89 Other (income) expense, net — (370 ) — 394 — 24 Operating profit (loss) — 229 — 1,045 1 1,275 Interest income — — — (96 ) 1 (95 ) Interest expense — 166 — 11 (1 ) 176 Interest (income) expense, net — 166 — (85 ) — 81 Equity in net (income) loss of subsidiaries — (975 ) — — 975 — Income from operations before income taxes — 1,038 — 1,130 (974 ) 1,194 Provision (benefit) for income taxes — 61 — 156 — 217 Net income — 977 — 974 (974 ) 977 Other comprehensive income, net of tax — (155 ) — 34 (34 ) (155 ) Total comprehensive income $ — $ 822 $ — $ 1,008 $ (1,008 ) $ 822 Consolidating Statement of Comprehensive Income Nine Months Ended January 23, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 913 $ — $ 12,957 $ (913 ) $ 12,957 Costs and expenses: Cost of products sold — 655 — 3,628 (908 ) 3,375 Research and development expense — 303 — 809 — 1,112 Selling, general, and administrative expense — 661 — 3,839 — 4,500 Special (gains) charges, net — 2 — (40 ) — (38 ) Restructuring charges, net — — — 30 — 30 Acquisition-related items — 180 — 2 — 182 Amortization of intangible assets — 9 — 256 — 265 Other (income) expense, net — (903 ) — 1,041 — 138 Operating profit (loss) — 6 — 3,392 (5 ) 3,393 Interest income — — — (275 ) 1 (274 ) Interest expense — 339 — 30 (1 ) 368 Interest (income) expense, net — 339 — (245 ) — 94 Equity in net income of subsidiaries — (3,001 ) — — 3,001 — Income from operations before income taxes — 2,668 — 3,637 (3,006 ) 3,299 Provision (benefit) for income taxes — (8 ) — 631 — 623 Net income — 2,676 — 3,006 (3,006 ) 2,676 Other comprehensive income, net of tax — (64 ) — 1 (1 ) (64 ) Total comprehensive income $ — $ 2,612 $ — $ 3,007 $ (3,007 ) $ 2,612 Condensed Consolidating Balance Sheet January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 29 $ 1 $ 2,691 $ — $ 2,721 Investments — — — 14,565 — 14,565 Accounts receivable, net — — — 4,863 — 4,863 Inventories — 164 — 3,593 (221 ) 3,536 Intercompany receivable 249 162,357 — 164,957 (327,563 ) — Tax assets — 237 — 265 — 502 Prepaid expenses and other current assets 4 128 — 1,250 — 1,382 Total current assets 253 162,915 1 192,184 (327,784 ) 27,569 Property, plant, and equipment, net — 1,058 — 3,578 — 4,636 Goodwill — 1,672 — 38,704 — 40,376 Other intangible assets, net — 34 — 27,282 — 27,316 Long-term tax assets — 550 — 510 — 1,060 Investment in subsidiaries 71,188 37,072 64,991 — (173,251 ) — Intercompany loans receivable 3,000 7,491 10,539 12,763 (33,793 ) — Other assets — 750 — 999 — 1,749 Total assets $ 74,441 $ 211,542 $ 75,531 $ 276,020 $ (534,828 ) $ 102,706 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 501 $ 1,292 $ 360 $ — $ 2,153 Accounts payable — 266 — 1,171 — 1,437 Intercompany payable 20,490 151,745 — 155,328 (327,563 ) — Accrued compensation 6 516 — 959 — 1,481 Accrued income taxes 8 — 2 444 — 454 Deferred tax liabilities — — — — — — Other accrued expenses 1 666 — 1,949 — 2,616 Total current liabilities 20,505 153,694 1,294 160,211 (327,563 ) 8,141 Long-term debt — 29,017 — 4,664 — 33,681 Long-term accrued compensation and retirement benefits — 1,016 — 569 — 1,585 Long-term accrued income taxes 10 1,369 — 1,443 — 2,822 Long-term intercompany loans payable 3,110 10,122 10,053 10,508 (33,793 ) — Long-term deferred tax liabilities — — — 3,802 — 3,802 Other long-term liabilities — 200 — 1,659 — 1,859 Total liabilities 23,625 195,418 11,347 182,856 (361,356 ) 51,890 Shareholders’ equity 50,816 16,124 64,184 93,164 (173,472 ) 50,816 Total liabilities and shareholders’ equity $ 74,441 $ 211,542 $ 75,531 $ 276,020 $ (534,828 ) $ 102,706 Condensed Consolidating Balance Sheet April 24, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 263 $ 1,071 $ 170 $ 3,339 $ — $ 4,843 Investments — — — 14,637 — 14,637 Accounts receivable, net — — — 5,112 — 5,112 Inventories — 165 — 3,497 (199 ) 3,463 Intercompany receivable 259 146,942 — 144,638 (291,839 ) — Tax assets — 295 — 1,040 — 1,335 Prepaid expenses and other current assets 4 128 — 1,322 — 1,454 Total current assets 526 148,601 170 173,585 (292,038 ) 30,844 Property, plant, and equipment, net — 976 — 3,723 — 4,699 Goodwill — 1,607 — 38,923 — 40,530 Other intangible assets, net — 39 — 28,062 — 28,101 Long-term tax assets — 294 — 480 — 774 Investment in subsidiaries 70,233 42,250 63,064 — (175,547 ) — Intercompany loans receivable 3,000 6,516 10,000 10,218 (29,734 ) — Other assets — 678 — 1,059 — 1,737 Total assets $ 73,759 $ 200,961 $ 73,234 $ 256,050 $ (497,319 ) $ 106,685 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 1,110 $ — $ 1,324 $ — $ 2,434 Accounts payable — 261 — 1,349 — 1,610 Intercompany payable 20,506 135,660 — 135,673 (291,839 ) — Accrued compensation 1 490 — 1,120 — 1,611 Accrued income taxes 19 — — 916 — 935 Deferred tax liabilities 3 — — 116 — 119 Other accrued expenses — 628 — 1,836 — 2,464 Total current liabilities 20,529 138,149 — 142,334 (291,839 ) 9,173 Long-term debt — 29,004 — 4,748 — 33,752 Long-term accrued compensation and retirement benefits — 965 — 570 — 1,535 Long-term accrued income taxes — 1,048 — 1,428 — 2,476 Long-term intercompany loans payable — 10,218 10,000 9,516 (29,734 ) — Long-term deferred tax liabilities — — — 4,700 — 4,700 Other long-term liabilities — 207 — 1,612 — 1,819 Total liabilities 20,529 179,591 10,000 164,908 (321,573 ) 53,455 Shareholders’ equity 53,230 21,370 63,234 91,142 (175,746 ) 53,230 Total liabilities and shareholders’ equity $ 73,759 $ 200,961 $ 73,234 $ 256,050 $ (497,319 ) $ 106,685 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (15 ) $ 839 $ 525 $ 4,051 $ (1,508 ) $ 3,892 Investing Activities: Acquisitions, net of cash acquired — — — (1,132 ) — (1,132 ) Additions to property, plant, and equipment — (210 ) — (483 ) — (693 ) Purchases of marketable securities — — — (4,509 ) — (4,509 ) Sales and maturities of marketable securities — — — 4,017 — 4,017 Net increase (decrease) in intercompany loans — (975 ) (539 ) (2,544 ) 4,058 — Increase in investment in subsidiary — — — — — — Other investing activities, net — — — (11 ) — (11 ) Net cash provided by (used in) investing activities — (1,185 ) (539 ) (4,662 ) 4,058 (2,328 ) Financing Activities: Acquisition-related contingent consideration — — — (21 ) — (21 ) Change in short-term borrowings, net — — 1,201 22 — 1,223 Repayment of short-term borrowings (maturities greater than 90 days) — — (48 ) — — (48 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — 139 — — 139 Payments on long-term debt — (600 ) — (1,012 ) — (1,612 ) Dividends to shareholders (1,608 ) — — — — (1,608 ) Issuance of ordinary shares 360 — — — — 360 Repurchase of ordinary shares (2,170 ) — — — — (2,170 ) Net intercompany loan borrowings (repayments) 3,110 (96 ) 53 991 (4,058 ) — Intercompany dividend paid — — — (8 ) 8 — Capital contribution — — (1,500 ) — 1,500 — Other financing activities 60 — — — — 60 Net cash provided by (used in) financing activities (248 ) (696 ) (155 ) (28 ) (2,550 ) (3,677 ) Effect of exchange rate changes on cash and cash equivalents — — — (9 ) — (9 ) Net change in cash and cash equivalents (263 ) (1,042 ) (169 ) (648 ) — (2,122 ) Cash and cash equivalents at beginning of period 263 1,071 170 3,339 — 4,843 Cash and cash equivalents at end of period $ — $ 29 $ 1 $ 2,691 $ — $ 2,721 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 23, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by operating activities $ — $ 995 $ — $ 2,021 $ (26 ) $ 2,990 Investing Activities: Acquisitions, net of cash acquired — — — (611 ) — (611 ) Additions to property, plant, and equipment — (116 ) — (200 ) — (316 ) Purchases of marketable securities — — — (5,327 ) — (5,327 ) Sales and maturities of marketable securities — — — 4,351 — 4,351 Net decrease in intercompany loans — 3 — 39 (42 ) — Other investing activities, net — — — 60 — 60 Net cash used in investing activities — (113 ) — (1,688 ) (42 ) (1,843 ) Financing Activities: Acquisition-related contingent consideration — — — (5 ) — (5 ) Change in short-term borrowings, net — 7 — — — 7 Repayment of short-term borrowings (maturities greater than 90 days) — (150 ) — — — (150 ) Proceeds from short-term borrowings (maturities greater than 90 days) — 150 — — — 150 Issuance of long-term debt — 16,918 — — — 16,918 Payments on long-term debt — (13 ) — — — (13 ) Dividends to shareholders — (902 ) — — — (902 ) Issuance of ordinary shares — 477 — — — 477 Repurchase of ordinary shares — (1,620 ) — — — (1,620 ) Net intercompany loan borrowings (repayments) — (39 ) — (3 ) 42 — Intercompany dividend paid — — — (26 ) 26 — Other financing activities — (64 ) — — — (64 ) Net cash (used in) provided by financing activities — 14,764 — (34 ) 68 14,798 Effect of exchange rate changes on cash and cash equivalents — — — (117 ) — (117 ) Net change in cash and cash equivalents — 15,646 — 182 — 15,828 Cash and cash equivalents at beginning of period — 264 — 1,139 — 1,403 Cash and cash equivalents at end of period $ — $ 15,910 $ — $ 1,321 $ — $ 17,231 Consolidating Statement of Comprehensive Income Three Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 6,934 $ — $ 6,934 Costs and expenses: Cost of products sold — — — 2,141 — 2,141 Research and development expense — — — 546 — 546 Selling, general, and administrative expense 31 — 3 2,283 — 2,317 Restructuring charges, net — — — 19 — 19 Certain litigation charges, net — — — — — — Acquisition-related items — — — 63 — 63 Amortization of intangible assets — — — 484 — 484 Other (income) expense, net — — 11 (2 ) — 9 Operating profit (loss) (31 ) — (14 ) 1,400 — 1,355 Interest income — (112 ) (175 ) (100 ) 288 (99 ) Interest expense 7 41 3 512 (288 ) 275 Interest expense (income), net 7 (71 ) (172 ) 412 — 176 Equity in net (income) loss of subsidiaries (1,130 ) (585 ) (972 ) — 2,687 — Income from operations before income taxes 1,092 656 1,130 988 (2,687 ) 1,179 Provision (benefit) for income taxes (3 ) — — 87 — 84 Net income 1,095 656 1,130 901 (2,687 ) 1,095 Other comprehensive loss, net of tax (1,494 ) (40 ) (1,494 ) (1,391 ) 2,925 (1,494 ) Total comprehensive income (loss) $ (399 ) $ 616 $ (364 ) $ (490 ) $ 238 $ (399 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 21,266 $ — $ 21,266 Costs and expenses: Cost of products sold — — — 6,779 — 6,779 Research and development expense — — — 1,649 — 1,649 Selling, general, and administrative expense 93 — 3 7,013 — 7,109 Restructuring charges, net — — — 159 — 159 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — — — 183 — 183 Amortization of intangible assets — — — 1,448 — 1,448 Other (income) expense, net — 1 11 115 — 127 Operating profit (loss) (93 ) (1 ) (14 ) 3,894 — 3,786 Interest income — (422 ) (533 ) (330 ) 964 (321 ) Interest expense 12 100 6 1,751 (964 ) 905 Interest expense (income), net 12 (322 ) (527 ) 1,421 — 584 Equity in net (income) loss of subsidiaries (2,529 ) (7,847 ) (2,016 ) — 12,392 — Income from operations before income taxes 2,424 8,168 2,529 2,473 (12,392 ) 3,202 Provision (benefit) for income taxes (11 ) — — 778 — 767 Net income 2,435 8,168 2,529 1,695 (12,392 ) 2,435 Other comprehensive loss, net of tax (1,781 ) (103 ) (1,781 ) (1,678 ) 3,562 (1,781 ) Total comprehensive income (loss) $ 654 $ 8,065 $ 748 $ 17 $ (8,830 ) $ 654 Condensed Consolidating Balance Sheet January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 36 $ 1 $ 2,684 $ — $ 2,721 Investments — — — 14,565 — 14,565 Accounts receivable, net — — — 4,863 — 4,863 Inventories — — — 3,536 — 3,536 Intercompany receivable 249 — 60 20,504 (20,813 ) — Tax assets — — — 502 — 502 Prepaid expenses and other current assets 4 — 5 1,373 — 1,382 Total current assets 253 36 66 48,027 (20,813 ) 27,569 Property, plant, and equipment, net — — — 4,636 — 4,636 Goodwill — — — 40,376 — 40,376 Other intangible assets, net — — — 27,316 — 27,316 Long-term tax assets — — — 1,060 — 1,060 Investment in subsidiaries 71,188 33,441 63,719 — (168,348 ) — Intercompany loans receivable 3,000 2,810 12,025 17,264 (35,099 ) — Other assets — — — 1,749 — 1,749 Total assets $ 74,441 $ 36,287 $ 75,810 $ 140,428 $ (224,260 ) $ 102,706 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ — $ 1,292 $ 861 $ — $ 2,153 Accounts payable — — — 1,437 — 1,437 Intercompany payable 20,490 — 277 46 (20,813 ) — Accrued compensation 6 — — 1,475 — 1,481 Accrued income taxes 8 — 2 444 — 454 Deferred tax liabilities — — — — — — Other accrued expenses 1 45 — 2,570 — 2,616 Total current liabilities 20,505 45 1,571 6,833 (20,813 ) 8,141 Long-term debt — 4,519 — 29,162 — 33,681 Long-term accrued compensation and retirement benefits — — — 1,585 — 1,585 Long-term accrued income taxes 10 — — 2,812 — 2,822 Long-term intercompany loans payable 3,110 8,696 10,054 13,239 (35,099 ) — Long-term deferred tax liabilities — — — 3,802 — 3,802 Other long-term liabilities — — — 1,859 — 1,859 Total liabilities 23,625 13,260 11,625 59,292 (55,912 ) 51,890 Shareholders’ equity 50,816 23,027 64,185 81,136 (168,348 ) 50,816 Total liabilities and shareholders’ equity $ 74,441 $ 36,287 $ 75,810 $ 140,428 $ (224,260 ) $ 102,706 Condensed Consolidating Balance Sheet April 24, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 263 $ 728 $ 170 $ 3,682 $ — $ 4,843 Investments — — — 14,637 — 14,637 Accounts receivable, net — — — 5,112 — 5,112 Inventories — — — 3,463 — 3,463 Intercompany receivable 259 — 269 20,507 (21,035 ) — Tax assets — — — 1,335 — 1,335 Prepaid expenses and other current assets 4 — 6 1,444 — 1,454 Total current assets 526 728 445 50,180 (21,035 ) 30,844 Property, plant, and equipment, net — — 1 4,698 — 4,699 Goodwill — — — 40,530 — 40,530 Other intangible assets, net — — — 28,101 — 28,101 Long-term tax assets — — — 774 — 774 Investment in subsidiaries 70,233 20,836 61,769 — (152,838 ) — Intercompany loans receivable 3,000 7,401 11,303 17,082 (38,786 ) — Other assets — — — 1,737 — 1,737 Total assets $ 73,759 $ 28,965 $ 73,518 $ 143,102 $ (212,659 ) $ 106,685 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 1,002 $ — $ 1,432 $ — $ 2,434 Accounts payable — — 2 1,608 — 1,610 Intercompany payable 20,506 — 279 250 (21,035 ) — Accrued compensation 1 — — 1,610 — 1,611 Accrued income taxes 19 — — 916 — 935 Deferred tax liabilities 3 — — 116 — 119 Other accrued expenses — 40 1 2,423 — 2,464 Total current liabilities 20,529 1,042 282 8,355 (21,035 ) 9,173 Long-term debt — 4,581 — 29,171 — 33,752 Long-term accrued compensation and retirement benefits — — — 1,535 — 1,535 Long-term accrued income taxes — — — 2,476 — 2,476 Long-term intercompany loans payable — 8,385 10,002 20,399 (38,786 ) — Long-term deferred tax liabilities — — — 4,700 — 4,700 Other long-term liabilities — — — 1,819 — 1,819 Total liabilities 20,529 14,008 10,284 68,455 (59,821 ) 53,455 Shareholders’ equity 53,230 14,957 63,234 74,647 (152,838 ) 53,230 Total liabilities and shareholders’ equity $ 73,759 $ 28,965 $ 73,518 $ 143,102 $ (212,659 ) $ 106,685 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (15 ) $ 3,316 $ 709 $ 12,343 $ (12,461 ) $ 3,892 Investing Activities: Acquisitions, net of cash acquired — — — (1,132 ) — (1,132 ) Additions to property, plant, and equipment — — — (693 ) — (693 ) Purchases of marketable securities — — — (4,509 ) — (4,509 ) Sales and maturities of marketable securities — — — 4,017 — 4,017 Net (increase) decrease in intercompany loans receivable — 4,592 (722 ) (181 ) (3,689 ) — Other investing activities, net — — — (11 ) — (11 ) Net cash provided by (used in) investing activities — 4,592 (722 ) (2,509 ) (3,689 ) (2,328 ) Financing Activities: Acquisition-related contingent consideration — — — (21 ) — (21 ) Change in short-term borrowings, net — — 1,201 22 — 1,223 Repayment of short-term borrowings (maturities greater than 90 days) — — (48 ) — — (48 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — 139 — — 139 Payments on long-term debt — (1,000 ) — (612 ) — (1,612 ) Dividends to shareholders (1,608 ) — — — — (1,608 ) Issuance of ordinary shares 360 — — — — 360 Repurchase of ordinary shares (2,170 ) — — — — (2,170 ) Net intercompany loan borrowings (repayments) 3,110 311 52 (7,162 ) 3,689 — Intercompany dividend paid — — — (3,050 ) 3,050 — Capital contribution — (7,911 ) (1,500 ) — 9,411 — Other financing activities 60 — — — — 60 Net cash provided by (used in) financing activities (248 ) (8,600 ) (156 ) (10,823 ) 16,150 (3,677 ) Effect of exchange rate changes on cash and cash equivalents — — — (9 ) — (9 ) Net change in cash and cash equivalents (263 ) (692 ) (169 ) (998 ) — (2,122 ) Cash and cash equivalents at beginning of period 263 728 170 3,682 — 4,843 Cash and cash equivalents at end of period $ — $ 36 $ 1 $ 2,684 $ — $ 2,721

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Jan. 29, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic or the Company) for the periods presented. Medtronic plc is the successor registrant to Medtronic, Inc. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended 2015 .
Fiscal Period	The Company’s fiscal years 2016 , 2015 , and 2014 will end or ended on April 29, 2016 , April 24, 2015 , and April 25, 2014 , respectively. Fiscal year 2016 is a 53-week year, and the extra week occurred during the first quarter.
New Accounting Pronouncements	Recently Adopted In April 2014, the Financial Accounting Standards Board (FASB) issued amended guidance for reporting discontinued operations. The amended guidance changes the criteria for determining when the results of operations are to be reported as discontinued operations and expands the related disclosure requirements. The guidance defines a discontinued operation as a component or group of components that is disposed of or classified as held for sale, which is a strategic shift that has, or will have, a major effect on financial position and results of operations. The Company prospectively adopted this accounting guidance in the first quarter of fiscal year 2016. Its adoption did not have a material impact on the Company's condensed consolidated financial statements. In September 2015, the FASB issued accounting guidance which eliminates the requirement for an acquirer in a business combination to restate prior period financial statements for measurement period adjustments. An acquirer in a business combination is required to report provisional amounts when measurements are incomplete at the end of the reporting period covering the business combination. Prior to the issuance of the new guidance, an acquirer was required to adjust such provisional amounts by restating prior period financial statements. Under the new guidance, the acquirer will recognize the measurement-period adjustment in the period the adjustment is determined. The Company prospectively adopted this accounting guidance in the third quarter of fiscal year 2016. Its adoption did not have a material impact on the Company's condensed consolidated financial statements. In November 2015, the FASB issued accounting guidance that requires all deferred tax assets and liabilities, along with any related valuation allowance, to be classified as noncurrent on the Condensed Consolidated Balance Sheets. Current guidance requires the deferred taxes for each jurisdiction to be presented as a net current asset or liability and net noncurrent asset or liability. As a result of the new guidance, each jurisdiction will now only have one net noncurrent deferred tax asset or liability. The new guidance does not change the existing requirement that only permits offsetting deferred tax assets and liabilities within a single jurisdiction. Entities have the option to apply the new guidance prospectively or retrospectively. This accounting guidance is effective for financial statements issued for annual periods beginning after December 15, 2016, with early adoption permitted. The Company prospectively adopted this accounting guidance in the third quarter of fiscal year 2016. Prior periods have not been retrospectively adjusted for adoption of this statement. Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s condensed consolidated financial statements.

Acquisitions and Acquisition-27

Acquisitions and Acquisition-Related Items (Tables)	9 Months Ended
	Jan. 29, 2016
Business Acquisition [Line Items]
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at ($ in millions) January 29, 2016 Valuation Technique Unobservable Input Range Discount rate 11% - 27.2% Revenue-based payments $191 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2016 - 2025 Discount rate 0.3% - 5.5% Product development-based payments $180 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2016 - 2025
Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent consideration associated with acquisitions subsequent to April 24, 2009: Three months ended Nine months ended (in millions) January 29, 2016 January 23, 2015 January 29, 2016 January 23, 2015 Beginning Balance $ 368 $ 91 $ 264 $ 68 Purchase price contingent consideration 14 6 149 29 Contingent consideration payments (2 ) — (22 ) (5 ) Change in fair value of contingent consideration (9 ) (4 ) (20 ) 1 Ending Balance $ 371 $ 93 $ 371 $ 93
Covidien plc [Member]
Business Acquisition [Line Items]
Fair Value of Assets Acquired and Liabilities Assumed	The fair values of the assets acquired and liabilities assumed in connection with the Transactions are as follows: (estimated in millions) January 26, 2015 (as previously reported) Adjustments January 26, 2015 (as adjusted) Accounts receivable $ 1,349 $ — $ 1,349 Inventories 2,222 (3 ) 2,219 Other current assets 2,949 232 3,181 Property, plant, and equipment 2,354 (61 ) 2,293 Goodwill 29,586 393 29,979 Intangible assets 26,265 (55 ) 26,210 Other assets 747 14 761 Total assets acquired 65,472 520 65,992 Short-term borrowings 1,011 — 1,011 Other current liabilities 2,331 103 2,434 Long-term debt 4,623 — 4,623 Long-term deferred tax liabilities 4,736 9 4,745 Other long-term liabilities 2,783 408 3,191 Total liabilities assumed 15,484 520 16,004 Net assets acquired $ 49,988 $ — $ 49,988
Acquisitions 2016 [Member]
Business Acquisition [Line Items]
Fair Value of Assets Acquired and Liabilities Assumed	The fair values of the assets acquired and liabilities assumed during the nine months ended January 29, 2016 are as follows: (in millions) Twelve, Inc. RF Surgical Systems, Inc. Medina Medical All Other Total Other current assets $ 60 $ 43 $ 11 $ 40 $ 154 Property, plant, and equipment — 3 — 5 8 IPR&D 192 — 122 143 457 Other intangible assets — 115 — 184 299 Goodwill 301 132 126 238 797 Other assets — 2 — 15 17 Total assets acquired 553 295 259 625 1,732 Current liabilities 37 28 6 21 92 Long-term deferred tax liabilities, net 44 27 34 56 161 Other liabilities — — — 2 2 Total liabilities assumed 81 55 40 79 255 Net assets acquired $ 472 $ 240 $ 219 $ 546 $ 1,477
Acquisitions 2015 [Member]
Business Acquisition [Line Items]
Fair Value of Assets Acquired and Liabilities Assumed	The fair values of the assets acquired and liabilities assumed from acquisitions during fiscal year 2015, other than the Covidien acquisition, are as follows: (in millions) NGC Medical S.p.A. Sapiens Steering Brain Stimulation All Other Total Other current assets $ 55 $ 3 $ 12 $ 70 Property, plant, and equipment 15 1 2 18 IPR&D — 30 39 69 Other intangible assets 159 — 157 316 Goodwill 197 170 108 475 Other assets 3 3 49 55 Total assets acquired 429 207 367 1,003 Current liabilities 34 4 6 44 Long-term deferred tax liabilities, net 51 — 66 117 Other liabilities 4 — — 4 Total liabilities assumed 89 4 72 165 Net assets acquired $ 340 $ 203 $ 295 $ 838

Restructuring Charges, Net (Tab

Restructuring Charges, Net (Tables)	9 Months Ended
	Jan. 29, 2016
Cost Synergies Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	A summary of the activity related to the cost synergies initiative is presented below: (in millions) Employee Termination Costs Asset Write-downs Other Costs Total Balance as of April 24, 2015 $ 136 $ — $ 7 $ 143 Restructuring charges 52 — 15 67 Payments/write-downs (76 ) — (7 ) (83 ) Balance as of July 31, 2015 $ 112 $ — $ 15 $ 127 Restructuring charges 64 10 12 86 Payments/write-downs (28 ) (10 ) (6 ) (44 ) Reversal of excess accrual (13 ) — — (13 ) Balance as of October 30, 2015 $ 135 $ — $ 21 $ 156 Restructuring charges 36 12 7 55 Payments/write-downs (30 ) (12 ) (8 ) (50 ) Reversal of excess accrual (17 ) — (2 ) (19 ) Balance as of January 29, 2016 $ 124 $ — $ 18 $ 142
Covidien Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	A summary of the activity related to the Covidien initiative is presented below: (in millions) Employee Termination Costs Other Costs Total Balance as of April 24, 2015 $ 61 $ 17 $ 78 Payments (13 ) (5 ) (18 ) Balance as of July 31, 2015 $ 48 $ 12 $ 60 Payments (8 ) (6 ) (14 ) Balance as of October 30, 2015 $ 40 $ 6 $ 46 Payments (12 ) (2 ) (14 ) Reversal of excess accrual (2 ) — (2 ) Balance as of January 29, 2016 $ 26 $ 4 $ 30

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Jan. 29, 2016
Investments [Abstract]
Investments by Category and Related Balance Sheet Presentation	The following table summarizes the Company's investments by significant investment categories and the related condensed consolidated balance sheets presentation at January 29, 2016 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities Level 1: U.S. government and agency securities $ 1,517 $ 14 $ (1 ) $ 1,530 $ 1,530 $ — Marketable equity securities 77 24 (5 ) 96 — 96 Total Level 1 1,594 38 (6 ) 1,626 1,530 96 Level 2: Corporate debt securities 6,568 56 (95 ) 6,529 6,526 3 U.S. government and agency securities 1,683 4 (1 ) 1,686 1,686 — Mortgage-backed securities 1,407 12 (16 ) 1,403 1,403 — Foreign government and agency securities 27 — — 27 27 — Certificates of deposit 28 — — 28 28 — Other asset-backed securities 517 3 — 520 520 — Debt funds 3,148 1 (379 ) 2,770 2,770 — Total Level 2 13,378 76 (491 ) 12,963 12,960 3 Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 109 — (7 ) 102 — 102 Total Level 3 110 — (7 ) 103 — 103 Total available-for-sale securities 15,082 114 (504 ) 14,692 14,490 202 Trading securities: Level 1: Exchange-traded funds 65 12 (2 ) 75 75 — Total Level 1: 65 12 (2 ) 75 75 — Total trading securities 65 12 (2 ) 75 75 — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 524 — — N/A — 524 Total Level 3: 524 — — N/A — 524 Total cost method, equity method, and other investments 524 — — N/A — 524 Total investments $ 15,671 $ 126 $ (506 ) $ 14,767 $ 14,565 $ 726 The following table summarizes the Company's investments by significant investment categories and the related condensed consolidated balance sheets presentation at April 24, 2015 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 1,525 $ 17 $ (1 ) $ 1,541 $ 1,541 $ — Marketable equity securities 64 35 (19 ) 80 — 80 Total Level 1 1,589 52 (20 ) 1,621 1,541 80 Level 2: Corporate debt securities 6,282 105 (10 ) 6,377 6,377 — U.S. government and agency securities 1,597 4 (3 ) 1,598 1,598 — Mortgage-backed securities 1,462 22 (6 ) 1,478 1,478 — Foreign government and agency securities 85 — — 85 85 — Certificates of deposit 44 — — 44 44 — Other asset-backed securities 504 3 — 507 507 — Debt funds 3,061 19 (150 ) 2,930 2,930 — Total Level 2 13,035 153 (169 ) 13,019 13,019 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 109 — (4 ) 105 — 105 Total Level 3 110 — (4 ) 106 — 106 Total available-for-sale securities 14,734 205 (193 ) 14,746 14,560 186 Trading securities: Level 1: Exchange-traded funds 58 19 — 77 77 — Total Level 1 58 19 — 77 77 — Total trading securities 58 19 — 77 77 — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 520 — — N/A — 520 Total Level 3 520 — — N/A — 520 Total cost method, equity method, and other investments 520 — — N/A — 520 Total investments $ 15,312 $ 224 $ (193 ) $ 14,823 $ 14,637 $ 706
Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category	The following tables show the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category as of January 29, 2016 and April 24, 2015 : January 29, 2016 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 2,817 $ (80 ) $ 186 $ (16 ) Auction rate securities — — 102 (7 ) Mortgage-backed securities 626 (11 ) 223 (6 ) U.S. government and agency securities 716 (1 ) 103 — Debt funds 1,231 (62 ) 1,538 (317 ) Marketable equity securities 51 (6 ) — — Total $ 5,441 $ (160 ) $ 2,152 $ (346 ) April 24, 2015 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 944 $ (9 ) $ 34 $ (1 ) Auction rate securities — — 105 (4 ) Mortgage-backed securities 346 (3 ) 206 (3 ) U.S. government and agency securities 356 (1 ) 267 (3 ) Debt funds 1,291 (109 ) 559 (41 ) Marketable equity securities 4 (19 ) — — Total $ 2,941 $ (141 ) $ 1,171 $ (52 )
Unobservable Inputs Utilized in the Fair Value Measurement of Auction Rate Securities Classified as Level 3	The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 as of January 29, 2016 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6%
Reconciliation of Beginning and Ending Balances of Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3)	The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): Three months ended January 29, 2016 (in millions) Total Level 3 Corporate debt Auction rate Balance as of October 30, 2015 $ 103 $ 1 $ 102 Total unrealized gains included in other comprehensive income — — — Balance as of January 29, 2016 $ 103 $ 1 $ 102 Three months ended January 23, 2015 (in millions) Total Level 3 Corporate debt Auction rate Balance as of October 24, 2014 $ 108 $ 9 $ 99 Total unrealized gains included in other comprehensive income — — — Balance as of January 23, 2015 $ 108 $ 9 $ 99 Nine months ended January 29, 2016 (in millions) Total Level 3 Corporate debt Auction rate Balance as of April 24, 2015 $ 106 $ 1 $ 105 Total unrealized losses included in other comprehensive income (3 ) — (3 ) Balance as of January 29, 2016 $ 103 $ 1 $ 102 Nine months ended January 23, 2015 (in millions) Total Level 3 Corporate debt Auction rate Balance as of April 24, 2014 $ 106 $ 9 $ 97 Total unrealized gains included in other comprehensive income 2 — 2 Balance as of January 23, 2015 $ 108 $ 9 $ 99
Activity Related to the Company's Investment Portfolio	Activity related to the Company’s investment portfolio is as follows: Three months ended January 29, 2016 January 23, 2015 (in millions) Debt (a) Equity (b) Debt (a) Equity (b) Proceeds from sales $ 1,261 $ 4 $ 1,478 $ 208 Gross realized gains 2 4 10 99 Gross realized losses (9 ) — (4 ) — Impairment losses recognized — (2 ) — (1 ) Nine months ended January 29, 2016 January 23, 2015 (in millions) Debt (a) Equity (b) (c) Debt (a) Equity (b) (d) Proceeds from sales $ 3,979 $ 38 $ 4,114 $ 237 Gross realized gains 11 36 26 157 Gross realized losses (21 ) — (9 ) — Impairment losses recognized — (43 ) — (22 ) (a) Includes available-for-sale debt securities. (b) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments. (c) As a result of certain acquisitions that occurred during the nine months ended January 29, 2016 , the Company recognized a non-cash realized gain of $9 million on its previously-held minority investment included in other expense, net on the condensed consolidated statement of income. (d) As a result of certain acquisitions that occurred during the nine months ended January 23, 2015 , the Company recognized a non-cash realized gain of $41 million on its previously-held minority investments included in other expense, net on the condensed consolidated statement of income.
Available-for-sale Debt Securities Contractual Maturities	The January 29, 2016 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) January 29, 2016 Due in one year or less $ 2,197 Due after one year through five years 6,294 Due after five years through ten years 3,050 Due after ten years 285 Total $ 11,826

Financing Arrangements (Tables)

Financing Arrangements (Tables)	9 Months Ended
	Jan. 29, 2016
Debt Disclosure [Abstract]
Long-term Debt	Long-term debt consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year Payable as of January 29, 2016 Payable as of April 24, 2015 Floating rate three-year 2014 senior notes 2017 $ 250 $ 250 0.875 percent three-year 2014 senior notes 2017 250 250 6.000 percent ten-year 2008 CIFSA senior notes 2018 1,150 1,150 1.500 percent three-year 2015 senior notes 2018 1,000 1,000 1.375 percent five-year 2013 senior notes 2018 1,000 1,000 5.600 percent ten-year 2009 senior notes 2019 400 400 4.450 percent ten-year 2010 senior notes 2020 1,250 1,250 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 1,250 1,250 2.950 percent ten-year 2013 CIFSA senior notes 2024 750 750 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 4.375 percent twenty-year 2015 senior notes 2035 2,500 2,500 6.550 percent thirty-year 2008 CIFSA senior notes 2038 850 850 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 750 750 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,000 4,000 Three-year term loan 2018 3,000 3,000 Interest rate swaps (Note 8) 2017 - 2022 87 79 Deferred gains from interest rate swap terminations, net - — 3 Capital lease obligations 2017 - 2025 117 129 Bank borrowings 2021 31 17 Debt premium 2017 - 2045 421 499 Total Long-Term Debt $ 33,681 $ 33,752

Derivatives and Foreign Excha31

Derivatives and Foreign Exchange Risk Management (Tables)	9 Months Ended
	Jan. 29, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amount and location of the gains (losses) in the condensed consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and nine months ended January 29, 2016 and January 23, 2015 are as follows: (in millions) Three months ended Derivatives Not Designated as Hedging Instruments Location January 29, 2016 January 23, 2015 Foreign currency exchange rate contracts gains (losses) Other expense, net $ 19 $ 153 (in millions) Nine months ended Derivatives Not Designated as Hedging Instruments Location January 29, 2016 January 23, 2015 Foreign currency exchange rate contracts gains (losses) Other expense, net $ 35 $ 202
Amount and Location of Gains (Losses) in Statements of Income and OCI, Derivative Instruments Designated as Cash Flow Hedges	The amount of gains (losses) and location of the gains (losses) in the condensed consolidated statements of income and other comprehensive (loss) income (OCI) related to foreign currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended January 29, 2016 and January 23, 2015 are as follows: Three months ended January 29, 2016 Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 104 Other expense, net $ 111 Cost of products sold (9 ) Total $ 104 $ 102 Three months ended January 23, 2015 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 265 Other expense, net $ 65 Cost of products sold (27 ) Total $ 265 $ 38 Nine months ended January 29, 2016 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 108 Other expense, net $ 295 Cost of products sold (45 ) Total $ 108 $ 250 Nine months ended January 23, 2015 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Location Amount Foreign currency exchange rate contracts $ 556 Other expense, net $ 86 Cost of products sold (28 ) Total $ 556 $ 58
Location and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets as of January 29, 2016 and April 24, 2015 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories. January 29, 2016 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments Interest rate contracts Prepaid expenses and $ 1 Other accrued expenses $ — Foreign currency exchange rate contracts Prepaid expenses and other current assets 281 Other accrued expenses 13 Interest rate contracts Other assets 87 Other long-term liabilities 41 Foreign currency exchange rate contracts Other assets 85 Other long-term liabilities 8 Total derivatives designated as hedging instruments $ 454 $ 62 Derivatives not designated as hedging instruments Commodity derivatives Prepaid expenses and $ — Other accrued expenses $ 5 Foreign currency exchange rate contracts Prepaid expenses and other current assets 21 Other accrued expenses 19 Cross currency interest rate contracts Other assets 21 Other long-term liabilities 5 Total derivatives not designated as hedging instruments $ 42 $ 29 Total derivatives $ 496 $ 91 April 24, 2015 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments Interest rate contracts Prepaid expenses and $ 10 Other accrued expenses $ — Foreign currency exchange rate contracts Prepaid expenses and other current assets 382 Other accrued expenses 12 Interest rate contracts Other assets 79 Other long-term liabilities 71 Foreign currency exchange rate contracts Other assets 143 Other long-term liabilities 3 Total derivatives designated as hedging instruments $ 614 $ 86 Derivatives not designated as hedging instruments Foreign currency exchange rate contracts Prepaid expenses and other current assets $ 119 Other accrued expenses $ 30 Total derivatives not designated as hedging instruments $ 119 $ 30 Total derivatives $ 733 $ 116
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis as of October 30, 2015 and April 24, 2015: (in millions) January 29, 2016 April 24, 2015 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative Assets $ 387 $ 109 $ — $ 644 $ 89 $ — Derivative Liabilities 40 51 — 45 71 —
Offsetting Assets	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 387 $ (63 ) $ (197 ) $ 127 Interest rate contracts 88 (6 ) (15 ) 67 Cross currency interest rate contracts 21 — — 21 $ 496 $ (69 ) $ (212 ) $ 215 Derivative Liabilities Foreign currency exchange rate contracts $ (40 ) $ 33 $ — $ (7 ) Interest rate contracts (41 ) 36 — (5 ) Cross currency interest rate contracts (5 ) — — (5 ) Commodity derivatives (5 ) — — (5 ) $ (91 ) $ 69 $ — $ (22 ) Total $ 405 $ — $ (212 ) $ 193 April 24, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 644 $ (61 ) $ (325 ) $ 258 Interest rate contracts 89 (10 ) (13 ) 66 $ 733 $ (71 ) $ (338 ) $ 324 Derivative Liabilities Foreign currency exchange rate contracts $ (45 ) $ 31 $ — $ (14 ) Interest rate contracts (71 ) 40 8 (23 ) $ (116 ) $ 71 $ 8 $ (37 ) Total $ 617 $ — $ (330 ) $ 287
Offsetting Liabilities	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 387 $ (63 ) $ (197 ) $ 127 Interest rate contracts 88 (6 ) (15 ) 67 Cross currency interest rate contracts 21 — — 21 $ 496 $ (69 ) $ (212 ) $ 215 Derivative Liabilities Foreign currency exchange rate contracts $ (40 ) $ 33 $ — $ (7 ) Interest rate contracts (41 ) 36 — (5 ) Cross currency interest rate contracts (5 ) — — (5 ) Commodity derivatives (5 ) — — (5 ) $ (91 ) $ 69 $ — $ (22 ) Total $ 405 $ — $ (212 ) $ 193 April 24, 2015 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) or Posted Net Amount Derivative Assets Foreign currency exchange rate contracts $ 644 $ (61 ) $ (325 ) $ 258 Interest rate contracts 89 (10 ) (13 ) 66 $ 733 $ (71 ) $ (338 ) $ 324 Derivative Liabilities Foreign currency exchange rate contracts $ (45 ) $ 31 $ — $ (14 ) Interest rate contracts (71 ) 40 8 (23 ) $ (116 ) $ 71 $ 8 $ (37 ) Total $ 617 $ — $ (330 ) $ 287

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jan. 29, 2016
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances were as follows: (in millions) January 29, 2016 April 24, 2015 Finished goods $ 2,244 $ 2,268 Work in-process 520 509 Raw materials 772 686 Total $ 3,536 $ 3,463

Goodwill and Other Intangible33

Goodwill and Other Intangible Assets, Net (Tables)	9 Months Ended
	Jan. 29, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the nine months ended January 29, 2016 are as follows: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total Balance as of April 24, 2015 $ 5,855 $ 23,399 $ 9,424 $ 1,852 $ 40,530 Goodwill as a result of acquisitions 409 196 197 — 802 Purchase accounting adjustments, net 13 346 34 — 393 Currency adjustment, net (95 ) (1,120 ) (135 ) 1 (1,349 ) Balance as of January 29, 2016 $ 6,182 $ 22,821 $ 9,520 $ 1,853 $ 40,376
Gross Carrying Amount of Non-Amortizable Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at January 29, 2016 and April 24, 2015 are as follows: January 29, 2016 April 24, 2015 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortizable: Customer-related $ 18,558 $ (1,066 ) $ 18,492 $ (273 ) Purchased technology and patents 11,305 (2,722 ) 11,118 (2,268 ) Trademarks and tradenames 852 (429 ) 640 (363 ) Other 71 (28 ) 79 (44 ) Total $ 30,786 $ (4,245 ) $ 30,329 $ (2,948 ) Non-Amortizable: IPR&D $ 775 $ 470 Tradenames — 250 Total $ 775 $ 720
Gross Carrying Amount and Accumulated Amortization of Amortizable Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at January 29, 2016 and April 24, 2015 are as follows: January 29, 2016 April 24, 2015 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Amortizable: Customer-related $ 18,558 $ (1,066 ) $ 18,492 $ (273 ) Purchased technology and patents 11,305 (2,722 ) 11,118 (2,268 ) Trademarks and tradenames 852 (429 ) 640 (363 ) Other 71 (28 ) 79 (44 ) Total $ 30,786 $ (4,245 ) $ 30,329 $ (2,948 ) Non-Amortizable: IPR&D $ 775 $ 470 Tradenames — 250 Total $ 775 $ 720
Estimated Future Aggregate Amortization Expense, Amortizable Intangible Assets	Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets as of January 29, 2016 , excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows: (in millions) Fiscal Year Estimated Amortization Expense Remaining 2016 $ 484 2017 1,925 2018 1,893 2019 1,799 2020 1,751 2021 1,734

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Jan. 29, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings per share: Three months ended Nine months ended (in millions, except per share data) January 29, January 23, January 29, January 23, Numerator: Net income attributable to ordinary shareholders $ 1,095 $ 977 $ 2,435 $ 2,676 Denominator: Basic – weighted average shares outstanding 1,406.6 983.8 1,412.5 986.6 Effect of dilutive securities: Employee stock options 12.0 8.0 12.5 7.6 Employee restricted stock units 3.5 3.9 4.1 4.2 Other 0.1 0.1 0.1 0.1 Diluted – weighted average shares outstanding 1,422.2 995.8 1,429.2 998.5 Basic earnings per share $ 0.78 $ 0.99 $ 1.72 $ 2.71 Diluted earnings per share $ 0.77 $ 0.98 $ 1.70 $ 2.68

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Jan. 29, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense recognized for the three and nine months ended January 29, 2016 and January 23, 2015 : Three months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Stock options $ 43 $ 7 $ 162 $ 27 Restricted stock awards 33 24 113 78 Employee stock purchase plan 5 2 15 10 Total stock-based compensation expense $ 81 $ 33 $ 290 $ 115 Cost of products sold $ 12 $ 4 $ 38 $ 12 Research and development expense 8 5 28 20 Selling, general, and administrative expense 47 24 162 83 Restructuring charges, net 2 — 16 — Acquisition-related items 12 — 46 — Total stock-based compensation expense $ 81 $ 33 $ 290 $ 115 Income tax benefits (23 ) (8 ) (86 ) (31 ) Total stock-based compensation expense, net of tax $ 58 $ 25 $ 204 $ 84

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	9 Months Ended
	Jan. 29, 2016
Compensation and Retirement Disclosure [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three and nine months ended January 29, 2016 and January 23, 2015 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) January 29, January 23, January 29, January 23, Service cost $ 30 $ 26 $ 22 $ 15 Interest cost 31 26 9 8 Expected return on plan assets (45 ) (39 ) (13 ) (10 ) Amortization of net actuarial loss 24 16 6 3 Net periodic benefit cost $ 40 $ 29 $ 24 $ 16 U.S. Pension Benefits Non-U.S. Pension Benefits Nine months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Service cost $ 90 $ 78 $ 66 $ 45 Interest cost 93 78 27 24 Expected return on plan assets (135 ) (117 ) (39 ) (30 ) Amortization of net actuarial loss 72 48 18 9 Net periodic benefit cost $ 120 $ 87 $ 72 $ 48

Accumulated Other Comprehensi37

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Jan. 29, 2016
Equity [Abstract]
Changes in AOCI by Component	Changes in AOCI by component are as follows: (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustments (a) Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivatives Total Accumulated Other Comprehensive (Loss) Income Balance as of April 24, 2015, net of tax $ 14 $ (277 ) $ (1,131 ) $ 210 $ (1,184 ) Other comprehensive (loss) income before reclassifications, before tax (399 ) (1,513 ) 2 134 (1,776 ) Tax benefit (expense) 143 — — (50 ) 93 Other comprehensive (loss) income before reclassifications, net of tax (256 ) (1,513 ) 2 84 (1,683 ) Reclassifications, before tax (18 ) — 90 (232 ) (160 ) Tax benefit (expense) 6 — (30 ) 86 62 Reclassifications, net of tax (12 ) (b) — 60 (c) (146 ) (d) (98 ) Other comprehensive (loss) income, net of tax (268 ) (1,513 ) 62 (62 ) (1,781 ) Balance as of January 29, 2016, net of tax $ (254 ) $ (1,790 ) $ (1,069 ) $ 148 $ (2,965 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustments (a) Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivatives Total Accumulated Other Comprehensive (Loss) Income Balance as of April 25, 2014, net of tax $ (6 ) $ 218 $ (765 ) $ (44 ) $ (597 ) Other comprehensive income (loss) before reclassifications, before tax 110 (332 ) 24 397 199 Tax expense (40 ) — — (141 ) (181 ) Other comprehensive income (loss) before reclassifications, net of tax 70 (332 ) 24 256 18 Reclassifications, before tax (134 ) — 57 (50 ) (127 ) Tax benefit (expense) 47 — (18 ) 16 45 Reclassifications, net of tax (87 ) (b) — 39 (c) (34 ) (d) (82 ) Other comprehensive (loss) income, net of tax (17 ) (332 ) 63 222 (64 ) Balance as of January 23, 2015, net of tax $ (23 ) $ (114 ) $ (702 ) $ 178 $ (661 ) (a) Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. (b) Represents net realized gains on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 6 ). (c) Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 14 ). (d) Relates to foreign currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 8 ).

Segment and Geographic Inform38

Segment and Geographic Information (Tables)	9 Months Ended
	Jan. 29, 2016
Segment Reporting [Abstract]
Net Sales by Segment	Net sales and income from operations before income taxes by reportable segment are as follows: Three months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Cardiac and Vascular Group $ 2,410 $ 2,224 $ 7,460 $ 6,765 Minimally Invasive Therapies Group 2,291 — 7,103 — Restorative Therapies Group 1,759 1,645 5,335 4,897 Diabetes Group 474 449 1,368 1,295 Total Net Sales $ 6,934 $ 4,318 $ 21,266 $ 12,957
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Three months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Cardiac and Vascular Group $ 726 $ 722 $ 2,298 $ 2,148 Minimally Invasive Therapies Group 282 — 963 — Restorative Therapies Group 496 482 1,460 1,318 Diabetes Group 140 144 379 381 Total Reportable Segments’ Income Before Income Taxes 1,644 1,348 5,100 3,847 Special charges — 138 — 38 Impact of inventory step-up — — (226 ) — Restructuring charges, net (19 ) — (159 ) (30 ) Certain litigation charges — — (26 ) — Acquisition-related items (63 ) (80 ) (183 ) (182 ) Interest expense, net (176 ) (81 ) (584 ) (94 ) Corporate (207 ) (131 ) (720 ) (280 ) Total Income From Operations Before Income Taxes $ 1,179 $ 1,194 $ 3,202 $ 3,299
Net Sales to External Customers by Geography	Net sales to external customers by geography are as follows: Three months ended Nine months ended (in millions) January 29, January 23, January 29, January 23, Americas (a) $ 4,229 $ 2,615 $ 13,064 $ 7,747 EMEA (b) (c) 1,607 1,074 4,843 3,276 Asia-Pacific 729 403 2,235 1,270 Greater China 369 226 1,124 664 Total Net Sales $ 6,934 $ 4,318 $ 21,266 $ 12,957 (a) The U.S., which is included in the Americas, had net sales to external customers of $3.965 billion and $12.205 billion for the three and nine months ended January 29, 2016 , respectively, compared to $2.459 billion and $7.248 billion in the three and nine months ended January 23, 2015 , respectively. (b) EMEA consists of the following regions: Europe, Middle East, and Africa. (c) Sales within Ireland were insignificant during all periods presented.

Guarantor Financial Informati39

Guarantor Financial Information (Tables)	9 Months Ended
	Jan. 29, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Consolidating Statement of Comprehensive Income	Consolidating Statement of Comprehensive Income Three Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 349 $ — $ 6,934 $ (349 ) $ 6,934 Costs and expenses: Cost of products sold — 242 — 2,261 (362 ) 2,141 Research and development expense — 66 — 480 — 546 Selling, general, and administrative expense 31 79 — 2,207 — 2,317 Restructuring charges, net — — — 19 — 19 Certain litigation charges — — — — — — Acquisition-related items — 36 — 27 — 63 Amortization of intangible assets — 3 — 481 — 484 Other (income) expense, net — (280 ) — 289 — 9 Operating profit (loss) (31 ) 203 — 1,170 13 1,355 Interest income — (58 ) (173 ) (99 ) 231 (99 ) Interest expense 7 408 3 88 (231 ) 275 Interest (income) expense, net 7 350 (170 ) (11 ) — 176 Equity in net (income) loss of subsidiaries (1,130 ) (228 ) (962 ) — 2,320 — Income (loss) from operations before income taxes 1,092 81 1,132 1,181 (2,307 ) 1,179 Provision (benefit) for income taxes (3 ) (16 ) 2 101 — 84 Net income (loss) 1,095 97 1,130 1,080 (2,307 ) 1,095 Other comprehensive income (loss), net of tax (1,494 ) (120 ) (1,615 ) (1,212 ) 2,947 (1,494 ) Total comprehensive income (loss) $ (399 ) $ (23 ) $ (485 ) $ (132 ) $ 640 $ (399 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 1,085 $ — $ 21,266 $ (1,085 ) $ 21,266 Costs and expenses: Cost of products sold — 753 — 7,089 (1,063 ) 6,779 Research and development expense — 348 — 1,301 — 1,649 Selling, general, and administrative expense 93 228 — 6,788 — 7,109 Restructuring charges, net — 4 — 155 — 159 Certain litigation charges — — — 26 — 26 Acquisition-related items — 91 — 92 — 183 Amortization of intangible assets — 9 — 1,439 — 1,448 Other (income) expense, net — (859 ) — 986 — 127 Operating profit (loss) (93 ) 511 — 3,390 (22 ) 3,786 Interest (income) — (179 ) (531 ) (328 ) 717 (321 ) Interest expense 12 1,307 6 297 (717 ) 905 Interest (income) expense, net 12 1,128 (525 ) (31 ) — 584 Equity in net (income) of subsidiaries (2,529 ) 4,729 (2,006 ) — (194 ) — Income (loss) from operations before income taxes 2,424 (5,346 ) 2,531 3,421 172 3,202 Provision (benefit) for income taxes (11 ) (94 ) 2 870 — 767 Net income (loss) 2,435 (5,252 ) 2,529 2,551 172 2,435 Other comprehensive income (loss), net of tax (1,781 ) (367 ) (1,781 ) (1,414 ) 3,562 (1,781 ) Total comprehensive income $ 654 $ (5,619 ) $ 748 $ 1,137 $ 3,734 $ 654 Consolidating Statement of Comprehensive Income Three Months Ended January 23, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 301 $ — $ 4,318 $ (301 ) $ 4,318 Costs and expenses: Cost of products sold — 214 — 1,216 (302 ) 1,128 Research and development expense — 69 — 304 — 373 Selling, general, and administrative expense — 178 — 1,309 — 1,487 Special (gains) charges, net — (98 ) — (40 ) — (138 ) Acquisition-related items — 76 — 4 — 80 Amortization of intangible assets — 3 — 86 — 89 Other (income) expense, net — (370 ) — 394 — 24 Operating profit (loss) — 229 — 1,045 1 1,275 Interest income — — — (96 ) 1 (95 ) Interest expense — 166 — 11 (1 ) 176 Interest (income) expense, net — 166 — (85 ) — 81 Equity in net (income) loss of subsidiaries — (975 ) — — 975 — Income from operations before income taxes — 1,038 — 1,130 (974 ) 1,194 Provision (benefit) for income taxes — 61 — 156 — 217 Net income — 977 — 974 (974 ) 977 Other comprehensive income, net of tax — (155 ) — 34 (34 ) (155 ) Total comprehensive income $ — $ 822 $ — $ 1,008 $ (1,008 ) $ 822 Consolidating Statement of Comprehensive Income Nine Months Ended January 23, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 913 $ — $ 12,957 $ (913 ) $ 12,957 Costs and expenses: Cost of products sold — 655 — 3,628 (908 ) 3,375 Research and development expense — 303 — 809 — 1,112 Selling, general, and administrative expense — 661 — 3,839 — 4,500 Special (gains) charges, net — 2 — (40 ) — (38 ) Restructuring charges, net — — — 30 — 30 Acquisition-related items — 180 — 2 — 182 Amortization of intangible assets — 9 — 256 — 265 Other (income) expense, net — (903 ) — 1,041 — 138 Operating profit (loss) — 6 — 3,392 (5 ) 3,393 Interest income — — — (275 ) 1 (274 ) Interest expense — 339 — 30 (1 ) 368 Interest (income) expense, net — 339 — (245 ) — 94 Equity in net income of subsidiaries — (3,001 ) — — 3,001 — Income from operations before income taxes — 2,668 — 3,637 (3,006 ) 3,299 Provision (benefit) for income taxes — (8 ) — 631 — 623 Net income — 2,676 — 3,006 (3,006 ) 2,676 Other comprehensive income, net of tax — (64 ) — 1 (1 ) (64 ) Total comprehensive income $ — $ 2,612 $ — $ 3,007 $ (3,007 ) $ 2,612 Consolidating Statement of Comprehensive Income Three Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 6,934 $ — $ 6,934 Costs and expenses: Cost of products sold — — — 2,141 — 2,141 Research and development expense — — — 546 — 546 Selling, general, and administrative expense 31 — 3 2,283 — 2,317 Restructuring charges, net — — — 19 — 19 Certain litigation charges, net — — — — — — Acquisition-related items — — — 63 — 63 Amortization of intangible assets — — — 484 — 484 Other (income) expense, net — — 11 (2 ) — 9 Operating profit (loss) (31 ) — (14 ) 1,400 — 1,355 Interest income — (112 ) (175 ) (100 ) 288 (99 ) Interest expense 7 41 3 512 (288 ) 275 Interest expense (income), net 7 (71 ) (172 ) 412 — 176 Equity in net (income) loss of subsidiaries (1,130 ) (585 ) (972 ) — 2,687 — Income from operations before income taxes 1,092 656 1,130 988 (2,687 ) 1,179 Provision (benefit) for income taxes (3 ) — — 87 — 84 Net income 1,095 656 1,130 901 (2,687 ) 1,095 Other comprehensive loss, net of tax (1,494 ) (40 ) (1,494 ) (1,391 ) 2,925 (1,494 ) Total comprehensive income (loss) $ (399 ) $ 616 $ (364 ) $ (490 ) $ 238 $ (399 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 21,266 $ — $ 21,266 Costs and expenses: Cost of products sold — — — 6,779 — 6,779 Research and development expense — — — 1,649 — 1,649 Selling, general, and administrative expense 93 — 3 7,013 — 7,109 Restructuring charges, net — — — 159 — 159 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — — — 183 — 183 Amortization of intangible assets — — — 1,448 — 1,448 Other (income) expense, net — 1 11 115 — 127 Operating profit (loss) (93 ) (1 ) (14 ) 3,894 — 3,786 Interest income — (422 ) (533 ) (330 ) 964 (321 ) Interest expense 12 100 6 1,751 (964 ) 905 Interest expense (income), net 12 (322 ) (527 ) 1,421 — 584 Equity in net (income) loss of subsidiaries (2,529 ) (7,847 ) (2,016 ) — 12,392 — Income from operations before income taxes 2,424 8,168 2,529 2,473 (12,392 ) 3,202 Provision (benefit) for income taxes (11 ) — — 778 — 767 Net income 2,435 8,168 2,529 1,695 (12,392 ) 2,435 Other comprehensive loss, net of tax (1,781 ) (103 ) (1,781 ) (1,678 ) 3,562 (1,781 ) Total comprehensive income (loss) $ 654 $ 8,065 $ 748 $ 17 $ (8,830 ) $ 654
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 29 $ 1 $ 2,691 $ — $ 2,721 Investments — — — 14,565 — 14,565 Accounts receivable, net — — — 4,863 — 4,863 Inventories — 164 — 3,593 (221 ) 3,536 Intercompany receivable 249 162,357 — 164,957 (327,563 ) — Tax assets — 237 — 265 — 502 Prepaid expenses and other current assets 4 128 — 1,250 — 1,382 Total current assets 253 162,915 1 192,184 (327,784 ) 27,569 Property, plant, and equipment, net — 1,058 — 3,578 — 4,636 Goodwill — 1,672 — 38,704 — 40,376 Other intangible assets, net — 34 — 27,282 — 27,316 Long-term tax assets — 550 — 510 — 1,060 Investment in subsidiaries 71,188 37,072 64,991 — (173,251 ) — Intercompany loans receivable 3,000 7,491 10,539 12,763 (33,793 ) — Other assets — 750 — 999 — 1,749 Total assets $ 74,441 $ 211,542 $ 75,531 $ 276,020 $ (534,828 ) $ 102,706 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 501 $ 1,292 $ 360 $ — $ 2,153 Accounts payable — 266 — 1,171 — 1,437 Intercompany payable 20,490 151,745 — 155,328 (327,563 ) — Accrued compensation 6 516 — 959 — 1,481 Accrued income taxes 8 — 2 444 — 454 Deferred tax liabilities — — — — — — Other accrued expenses 1 666 — 1,949 — 2,616 Total current liabilities 20,505 153,694 1,294 160,211 (327,563 ) 8,141 Long-term debt — 29,017 — 4,664 — 33,681 Long-term accrued compensation and retirement benefits — 1,016 — 569 — 1,585 Long-term accrued income taxes 10 1,369 — 1,443 — 2,822 Long-term intercompany loans payable 3,110 10,122 10,053 10,508 (33,793 ) — Long-term deferred tax liabilities — — — 3,802 — 3,802 Other long-term liabilities — 200 — 1,659 — 1,859 Total liabilities 23,625 195,418 11,347 182,856 (361,356 ) 51,890 Shareholders’ equity 50,816 16,124 64,184 93,164 (173,472 ) 50,816 Total liabilities and shareholders’ equity $ 74,441 $ 211,542 $ 75,531 $ 276,020 $ (534,828 ) $ 102,706 Condensed Consolidating Balance Sheet April 24, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 263 $ 1,071 $ 170 $ 3,339 $ — $ 4,843 Investments — — — 14,637 — 14,637 Accounts receivable, net — — — 5,112 — 5,112 Inventories — 165 — 3,497 (199 ) 3,463 Intercompany receivable 259 146,942 — 144,638 (291,839 ) — Tax assets — 295 — 1,040 — 1,335 Prepaid expenses and other current assets 4 128 — 1,322 — 1,454 Total current assets 526 148,601 170 173,585 (292,038 ) 30,844 Property, plant, and equipment, net — 976 — 3,723 — 4,699 Goodwill — 1,607 — 38,923 — 40,530 Other intangible assets, net — 39 — 28,062 — 28,101 Long-term tax assets — 294 — 480 — 774 Investment in subsidiaries 70,233 42,250 63,064 — (175,547 ) — Intercompany loans receivable 3,000 6,516 10,000 10,218 (29,734 ) — Other assets — 678 — 1,059 — 1,737 Total assets $ 73,759 $ 200,961 $ 73,234 $ 256,050 $ (497,319 ) $ 106,685 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 1,110 $ — $ 1,324 $ — $ 2,434 Accounts payable — 261 — 1,349 — 1,610 Intercompany payable 20,506 135,660 — 135,673 (291,839 ) — Accrued compensation 1 490 — 1,120 — 1,611 Accrued income taxes 19 — — 916 — 935 Deferred tax liabilities 3 — — 116 — 119 Other accrued expenses — 628 — 1,836 — 2,464 Total current liabilities 20,529 138,149 — 142,334 (291,839 ) 9,173 Long-term debt — 29,004 — 4,748 — 33,752 Long-term accrued compensation and retirement benefits — 965 — 570 — 1,535 Long-term accrued income taxes — 1,048 — 1,428 — 2,476 Long-term intercompany loans payable — 10,218 10,000 9,516 (29,734 ) — Long-term deferred tax liabilities — — — 4,700 — 4,700 Other long-term liabilities — 207 — 1,612 — 1,819 Total liabilities 20,529 179,591 10,000 164,908 (321,573 ) 53,455 Shareholders’ equity 53,230 21,370 63,234 91,142 (175,746 ) 53,230 Total liabilities and shareholders’ equity $ 73,759 $ 200,961 $ 73,234 $ 256,050 $ (497,319 ) $ 106,685 Condensed Consolidating Balance Sheet January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 36 $ 1 $ 2,684 $ — $ 2,721 Investments — — — 14,565 — 14,565 Accounts receivable, net — — — 4,863 — 4,863 Inventories — — — 3,536 — 3,536 Intercompany receivable 249 — 60 20,504 (20,813 ) — Tax assets — — — 502 — 502 Prepaid expenses and other current assets 4 — 5 1,373 — 1,382 Total current assets 253 36 66 48,027 (20,813 ) 27,569 Property, plant, and equipment, net — — — 4,636 — 4,636 Goodwill — — — 40,376 — 40,376 Other intangible assets, net — — — 27,316 — 27,316 Long-term tax assets — — — 1,060 — 1,060 Investment in subsidiaries 71,188 33,441 63,719 — (168,348 ) — Intercompany loans receivable 3,000 2,810 12,025 17,264 (35,099 ) — Other assets — — — 1,749 — 1,749 Total assets $ 74,441 $ 36,287 $ 75,810 $ 140,428 $ (224,260 ) $ 102,706 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ — $ 1,292 $ 861 $ — $ 2,153 Accounts payable — — — 1,437 — 1,437 Intercompany payable 20,490 — 277 46 (20,813 ) — Accrued compensation 6 — — 1,475 — 1,481 Accrued income taxes 8 — 2 444 — 454 Deferred tax liabilities — — — — — — Other accrued expenses 1 45 — 2,570 — 2,616 Total current liabilities 20,505 45 1,571 6,833 (20,813 ) 8,141 Long-term debt — 4,519 — 29,162 — 33,681 Long-term accrued compensation and retirement benefits — — — 1,585 — 1,585 Long-term accrued income taxes 10 — — 2,812 — 2,822 Long-term intercompany loans payable 3,110 8,696 10,054 13,239 (35,099 ) — Long-term deferred tax liabilities — — — 3,802 — 3,802 Other long-term liabilities — — — 1,859 — 1,859 Total liabilities 23,625 13,260 11,625 59,292 (55,912 ) 51,890 Shareholders’ equity 50,816 23,027 64,185 81,136 (168,348 ) 50,816 Total liabilities and shareholders’ equity $ 74,441 $ 36,287 $ 75,810 $ 140,428 $ (224,260 ) $ 102,706 Condensed Consolidating Balance Sheet April 24, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ 263 $ 728 $ 170 $ 3,682 $ — $ 4,843 Investments — — — 14,637 — 14,637 Accounts receivable, net — — — 5,112 — 5,112 Inventories — — — 3,463 — 3,463 Intercompany receivable 259 — 269 20,507 (21,035 ) — Tax assets — — — 1,335 — 1,335 Prepaid expenses and other current assets 4 — 6 1,444 — 1,454 Total current assets 526 728 445 50,180 (21,035 ) 30,844 Property, plant, and equipment, net — — 1 4,698 — 4,699 Goodwill — — — 40,530 — 40,530 Other intangible assets, net — — — 28,101 — 28,101 Long-term tax assets — — — 774 — 774 Investment in subsidiaries 70,233 20,836 61,769 — (152,838 ) — Intercompany loans receivable 3,000 7,401 11,303 17,082 (38,786 ) — Other assets — — — 1,737 — 1,737 Total assets $ 73,759 $ 28,965 $ 73,518 $ 143,102 $ (212,659 ) $ 106,685 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Short-term borrowings $ — $ 1,002 $ — $ 1,432 $ — $ 2,434 Accounts payable — — 2 1,608 — 1,610 Intercompany payable 20,506 — 279 250 (21,035 ) — Accrued compensation 1 — — 1,610 — 1,611 Accrued income taxes 19 — — 916 — 935 Deferred tax liabilities 3 — — 116 — 119 Other accrued expenses — 40 1 2,423 — 2,464 Total current liabilities 20,529 1,042 282 8,355 (21,035 ) 9,173 Long-term debt — 4,581 — 29,171 — 33,752 Long-term accrued compensation and retirement benefits — — — 1,535 — 1,535 Long-term accrued income taxes — — — 2,476 — 2,476 Long-term intercompany loans payable — 8,385 10,002 20,399 (38,786 ) — Long-term deferred tax liabilities — — — 4,700 — 4,700 Other long-term liabilities — — — 1,819 — 1,819 Total liabilities 20,529 14,008 10,284 68,455 (59,821 ) 53,455 Shareholders’ equity 53,230 14,957 63,234 74,647 (152,838 ) 53,230 Total liabilities and shareholders’ equity $ 73,759 $ 28,965 $ 73,518 $ 143,102 $ (212,659 ) $ 106,685
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Nine Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (15 ) $ 839 $ 525 $ 4,051 $ (1,508 ) $ 3,892 Investing Activities: Acquisitions, net of cash acquired — — — (1,132 ) — (1,132 ) Additions to property, plant, and equipment — (210 ) — (483 ) — (693 ) Purchases of marketable securities — — — (4,509 ) — (4,509 ) Sales and maturities of marketable securities — — — 4,017 — 4,017 Net increase (decrease) in intercompany loans — (975 ) (539 ) (2,544 ) 4,058 — Increase in investment in subsidiary — — — — — — Other investing activities, net — — — (11 ) — (11 ) Net cash provided by (used in) investing activities — (1,185 ) (539 ) (4,662 ) 4,058 (2,328 ) Financing Activities: Acquisition-related contingent consideration — — — (21 ) — (21 ) Change in short-term borrowings, net — — 1,201 22 — 1,223 Repayment of short-term borrowings (maturities greater than 90 days) — — (48 ) — — (48 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — 139 — — 139 Payments on long-term debt — (600 ) — (1,012 ) — (1,612 ) Dividends to shareholders (1,608 ) — — — — (1,608 ) Issuance of ordinary shares 360 — — — — 360 Repurchase of ordinary shares (2,170 ) — — — — (2,170 ) Net intercompany loan borrowings (repayments) 3,110 (96 ) 53 991 (4,058 ) — Intercompany dividend paid — — — (8 ) 8 — Capital contribution — — (1,500 ) — 1,500 — Other financing activities 60 — — — — 60 Net cash provided by (used in) financing activities (248 ) (696 ) (155 ) (28 ) (2,550 ) (3,677 ) Effect of exchange rate changes on cash and cash equivalents — — — (9 ) — (9 ) Net change in cash and cash equivalents (263 ) (1,042 ) (169 ) (648 ) — (2,122 ) Cash and cash equivalents at beginning of period 263 1,071 170 3,339 — 4,843 Cash and cash equivalents at end of period $ — $ 29 $ 1 $ 2,691 $ — $ 2,721 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 23, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by operating activities $ — $ 995 $ — $ 2,021 $ (26 ) $ 2,990 Investing Activities: Acquisitions, net of cash acquired — — — (611 ) — (611 ) Additions to property, plant, and equipment — (116 ) — (200 ) — (316 ) Purchases of marketable securities — — — (5,327 ) — (5,327 ) Sales and maturities of marketable securities — — — 4,351 — 4,351 Net decrease in intercompany loans — 3 — 39 (42 ) — Other investing activities, net — — — 60 — 60 Net cash used in investing activities — (113 ) — (1,688 ) (42 ) (1,843 ) Financing Activities: Acquisition-related contingent consideration — — — (5 ) — (5 ) Change in short-term borrowings, net — 7 — — — 7 Repayment of short-term borrowings (maturities greater than 90 days) — (150 ) — — — (150 ) Proceeds from short-term borrowings (maturities greater than 90 days) — 150 — — — 150 Issuance of long-term debt — 16,918 — — — 16,918 Payments on long-term debt — (13 ) — — — (13 ) Dividends to shareholders — (902 ) — — — (902 ) Issuance of ordinary shares — 477 — — — 477 Repurchase of ordinary shares — (1,620 ) — — — (1,620 ) Net intercompany loan borrowings (repayments) — (39 ) — (3 ) 42 — Intercompany dividend paid — — — (26 ) 26 — Other financing activities — (64 ) — — — (64 ) Net cash (used in) provided by financing activities — 14,764 — (34 ) 68 14,798 Effect of exchange rate changes on cash and cash equivalents — — — (117 ) — (117 ) Net change in cash and cash equivalents — 15,646 — 182 — 15,828 Cash and cash equivalents at beginning of period — 264 — 1,139 — 1,403 Cash and cash equivalents at end of period $ — $ 15,910 $ — $ 1,321 $ — $ 17,231 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (15 ) $ 3,316 $ 709 $ 12,343 $ (12,461 ) $ 3,892 Investing Activities: Acquisitions, net of cash acquired — — — (1,132 ) — (1,132 ) Additions to property, plant, and equipment — — — (693 ) — (693 ) Purchases of marketable securities — — — (4,509 ) — (4,509 ) Sales and maturities of marketable securities — — — 4,017 — 4,017 Net (increase) decrease in intercompany loans receivable — 4,592 (722 ) (181 ) (3,689 ) — Other investing activities, net — — — (11 ) — (11 ) Net cash provided by (used in) investing activities — 4,592 (722 ) (2,509 ) (3,689 ) (2,328 ) Financing Activities: Acquisition-related contingent consideration — — — (21 ) — (21 ) Change in short-term borrowings, net — — 1,201 22 — 1,223 Repayment of short-term borrowings (maturities greater than 90 days) — — (48 ) — — (48 ) Proceeds from short-term borrowings (maturities greater than 90 days) — — 139 — — 139 Payments on long-term debt — (1,000 ) — (612 ) — (1,612 ) Dividends to shareholders (1,608 ) — — — — (1,608 ) Issuance of ordinary shares 360 — — — — 360 Repurchase of ordinary shares (2,170 ) — — — — (2,170 ) Net intercompany loan borrowings (repayments) 3,110 311 52 (7,162 ) 3,689 — Intercompany dividend paid — — — (3,050 ) 3,050 — Capital contribution — (7,911 ) (1,500 ) — 9,411 — Other financing activities 60 — — — — 60 Net cash provided by (used in) financing activities (248 ) (8,600 ) (156 ) (10,823 ) 16,150 (3,677 ) Effect of exchange rate changes on cash and cash equivalents — — — (9 ) — (9 ) Net change in cash and cash equivalents (263 ) (692 ) (169 ) (998 ) — (2,122 ) Cash and cash equivalents at beginning of period 263 728 170 3,682 — 4,843 Cash and cash equivalents at end of period $ — $ 36 $ 1 $ 2,684 $ — $ 2,721

Basis of Presentation (Details)

Basis of Presentation (Details)	9 Months Ended
	Jan. 29, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal year 2016 duration	371 days

Acquisitions and Acquisition-41

Acquisitions and Acquisition-Related Items - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jan. 26, 2015	Jan. 29, 2016	Oct. 02, 2015	Aug. 31, 2015	Aug. 11, 2015	Apr. 24, 2015
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill		$ 40,376				$ 40,530
Covidien plc [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable	$ 1,349
Inventories	2,219
Other current assets	3,181
Property, plant, and equipment	2,293
Goodwill	29,979
Intangible assets	26,210
Other assets	761
Total assets acquired	65,992
Short-term borrowings	1,011
Other current liabilities	2,434
Long-term debt	4,623
Long-term deferred tax liabilities	4,745
Other long-term liabilities	3,191
Total liabilities assumed	16,004
Net assets acquired	49,988
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]
Accounts receivable	0
Inventories	(3)
Other current assets	232
Property, plant, and equipment	(61)
Goodwill	393
Intangible assets	(55)
Other assets	14
Total assets acquired	520
Short-term borrowings	0
Other current liabilities	103
Long-term debt	0
Long-term deferred tax liabilities	9
Other long-term liabilities	408
Total liabilities assumed	520
Net assets acquired	0
Covidien plc [Member] | Scenario, Previously Reported [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable	1,349
Inventories	2,222
Other current assets	2,949
Property, plant, and equipment	2,354
Goodwill	29,586
Intangible assets	26,265
Other assets	747
Total assets acquired	65,472
Short-term borrowings	1,011
Other current liabilities	2,331
Long-term debt	4,623
Long-term deferred tax liabilities	4,736
Other long-term liabilities	2,783
Total liabilities assumed	15,484
Net assets acquired	$ 49,988
Acquisitions 2016 [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets		154
Property, plant, and equipment		8
IPR&D		457
Other intangible assets		299
Goodwill		797
Other assets		17
Total assets acquired		1,732
Current liabilities		92
Long-term deferred tax liabilities		161
Other long-term liabilities		2
Total liabilities assumed		255
Net assets acquired		1,477
Twelve, Inc. [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets			$ 60
Property, plant, and equipment			0
IPR&D			192
Other intangible assets			0
Goodwill			301
Other assets			0
Total assets acquired			553
Current liabilities			37
Long-term deferred tax liabilities			44
Other long-term liabilities			0
Total liabilities assumed			81
Net assets acquired			$ 472
RF Surgical Systems, Inc. [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets					$ 43
Property, plant, and equipment					3
IPR&D					0
Other intangible assets					115
Goodwill					132
Other assets					2
Total assets acquired					295
Current liabilities					28
Long-term deferred tax liabilities					27
Other long-term liabilities					0
Total liabilities assumed					55
Net assets acquired					$ 240
Medina Medical [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets				$ 11
Property, plant, and equipment				0
IPR&D				122
Other intangible assets				0
Goodwill				126
Other assets				0
Total assets acquired				259
Current liabilities				6
Long-term deferred tax liabilities				34
Other long-term liabilities				0
Total liabilities assumed				40
Net assets acquired				$ 219
All Other 2016 [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets		40
Property, plant, and equipment		5
IPR&D		143
Other intangible assets		184
Goodwill		238
Other assets		15
Total assets acquired		625
Current liabilities		21
Long-term deferred tax liabilities		56
Other long-term liabilities		2
Total liabilities assumed		79
Net assets acquired		$ 546
Acquisitions 2015 [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets						70
Property, plant, and equipment						18
IPR&D						69
Other intangible assets						316
Goodwill						475
Other assets						55
Total assets acquired						1,003
Current liabilities						44
Long-term deferred tax liabilities						117
Other long-term liabilities						4
Total liabilities assumed						165
Net assets acquired						838
NGC Medical S.p.A. [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets						55
Property, plant, and equipment						15
IPR&D						0
Other intangible assets						159
Goodwill						197
Other assets						3
Total assets acquired						429
Current liabilities						34
Long-term deferred tax liabilities						51
Other long-term liabilities						4
Total liabilities assumed						89
Net assets acquired						340
Sapiens Steering Brain Stimulation [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets						3
Property, plant, and equipment						1
IPR&D						30
Other intangible assets						0
Goodwill						170
Other assets						3
Total assets acquired						207
Current liabilities						4
Long-term deferred tax liabilities						0
Other long-term liabilities						0
Total liabilities assumed						4
Net assets acquired						203
All Other 2015 [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets						12
Property, plant, and equipment						2
IPR&D						39
Other intangible assets						157
Goodwill						108
Other assets						49
Total assets acquired						367
Current liabilities						6
Long-term deferred tax liabilities						66
Other long-term liabilities						0
Total liabilities assumed						72
Net assets acquired						$ 295

Acquisitions and Acquisition-42

Acquisitions and Acquisition-Related Items - Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	$ 368	$ 91	$ 264	$ 68
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Beginning Balance	368	91	264	68
Purchase price contingent consideration	14	6	149	29
Contingent consideration payments	(2)	0	(22)	(5)
Change in fair value of contingent consideration	(9)	(4)	(20)	1
Ending Balance	371	$ 93	371	$ 93
Revenue-based payments [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	191		191
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Ending Balance	191		$ 191
Revenue-based payments [Member] | Minimum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate			11.00%
Probability of payment			30.00%
Revenue-based payments [Member] | Maximum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate			27.20%
Probability of payment			100.00%
Product development-based payments [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	180		$ 180
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Ending Balance	$ 180		$ 180
Product development-based payments [Member] | Minimum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate			0.30%
Probability of payment			75.00%
Product development-based payments [Member] | Maximum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate			5.50%
Probability of payment			100.00%

Acquisitions and Acquisition-43

Acquisitions and Acquisition-Related Items - Narrative (Details) $ / shares in Units, $ in Millions

Oct. 02, 2015USD ($)

Aug. 31, 2015USD ($)

Aug. 11, 2015USD ($)

Jan. 26, 2015USD ($)$ / shares

Jan. 29, 2016USD ($)

Jan. 23, 2015USD ($)

Jan. 29, 2016USD ($)

Jan. 23, 2015USD ($)

Oct. 30, 2015USD ($)

Apr. 24, 2015USD ($)

Oct. 24, 2014USD ($)

Apr. 25, 2014USD ($)

Business Acquisition [Line Items]

Goodwill

$ 40,376

$ 40,376

$ 40,530

Acquisition-related items

63

$ 80

183

$ 182

Fair value of contingent consideration

371

$ 93

371

$ 93

$ 368

264

$ 91

$ 68

Other long-term liabilities [Member]

Business Acquisition [Line Items]

Fair value of contingent consideration

311

311

242

Other accrued expenses [Member]

Business Acquisition [Line Items]

Fair value of contingent consideration

60

60

$ 22

Covidien plc [Member]

Business Acquisition [Line Items]

Cash consideration per Covidien share (usd per share) | $ / shares

$ 35.19

Consideration - number of shares issued for each Covidien share, conversion ratio

0.956

Consideration - total

$ 50,000

Consideration - cash

16,000

Consideration - non-cash

34,000

Percentage ownership by Medtronic shareholders subsequent to acquisition

69.00%

69.00%

Percentage ownership by Covidien shareholders subsequent to acquisition

31.00%

31.00%

Goodwill

29,979

Contingent liabilities assumed

2,700

Covidien plc [Member] | Contingent Liability, Income Tax [Member]

Business Acquisition [Line Items]

Contingent liabilities assumed

1,500

Covidien plc [Member] | Contingent Liability, Legal [Member]

Business Acquisition [Line Items]

Contingent liabilities assumed

1,200

Covidien plc [Member] | IPR&D [Member]

Business Acquisition [Line Items]

IPR&D

400

Covidien plc [Member] | Customer-related [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 18,300

Finite-lived intangible assets, useful life

18 years

Covidien plc [Member] | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 7,100

Finite-lived intangible assets, useful life

16 years

Covidien plc [Member] | Tradenames [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 400

Finite-lived intangible assets, useful life

6 years

Twelve, Inc. [Member]

Business Acquisition [Line Items]

Consideration - total

$ 472

Consideration - cash

428

Finite-lived intangible assets

0

IPR&D

192

Goodwill

301

Contingent consideration

$ 44

RF Surgical Systems, Inc. [Member]

Business Acquisition [Line Items]

Consideration - total

$ 240

Finite-lived intangible assets

115

IPR&D

0

Goodwill

132

RF Surgical Systems, Inc. [Member] | Customer-related [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 47

Finite-lived intangible assets, useful life

16 years

RF Surgical Systems, Inc. [Member] | Technology-Based Intangible Assets [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets

$ 68

Finite-lived intangible assets, useful life

18 years

Medina Medical [Member]

Business Acquisition [Line Items]

Consideration - total

$ 195

Consideration - cash

155

Finite-lived intangible assets

0

IPR&D

122

Goodwill

126

Contingent consideration

64

Consideration - total, including equity interest in acquiree held prior to combination

$ 219

Equity interest in acquiree held prior to acquisition

11.00%

Business combinations or purchases of intellectual property prior to April 24, 2009 [Member]

Business Acquisition [Line Items]

Maximum amount of future contingent consideration payments

$ 177

$ 177

Special Charges and Certain L44

Special Charges and Certain Litigation Charges (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Loss Contingencies [Line Items]
Special charges (gains)	$ 0	$ (138,000,000)	$ 0	$ (38,000,000)
Gain (loss) on sale of equity method investment		97,000,000
Charitable cash contribution				100,000,000
Certain litigation charges	0	0	26,000,000	$ 0
INFUSE [Member] | Product liability litigation [Member]
Loss Contingencies [Line Items]
Certain litigation charges	$ 0		$ 26,000,000
Surgical Technologies Division [Member]
Loss Contingencies [Line Items]
Gain (loss) on sale of product line		$ 41,000,000

Restructuring Charges, Net - Re

Restructuring Charges, Net - Restructuring Reserve (Details) - USD ($) $ in Millions	Jan. 26, 2015	Jan. 29, 2016	Oct. 30, 2015	Jul. 31, 2015	Apr. 24, 2015	Jan. 29, 2016
Restructuring Reserve [Roll Forward]
Reversal of excess accrual		$ (19)				$ (32)
Cost Synergies Initiative [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		156	$ 127	$ 143		143
Restructuring charges		55	86	67
Payments/write-downs		(50)	(44)	(83)
Reversal of excess accrual		(19)	(13)
Ending balance		142	156	127	$ 143	142
Cost Synergies Initiative [Member] | Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		135	112	136		136
Restructuring charges		36	64	52
Payments/write-downs		(30)	(28)	(76)
Reversal of excess accrual		(17)	(13)
Ending balance		124	135	112	136	124
Cost Synergies Initiative [Member] | Asset Write-downs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		0	0	0		0
Restructuring charges		12	10	0		22
Payments/write-downs		(12)	(10)	0
Reversal of excess accrual		0	0
Ending balance		0	0	0	0	0
Cost Synergies Initiative [Member] | Other Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		21	15	7		7
Restructuring charges		7	12	15
Payments/write-downs		(8)	(6)	(7)
Reversal of excess accrual		(2)	0
Ending balance		18	21	15	7	18
Covidien Initiative [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		46	60	78		78
Payments/write-downs		(14)	(14)	(18)
Reversal of excess accrual		(2)			(5)
Ending balance	$ 103	30	46	60	78	30
Covidien Initiative [Member] | Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		40	48	61		61
Restructuring charges	76
Payments/write-downs		(12)	(8)	(13)
Reversal of excess accrual		(2)
Ending balance		26	40	48	61	26
Covidien Initiative [Member] | Other Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance		6	12	17		17
Restructuring charges	$ 27
Payments/write-downs		(2)	(6)	(5)
Reversal of excess accrual		0
Ending balance		$ 4	$ 6	$ 12	$ 17	$ 4

Restructuring Charges, Net - Na

Restructuring Charges, Net - Narrative (Details) - USD ($) $ in Millions	Jan. 26, 2015	Jan. 29, 2016	Oct. 30, 2015	Jul. 31, 2015	Apr. 24, 2015	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		$ 19					$ 32
Covidien plc [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		2
Cost Synergies Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		19	$ 13
Restructuring charges		55	86	$ 67
Impairment of property, plant and equipment		3				$ 0	13
Restructuring reserve		142	156	127	$ 143		142
Cost Synergies Initiative [Member] | Employee termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		17	13
Restructuring charges		36	64	52
Restructuring reserve		124	135	112	136		124
Cost Synergies Initiative [Member] | Asset write-downs [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		0	0
Restructuring charges		12	10	0			22
Restructuring reserve		0	0	0	0		0
Cost Synergies Initiative [Member] | Inventory write-offs [Member]
Restructuring Cost and Reserve [Line Items]
Impairment of property, plant and equipment		9					9	$ 10
Cost Synergies Initiative [Member] | Other costs [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		2	0
Restructuring charges		7	12	15
Restructuring reserve		18	21	15	7		18
Cost Synergies Initiative [Member] | Covidien plc [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost synergies	$ 850
Covidien Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		2			5
Restructuring reserve	103	30	46	60	78		30
Covidien Initiative [Member] | Employee termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		2
Restructuring charges	76
Restructuring reserve		26	40	48	61		26
Covidien Initiative [Member] | Other costs [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual		0
Restructuring charges	$ 27
Restructuring reserve		$ 4	$ 6	$ 12	$ 17		$ 4

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Presentation, and AFS in Continuous Loss Position (Details) - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Available-for-sale securities:
Cost	$ 15,082	$ 14,734
Unrealized Gains	114	205
Unrealized Losses	(504)	(193)
Fair Value	14,692	14,746
Trading securities:
Cost	65	58
Unrealized Gains	12	19
Unrealized Losses	(2)	0
Fair Value	75	77
Cost method, equity method, and other investments:
Cost	524	520
Total investments [Abstract]
Cost	15,671	15,312
Unrealized Gains	126	224
Unrealized Losses	(506)	(193)
Fair Value	14,767	14,823
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	5,441	2,941
Less than 12 months, Unrealized Losses	(160)	(141)
More than 12 months, Fair Value	2,152	1,171
More than 12 months, Unrealized Losses	(346)	(52)
Investments [Member]
Available-for-sale securities:
Fair Value	14,490	14,560
Trading securities:
Fair Value	75	77
Cost method, equity method, and other investments:
Cost	0	0
Total investments [Abstract]
Fair Value	14,565	14,637
Other Assets [Member]
Available-for-sale securities:
Fair Value	202	186
Trading securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	524	520
Total investments [Abstract]
Fair Value	726	706
Level 1 [Member]
Available-for-sale securities:
Cost	1,594	1,589
Unrealized Gains	38	52
Unrealized Losses	(6)	(20)
Fair Value	1,626	1,621
Trading securities:
Cost	65	58
Unrealized Gains	12	19
Unrealized Losses	(2)	0
Fair Value	75	77
Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,530	1,541
Trading securities:
Fair Value	75	77
Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	96	80
Trading securities:
Fair Value	0	0
Level 2 [Member]
Available-for-sale securities:
Cost	13,378	13,035
Unrealized Gains	76	153
Unrealized Losses	(491)	(169)
Fair Value	12,963	13,019
Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	12,960	13,019
Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	3	0
Level 3 [Member]
Available-for-sale securities:
Cost	110	110
Unrealized Gains	0	0
Unrealized Losses	(7)	(4)
Fair Value	103	106
Cost method, equity method, and other investments:
Cost	524	520
Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	0	0
Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	103	106
Cost method, equity method, and other investments:
Cost	524	520
Corporate debt securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	2,817	944
Less than 12 months, Unrealized Losses	(80)	(9)
More than 12 months, Fair Value	186	34
More than 12 months, Unrealized Losses	(16)	(1)
Corporate debt securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	6,568	6,282
Unrealized Gains	56	105
Unrealized Losses	(95)	(10)
Fair Value	6,529	6,377
Corporate debt securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	6,526	6,377
Corporate debt securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	3	0
Corporate debt securities [Member] | Level 3 [Member]
Available-for-sale securities:
Cost	1	1
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	1	1
Corporate debt securities [Member] | Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities [Member] | Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	1	1
U.S. government and agency securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	716	356
Less than 12 months, Unrealized Losses	(1)	(1)
More than 12 months, Fair Value	103	267
More than 12 months, Unrealized Losses	0	(3)
U.S. government and agency securities [Member] | Level 1 [Member]
Available-for-sale securities:
Cost	1,517	1,525
Unrealized Gains	14	17
Unrealized Losses	(1)	(1)
Fair Value	1,530	1,541
U.S. government and agency securities [Member] | Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,530	1,541
U.S. government and agency securities [Member] | Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
U.S. government and agency securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	1,683	1,597
Unrealized Gains	4	4
Unrealized Losses	(1)	(3)
Fair Value	1,686	1,598
U.S. government and agency securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,686	1,598
U.S. government and agency securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	51	4
Less than 12 months, Unrealized Losses	(6)	(19)
More than 12 months, Fair Value	0	0
More than 12 months, Unrealized Losses	0	0
Marketable equity securities [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	96	80
Marketable equity securities [Member] | Level 1 [Member]
Available-for-sale securities:
Cost	77	64
Unrealized Gains	24	35
Unrealized Losses	(5)	(19)
Fair Value	96	80
Marketable equity securities [Member] | Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities [Member] | Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	96	80
Mortgage-backed securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	626	346
Less than 12 months, Unrealized Losses	(11)	(3)
More than 12 months, Fair Value	223	206
More than 12 months, Unrealized Losses	(6)	(3)
Mortgage-backed securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	1,407	1,462
Unrealized Gains	12	22
Unrealized Losses	(16)	(6)
Fair Value	1,403	1,478
Mortgage-backed securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,403	1,478
Mortgage-backed securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Foreign government and agency securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	27	85
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	27	85
Foreign government and agency securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	27	85
Foreign government and agency securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Certificates of deposit [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	28	44
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	28	44
Certificates of deposit [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	28	44
Certificates of deposit [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Other asset-backed securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	517	504
Unrealized Gains	3	3
Unrealized Losses	0	0
Fair Value	520	507
Other asset-backed securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	520	507
Other asset-backed securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Debt funds [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	1,231	1,291
Less than 12 months, Unrealized Losses	(62)	(109)
More than 12 months, Fair Value	1,538	559
More than 12 months, Unrealized Losses	(317)	(41)
Debt funds [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	3,148	3,061
Unrealized Gains	1	19
Unrealized Losses	(379)	(150)
Fair Value	2,770	2,930
Debt funds [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	2,770	2,930
Debt funds [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Auction rate securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	102	105
More than 12 months, Unrealized Losses	(7)	(4)
Auction rate securities [Member] | Level 3 [Member]
Available-for-sale securities:
Cost	109	109
Unrealized Gains	0	0
Unrealized Losses	(7)	(4)
Fair Value	102	105
Auction rate securities [Member] | Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Auction rate securities [Member] | Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	102	105
Exchange-traded funds [Member] | Level 1 [Member]
Trading securities:
Cost	65	58
Unrealized Gains	12	19
Unrealized Losses	(2)	0
Fair Value	75	77
Exchange-traded funds [Member] | Level 1 [Member] | Investments [Member]
Trading securities:
Fair Value	75	77
Exchange-traded funds [Member] | Level 1 [Member] | Other Assets [Member]
Trading securities:
Fair Value	$ 0	$ 0

Financial Instruments - Unobser

Financial Instruments - Unobservable Inputs, and Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3) (Details) - Recurring [Member] - Level 3 [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 103	$ 108	$ 106	$ 106
Total unrealized gains (losses) included in other comprehensive income	0	0	(3)	2
Ending balance	103	108	103	108
Corporate debt securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1	9	1	9
Total unrealized gains (losses) included in other comprehensive income	0	0	0	0
Ending balance	1	9	1	9
Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	102	99	105	97
Total unrealized gains (losses) included in other comprehensive income	0	0	(3)	2
Ending balance	$ 102	$ 99	$ 102	$ 99
Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			3 years
Illiquidity premium			6.00%
Minimum [Member] | Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			2 years
Maximum [Member] | Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			12 years

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
AFS Debt Maturities
Due in one year or less	$ 2,197		$ 2,197
Due after one year through five years	6,294		6,294
Due after five years through ten years	3,050		3,050
Due after ten years	285		285
Total	11,826		11,826
Debt [Member]
AFS Gross Realized Gain (Loss)
Proceeds from sales	1,261	$ 1,478	3,979	$ 4,114
Gross realized gains	2	10	11	26
Gross realized losses	(9)	(4)	(21)	(9)
Impairment losses recognized	0	0	0	0
Equity [Member]
AFS Gross Realized Gain (Loss)
Proceeds from sales	4	208	38	237
Gross realized gains	4	99	36	157
Gross realized losses	0	0	0	0
Impairment losses recognized	$ (2)	$ (1)	(43)	(22)
Equity [Member] | Other expense, net [Member]
AFS Gross Realized Gain (Loss)
Gross realized gains			$ 9	$ 41

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015	Apr. 24, 2015
Schedule of Investments [Line Items]
Marketable securities	$ 14,692		$ 14,692		$ 14,746
Cost	524		524		520
Other expense, net [Member]
Schedule of Investments [Line Items]
Impairment, cost method investments	2	$ 1	23	$ 14
Other assets [Member]
Schedule of Investments [Line Items]
Marketable securities	202		202		186
Cost	524		524		520
Debt securities [Member]
Schedule of Investments [Line Items]
Credit loss portion of other-than-temporary impairments	0		0		0
Reductions for available-for-sale securities sold	0	0	0	0
Other-than-temporary impairment losses on available-for-sale securities	0	$ 0	0	0
Marketable equity securities [Member] | Other expense, net [Member]
Schedule of Investments [Line Items]
Impairment charges, marketable securities	0		20	$ 7
Marketable equity securities [Member] | Other assets [Member]
Schedule of Investments [Line Items]
Marketable securities	$ 96		$ 96		$ 80

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 29, 2016	Apr. 24, 2015
Debt Instrument [Line Items]
Deferred gains from interest rate swap terminations, net	$ 0	$ 3
Debt premium	421	499
Total Long-Term Debt	$ 33,681	33,752
Senior notes [Member] | Floating rate three-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Term of debt instrument	3 years
Long-term Debt	$ 250	250
Senior notes [Member] | 0.875 percent three-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	0.875%
Term of debt instrument	3 years
Long-term Debt	$ 250	250
Senior notes [Member] | 6.000 percent ten-year 2008 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.00%
Term of debt instrument	10 years
Long-term Debt	$ 1,150	1,150
Senior notes [Member] | 1.500 percent three-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	1.50%
Term of debt instrument	3 years
Long-term Debt	$ 1,000	1,000
Senior notes [Member] | 1.375 percent five-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	1.375%
Term of debt instrument	5 years
Long-term Debt	$ 1,000	1,000
Senior notes [Member] | 5.600 percent ten-year 2009 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	5.60%
Term of debt instrument	10 years
Long-term Debt	$ 400	400
Senior notes [Member] | 4.450 percent ten-year 2010 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.45%
Term of debt instrument	10 years
Long-term Debt	$ 1,250	1,250
Senior notes [Member] | 2.500 percent five-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.50%
Term of debt instrument	5 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | Floating rate five-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Term of debt instrument	5 years
Long-term Debt	$ 500	500
Senior notes [Member] | 4.200 percent ten-year 2010 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.20%
Term of debt instrument	10 years
Long-term Debt	$ 600	600
Senior notes [Member] | 4.125 percent ten-year 2011 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term Debt	$ 500	500
Senior notes [Member] | 3.125 percent ten-year 2012 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term Debt	$ 675	675
Senior notes [Member] | 3.150 percent seven-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | 3.200 percent ten-year 2012 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term Debt	$ 650	650
Senior notes [Member] | 2.750 percent ten-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term Debt	$ 1,250	1,250
Senior notes [Member] | 2.950 percent ten-year 2013 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term Debt	$ 750	750
Senior notes [Member] | 3.625 percent ten-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term Debt	$ 850	850
Senior notes [Member] | 3.500 percent ten-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term Debt	$ 4,000	4,000
Senior notes [Member] | 4.375 percent twenty-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | 6.550 percent thirty-year 2008 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term Debt	$ 850	850
Senior notes [Member] | 6.500 percent thirty-year 2009 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term Debt	$ 300	300
Senior notes [Member] | 5.550 percent thirty-year 2010 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term Debt	$ 500	500
Senior notes [Member] | 4.500 percent thirty-year 2012 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term Debt	$ 400	400
Senior notes [Member] | 4.000 percent thirty-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term Debt	$ 750	750
Senior notes [Member] | 4.625 percent thirty-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term Debt	$ 650	650
Senior notes [Member] | 4.625 percent thirty-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term Debt	$ 4,000	4,000
Senior notes [Member] | Three-year term loan [Member]
Debt Instrument [Line Items]
Term of debt instrument	3 years
Long-term Debt	$ 3,000	3,000
Interest rate swaps [Member]
Debt Instrument [Line Items]
Long-term Debt	87	79
Capital lease obligations [Member]
Debt Instrument [Line Items]
Capital lease obligations	117	129
Bank borrowings [Member]
Debt Instrument [Line Items]
Long-term Debt	$ 31	$ 17

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended
	Jan. 29, 2016	Jan. 29, 2016	Apr. 24, 2015
Debt Instrument, Fair Value Disclosure [Abstract]
Long-term debt (including short-term portion), fair value	$ 31,781,000,000	$ 31,781,000,000	$ 34,637,000,000
Long-term debt (including short-term portion), principal value	30,525,000,000	30,525,000,000	32,125,000,000
2015 Commercial Paper Program [Member] | Commercial Paper [Member]
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount	3,500,000,000	$ 3,500,000,000
Commercial paper, maximum maturities		364 days
Commercial paper, amount outstanding	$ 1,293,000,000	$ 1,293,000,000	0
Weighted average original maturity	53 days	48 days
Weighted average interest rate	0.56%	0.48%
Amended and Restated Revolving Credit Agreement [Member] | Line of Credit [Member]
Line of Credit Facility
Line of credit, maximum capacity	$ 3,500,000,000	$ 3,500,000,000
Term of debt instrument		5 years
Line of credit, amount outstanding	$ 0	$ 0	$ 0

Derivatives and Foreign Excha53

Derivatives and Foreign Exchange Risk Management - Gains (Losses) on Derivatives and Amounts Reclassified into Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Other expense, net [Member] | Foreign currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency exchange rate contracts gains (losses)	$ 19	$ 153	$ 35	$ 202
Cash flow hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative	104	265	108	556
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income	102	38	250	58
Cash flow hedging [Member] | Foreign currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative	104	265	108	556
Cash flow hedging [Member] | Other expense, net [Member] | Foreign currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income	111	65	295	86
Cash flow hedging [Member] | Cost of products sold [Member] | Foreign currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income	$ (9)	$ (27)	$ (45)	$ (28)

Derivatives and Foreign Excha54

Derivatives and Foreign Exchange Risk Management - Location and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 496	$ 733
Liability Derivatives, Fair Value	91	116
Interest rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	88	89
Liability Derivatives, Fair Value	41	71
Foreign currency exchange rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	387	644
Liability Derivatives, Fair Value	40	45
Commodity derivatives [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	5
Cross currency interest rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	21
Liability Derivatives, Fair Value	5
Designated as hedging instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	454	614
Liability Derivatives, Fair Value	62	86
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Prepaid expenses and other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	1	10
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	87	79
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0	0
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other long-term liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	41	71
Designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Prepaid expenses and other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	281	382
Designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	85	143
Designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	13	12
Designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Other long-term liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	8	3
Not designated as hedging instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	42	119
Liability Derivatives, Fair Value	29	30
Not designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Prepaid expenses and other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	21	119
Not designated as hedging instrument [Member] | Foreign currency exchange rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	19	$ 30
Not designated as hedging instrument [Member] | Commodity derivatives [Member] | Prepaid expenses and other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	0
Not designated as hedging instrument [Member] | Commodity derivatives [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	5
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	21
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other long-term liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 5

Derivatives and Foreign Excha55

Derivatives and Foreign Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring [Member] - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets	$ 387	$ 644
Derivative Liabilities	40	45
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets	109	89
Derivative Liabilities	51	71
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Assets	0	0
Derivative Liabilities	$ 0	$ 0

Derivatives and Foreign Excha56

Derivatives and Foreign Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	$ 496	$ 733
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(69)	(71)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(212)	(338)
Derivative Assets, Net Amount	215	324
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(91)	(116)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	69	71
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	8
Derivative Liabilities, Net Amount	(22)	(37)
Gross Amount of Recognized Assets (Liabilities)	405	617
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(212)	(330)
Net Amount	193	287
Foreign currency exchange rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	387	644
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(63)	(61)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(197)	(325)
Derivative Assets, Net Amount	127	258
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(40)	(45)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	33	31
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	(7)	(14)
Interest rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	88	89
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(6)	(10)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(15)	(13)
Derivative Assets, Net Amount	67	66
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(41)	(71)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	36	40
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	8
Derivative Liabilities, Net Amount	(5)	$ (23)
Cross currency interest rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	21
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Assets, Net Amount	21
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(5)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Liabilities, Net Amount	(5)
Commodity derivatives [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(5)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Liabilities, Net Amount	$ (5)

Derivatives and Foreign Excha57

Derivatives and Foreign Exchange Risk Management - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015	Apr. 24, 2015
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Currency exchange rate gains (losses)	$ 69,000,000	$ 27,000,000	$ 167,000,000	$ 29,000,000
Gains (losses) relating to ineffectiveness of foreign currency cash flow hedges	0	0	0	0
Gain (losses) relating to ineffectiveness of forward starting interest rate derivatives	0	0	0	0
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	148,000,000		148,000,000		$ 210,000,000
Cash flow hedge unrealized gains to be reclassified over the next 12 months			174,000,000
Gains (losses) relating to ineffectiveness of interest rate fair value hedges	0	0	0	0
Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	102,000,000	38,000,000	250,000,000	58,000,000
Foreign currency exchange rate contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	10,739,000,000		10,739,000,000		9,782,000,000
Foreign currency exchange rate contracts [Member] | Not designated as hedging instrument [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	4,939,000,000		4,939,000,000		4,713,000,000
Foreign currency exchange rate contracts [Member] | Designated as hedging instrument [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 5,800,000,000		5,800,000,000		5,069,000,000
Maximum remaining maturity of foreign currency derivatives	3 years
Interest rate swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount		5,850,000,000		5,850,000,000
Cash received on hedge		79,000,000
Unrealized gains (losses) on outstanding forward starting interest rate swap derivative instruments	$ (41,000,000)		(41,000,000)		(71,000,000)
Interest rate swaps [Member] | Cash flow hedging [Member] | Interest expense, net [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	(3,000,000)	$ (4,000,000)	(9,000,000)	$ (8,000,000)
Interest rate swaps [Member] | Designated as hedging instrument [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 300,000,000		$ 300,000,000
Weighted average fixed rate of interest rate derivatives	3.10%		3.10%
Interest rate swaps [Member] | Designated as hedging instrument [Member] | Fair Value Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 1,425,000,000		$ 1,425,000,000		$ 2,025,000,000
Market value of outstanding interest rate swap agreements - net unrealized gain	47,000,000		47,000,000
Market value of hedged item - net unrealized loss	$ 47,000,000		$ 47,000,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Inventory Disclosure [Abstract]
Finished goods	$ 2,244	$ 2,268
Work in-process	520	509
Raw materials	772	686
Total	$ 3,536	$ 3,463

Goodwill and Other Intangible59

Goodwill and Other Intangible Assets, Net - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	9 Months Ended
	Jan. 29, 2016USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 40,530
Goodwill as a result of acquisitions	802
Purchase accounting adjustments, net	393
Currency adjustment, net	(1,349)
Ending balance	40,376
Cardiac and Vascular Group [Member]
Goodwill [Roll Forward]
Beginning balance	5,855
Goodwill as a result of acquisitions	409
Purchase accounting adjustments, net	13
Currency adjustment, net	(95)
Ending balance	6,182
Minimally Invasive Therapies Group [Member]
Goodwill [Roll Forward]
Beginning balance	23,399
Goodwill as a result of acquisitions	196
Purchase accounting adjustments, net	346
Currency adjustment, net	(1,120)
Ending balance	22,821
Restorative Therapies Group [Member]
Goodwill [Roll Forward]
Beginning balance	9,424
Goodwill as a result of acquisitions	197
Purchase accounting adjustments, net	34
Currency adjustment, net	(135)
Ending balance	9,520
Diabetes Group [Member]
Goodwill [Roll Forward]
Beginning balance	1,852
Goodwill as a result of acquisitions	0
Purchase accounting adjustments, net	0
Currency adjustment, net	1
Ending balance	$ 1,853

Goodwill and Other Intangible60

Goodwill and Other Intangible Assets, Net - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	$ 775	$ 720
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	30,786	30,329
Accumulated Amortization	(4,245)	(2,948)
IPR&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	775	470
Tradenames [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	0	250
Customer-related [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	18,558	18,492
Accumulated Amortization	(1,066)	(273)
Purchased technology and patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	11,305	11,118
Accumulated Amortization	(2,722)	(2,268)
Trademarks and tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	852	640
Accumulated Amortization	(429)	(363)
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	71	79
Accumulated Amortization	$ (28)	$ (44)

Goodwill and Other Intangible61

Goodwill and Other Intangible Assets, Net - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Jan. 29, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2,016	$ 484
2,017	1,925
2,018	1,893
2,019	1,799
2,020	1,751
2,021	$ 1,734

Goodwill and Other Intangible62

Goodwill and Other Intangible Assets, Net - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015	Apr. 24, 2015	Jan. 26, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Purchase accounting adjustments, net			$ 393,000,000
Amortization expense	$ 484,000,000	$ 89,000,000	1,448,000,000	$ 265,000,000
Carrying amount of goodwill	40,376,000,000		40,376,000,000		$ 40,530,000,000
Goodwill impairment	0	0	0	0
Carrying amount of amortizable intangible assets	26,541,000,000		26,541,000,000		27,381,000,000
Impairment of amortizable intangible assets	0	0	0	0
Indefinite-lived Intangible Assets [Line Items]
Currency adjustment, net			(1,349,000,000)
Carrying amount of non-amortizable intangible assets	775,000,000		775,000,000		720,000,000
IPR&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Carrying amount of non-amortizable intangible assets	775,000,000		775,000,000		$ 470,000,000
Impairment of non-amortizable intangible assets	$ 0	$ 0	0	$ 0
Covidien plc [Member]
Goodwill and Intangible Assets Disclosure [Abstract]
Carrying amount of goodwill						$ 29,979,000,000
Indefinite-lived Intangible Assets [Line Items]
Currency adjustment, net			$ 1,300,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015	Apr. 24, 2015
Income Tax Disclosure [Abstract]
Tax charge, primarily associated with internal reorganization of certain businesses	$ 25
Effective tax rate from continuing operations	7.10%	18.20%	24.00%	18.90%
Gross unrecognized tax benefits	$ 2,647		$ 2,647		$ 2,860
Accrued income tax interest and penalties	607		607
Unrecognized tax benefits that would impact effective tax rate	2,070		2,070
Gross unrecognized tax benefits, current liability	11		11
Gross unrecognized tax benefits, long-term liability	$ 2,636		$ 2,636

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Numerator:
Net income attributable to ordinary shareholders	$ 1,095	$ 977	$ 2,435	$ 2,676
Denominator:
Basic weighted average shares outstanding (shares)	1,406.6	983.8	1,412.5	986.6
Effect of dilutive securities:
Employee stock options (shares)	12	8	12.5	7.6
Employee restricted stock units (shares)	3.5	3.9	4.1	4.2
Other (shares)	0.1	0.1	0.1	0.1
Diluted weighted average shares outstanding (shares)	1,422.2	995.8	1,429.2	998.5
Basic earnings per share (usd per share)	$ 0.78	$ 0.99	$ 1.72	$ 2.71
Diluted earnings per share (usd per share)	$ 0.77	$ 0.98	$ 1.70	$ 2.68
Stock options and restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	21		21
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	5	2	4	2
Restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)		1		1

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 81	$ 33	$ 290	$ 115
Income tax benefits	(23)	(8)	(86)	(31)
Total stock-based compensation expense, net of tax	58	25	204	84
Cost of products sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12	4	38	12
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	8	5	28	20
Selling, general and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	47	24	162	83
Restructuring charges, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2	0	16	0
Acquisition-related items [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12	0	46	0
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	43	7	162	27
Restricted stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	33	24	113	78
Employee stock purchase plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5	$ 2	$ 15	$ 10

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
U.S. Pension Benefits [Member]
Net Periodic Benefit Cost
Service cost	$ 30	$ 26	$ 90	$ 78
Interest cost	31	26	93	78
Expected return on plan assets	(45)	(39)	(135)	(117)
Amortization of net actuarial loss	24	16	72	48
Net periodic benefit cost	40	29	120	87
Non-U.S. Pension Benefits [Member]
Net Periodic Benefit Cost
Service cost	22	15	66	45
Interest cost	9	8	27	24
Expected return on plan assets	(13)	(10)	(39)	(30)
Amortization of net actuarial loss	6	3	18	9
Net periodic benefit cost	$ 24	$ 16	$ 72	$ 48

Accumulated Other Comprehensi67

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			$ (1,184)	$ (597)
Other comprehensive (loss) income before reclassifications, before tax			(1,776)	199
Tax benefit (expense)			93	(181)
Other comprehensive (loss) income before reclassifications, net of tax			(1,683)	18
Reclassifications, before tax			(160)	(127)
Tax benefit (expense)			62	45
Reclassifications, net of tax			(98)	(82)
Other comprehensive loss	$ (1,494)	$ (155)	(1,781)	(64)
Ending balance	(2,965)	(661)	(2,965)	(661)
Unrealized Gain (Loss) on Available-for-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			14	(6)
Other comprehensive (loss) income before reclassifications, before tax			(399)	110
Tax benefit (expense)			143	(40)
Other comprehensive (loss) income before reclassifications, net of tax			(256)	70
Reclassifications, before tax			(18)	(134)
Tax benefit (expense)			6	47
Reclassifications, net of tax			(12)	(87)
Other comprehensive loss			(268)	(17)
Ending balance	(254)	(23)	(254)	(23)
Cumulative Translation Adjustments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(277)	218
Other comprehensive (loss) income before reclassifications, before tax			(1,513)	(332)
Tax benefit (expense)			0	0
Other comprehensive (loss) income before reclassifications, net of tax			(1,513)	(332)
Reclassifications, before tax			0	0
Tax benefit (expense)			0	0
Reclassifications, net of tax			0	0
Other comprehensive loss			(1,513)	(332)
Ending balance	(1,790)	(114)	(1,790)	(114)
Net Change in Retirement Obligations [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(1,131)	(765)
Other comprehensive (loss) income before reclassifications, before tax			2	24
Tax benefit (expense)			0	0
Other comprehensive (loss) income before reclassifications, net of tax			2	24
Reclassifications, before tax			90	57
Tax benefit (expense)			(30)	(18)
Reclassifications, net of tax			60	39
Other comprehensive loss			62	63
Ending balance	(1,069)	(702)	(1,069)	(702)
Unrealized Gain (Loss) on Derivatives [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			210	(44)
Other comprehensive (loss) income before reclassifications, before tax			134	397
Tax benefit (expense)			(50)	(141)
Other comprehensive (loss) income before reclassifications, net of tax			84	256
Reclassifications, before tax			(232)	(50)
Tax benefit (expense)			86	16
Reclassifications, net of tax			(146)	(34)
Other comprehensive loss			(62)	222
Ending balance	$ 148	$ 178	$ 148	$ 178

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions

Mar. 01, 2016claim

Jan. 21, 2016claim

Jan. 15, 2016USD ($)

Nov. 05, 2015claim

Aug. 07, 2015patent

Jan. 22, 2014patent

Aug. 19, 2010landfill

Jun. 29, 2007

Jul. 31, 2015USD ($)claim

Oct. 30, 2015USD ($)

Jan. 29, 2016USD ($)claim

Apr. 24, 2015USD ($)

Apr. 26, 2013USD ($)

Loss Contingencies [Line Items]

Accrued certain litigation charges

$ 1,062

$ 879

Covidien plc [Member]

Loss Contingencies [Line Items]

Tax sharing percentage, parent

42.00%

Tax sharing percentage, former parent

27.00%

Tax sharing percentage, former affiliate

31.00%

Indemnification Agreement [Member] | Tax Years Prior To 2013 [Member] | Covidien plc [Member]

Loss Contingencies [Line Items]

Maximum potential loss for tax indemnification

$ 200

Orrington, Maine Chemical Manufacturing Facility [Member]

Loss Contingencies [Line Items]

Number of landfills requiring removal | landfill

2

Number of landfills requiring capping | landfill

3

Penobscot River and Bay Remediation [Member]

Loss Contingencies [Line Items]

Low cost estimate for potential remediation

25

High cost estimate for potential remediation

$ 235

INFUSE [Member] | Product liability litigation [Member]

Loss Contingencies [Line Items]

Loss contingency, loss in period

$ 26

INFUSE [Member] | Subsequent Event [Member] | Product liability litigation [Member]

Loss Contingencies [Line Items]

Number of pending claims | claim

6,000

Number of claims settled | claim

3,900

Pelvic mesh [Member] | Product liability litigation [Member]

Loss Contingencies [Line Items]

Number of pending claims | claim

15,800

Number of claims settled | claim

11,000

Settlement receivable

$ 121

Pelvic mesh [Member] | Subsequent Event [Member] | Product liability litigation [Member]

Loss Contingencies [Line Items]

Number of claims settled | claim

4,200

Ethicon patent infringement [Member]

Loss Contingencies [Line Items]

Number of pending claims | claim

2

Patents found not infringed | patent

4

7

Patents found invalid | patent

5

Number of patents allegedly infringed upon | claim

6

6

Minimum [Member] | Domestic Tax Authority [Member]

Loss Contingencies [Line Items]

Income tax examination, settlement

$ 475

Maximum [Member] | Domestic Tax Authority [Member]

Loss Contingencies [Line Items]

Income tax examination, settlement

$ 525

Segment and Geographic Inform69

Segment and Geographic Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Segment Reporting Information [Line Items]
Net sales	$ 6,934	$ 4,318	$ 21,266	$ 12,957
Income before Income Taxes by Reportable Segment
Special charges	0	138	0	38
Restructuring charges, net	(19)	0	(159)	(30)
Certain litigation charges	0	0	(26)	0
Acquisition-related items	(63)	(80)	(183)	(182)
Interest expense, net	(176)	(81)	(584)	(94)
Income from operations before income taxes	1,179	1,194	3,202	3,299
Americas [Member]
Segment Reporting Information [Line Items]
Net sales	4,229	2,615	13,064	7,747
U.S. [Member]
Segment Reporting Information [Line Items]
Net sales	3,965	2,459	12,205	7,248
EMEA [Member]
Segment Reporting Information [Line Items]
Net sales	1,607	1,074	4,843	3,276
Asia Pacific [Member]
Segment Reporting Information [Line Items]
Net sales	729	403	2,235	1,270
Greater China [Member]
Segment Reporting Information [Line Items]
Net sales	369	226	1,124	664
Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	1,644	1,348	5,100	3,847
Segment Reconciling Items [Member]
Income before Income Taxes by Reportable Segment
Special charges	0	138	0	38
Impact of inventory step-up	0	0	(226)	0
Restructuring charges, net	(19)	0	(159)	(30)
Certain litigation charges	0	0	(26)	0
Acquisition-related items	(63)	(80)	(183)	(182)
Interest expense, net	(176)	(81)	(584)	(94)
Corporate, Non-Segment [Member]
Income before Income Taxes by Reportable Segment
Corporate	(207)	(131)	(720)	(280)
Cardiac and Vascular Group [Member]
Segment Reporting Information [Line Items]
Net sales	2,410	2,224	7,460	6,765
Cardiac and Vascular Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	726	722	2,298	2,148
Minimally Invasive Therapies Group [Member]
Segment Reporting Information [Line Items]
Net sales	2,291	0	7,103	0
Minimally Invasive Therapies Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	282	0	963	0
Restorative Therapies Group [Member]
Segment Reporting Information [Line Items]
Net sales	1,759	1,645	5,335	4,897
Restorative Therapies Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	496	482	1,460	1,318
Diabetes Group [Member]
Segment Reporting Information [Line Items]
Net sales	474	449	1,368	1,295
Diabetes Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	$ 140	$ 144	$ 379	$ 381

Guarantor Financial Informati70

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015	Jan. 29, 2016	Jan. 23, 2015
Condensed Statement of Income Captions [Line Items]
Net sales	$ 6,934	$ 4,318	$ 21,266	$ 12,957
Costs and expenses:
Cost of products sold	2,141	1,128	6,779	3,375
Research and development expense	546	373	1,649	1,112
Selling, general, and administrative expense	2,317	1,487	7,109	4,500
Special (gains) charges, net	0	(138)	0	(38)
Restructuring charges, net	19	0	159	30
Certain litigation charges	0	0	26	0
Acquisition-related items	63	80	183	182
Amortization of intangible assets	484	89	1,448	265
Other (income) expense, net	9	24	127	138
Operating profit	1,355	1,275	3,786	3,393
Interest income	(99)	(95)	(321)	(274)
Interest expense	275	176	905	368
Interest expense, net	176	81	584	94
Equity in net (income) loss of subsidiaries	0	0	0	0
Income from operations before income taxes	1,179	1,194	3,202	3,299
Provision (benefit) for income taxes	84	217	767	623
Net income	1,095	977	2,435	2,676
Other comprehensive income (loss), net of tax	(1,494)	(155)	(1,781)	(64)
Comprehensive (loss) income	(399)	822	654	2,612
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	(349)	(301)	(1,085)	(913)
Costs and expenses:
Cost of products sold	(362)	(302)	(1,063)	(908)
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special (gains) charges, net		0		0
Restructuring charges, net	0		0	0
Certain litigation charges	0		0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other (income) expense, net	0	0	0	0
Operating profit	13	1	(22)	(5)
Interest income	231	1	717	1
Interest expense	(231)	(1)	(717)	(1)
Interest expense, net	0	0	0	0
Equity in net (income) loss of subsidiaries	2,320	975	(194)	3,001
Income from operations before income taxes	(2,307)	(974)	172	(3,006)
Provision (benefit) for income taxes	0	0	0	0
Net income	(2,307)	(974)	172	(3,006)
Other comprehensive income (loss), net of tax	2,947	(34)	3,562	(1)
Comprehensive (loss) income	640	(1,008)	3,734	(3,007)
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0		0
Costs and expenses:
Cost of products sold	0		0
Research and development expense	0		0
Selling, general, and administrative expense	0		0
Restructuring charges, net	0		0
Certain litigation charges	0		0
Acquisition-related items	0		0
Amortization of intangible assets	0		0
Other (income) expense, net	0		0
Operating profit	0		0
Interest income	288		964
Interest expense	(288)		(964)
Interest expense, net	0		0
Equity in net (income) loss of subsidiaries	2,687		12,392
Income from operations before income taxes	(2,687)		(12,392)
Provision (benefit) for income taxes	0		0
Net income	(2,687)		(12,392)
Other comprehensive income (loss), net of tax	2,925		3,562
Comprehensive (loss) income	238		(8,830)
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	31	0	93	0
Special (gains) charges, net		0		0
Restructuring charges, net	0		0	0
Certain litigation charges	0		0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other (income) expense, net	0	0	0	0
Operating profit	(31)	0	(93)	0
Interest income	0	0	0	0
Interest expense	7	0	12	0
Interest expense, net	7	0	12	0
Equity in net (income) loss of subsidiaries	(1,130)	0	(2,529)	0
Income from operations before income taxes	1,092	0	2,424	0
Provision (benefit) for income taxes	(3)	0	(11)	0
Net income	1,095	0	2,435	0
Other comprehensive income (loss), net of tax	(1,494)	0	(1,781)	0
Comprehensive (loss) income	(399)	0	654	0
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0		0
Costs and expenses:
Cost of products sold	0		0
Research and development expense	0		0
Selling, general, and administrative expense	31		93
Restructuring charges, net	0		0
Certain litigation charges	0		0
Acquisition-related items	0		0
Amortization of intangible assets	0		0
Other (income) expense, net	0		0
Operating profit	(31)		(93)
Interest income	0		0
Interest expense	7		12
Interest expense, net	7		12
Equity in net (income) loss of subsidiaries	(1,130)		(2,529)
Income from operations before income taxes	1,092		2,424
Provision (benefit) for income taxes	(3)		(11)
Net income	1,095		2,435
Other comprehensive income (loss), net of tax	(1,494)		(1,781)
Comprehensive (loss) income	(399)		654
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	349	301	1,085	913
Costs and expenses:
Cost of products sold	242	214	753	655
Research and development expense	66	69	348	303
Selling, general, and administrative expense	79	178	228	661
Special (gains) charges, net		(98)		2
Restructuring charges, net	0		4	0
Certain litigation charges	0		0
Acquisition-related items	36	76	91	180
Amortization of intangible assets	3	3	9	9
Other (income) expense, net	(280)	(370)	(859)	(903)
Operating profit	203	229	511	6
Interest income	(58)	0	(179)	0
Interest expense	408	166	1,307	339
Interest expense, net	350	166	1,128	339
Equity in net (income) loss of subsidiaries	(228)	(975)	4,729	(3,001)
Income from operations before income taxes	81	1,038	(5,346)	2,668
Provision (benefit) for income taxes	(16)	61	(94)	(8)
Net income	97	977	(5,252)	2,676
Other comprehensive income (loss), net of tax	(120)	(155)	(367)	(64)
Comprehensive (loss) income	(23)	822	(5,619)	2,612
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0		0
Costs and expenses:
Cost of products sold	0		0
Research and development expense	0		0
Selling, general, and administrative expense	0		0
Restructuring charges, net	0		0
Certain litigation charges	0		0
Acquisition-related items	0		0
Amortization of intangible assets	0		0
Other (income) expense, net	0		1
Operating profit	0		(1)
Interest income	(112)		(422)
Interest expense	41		100
Interest expense, net	(71)		(322)
Equity in net (income) loss of subsidiaries	(585)		(7,847)
Income from operations before income taxes	656		8,168
Provision (benefit) for income taxes	0		0
Net income	656		8,168
Other comprehensive income (loss), net of tax	(40)		(103)
Comprehensive (loss) income	616		8,065
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special (gains) charges, net		0		0
Restructuring charges, net	0		0	0
Certain litigation charges	0		0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other (income) expense, net	0	0	0	0
Operating profit	0	0	0	0
Interest income	(173)	0	(531)	0
Interest expense	3	0	6	0
Interest expense, net	(170)	0	(525)	0
Equity in net (income) loss of subsidiaries	(962)	0	(2,006)	0
Income from operations before income taxes	1,132	0	2,531	0
Provision (benefit) for income taxes	2	0	2	0
Net income	1,130	0	2,529	0
Other comprehensive income (loss), net of tax	(1,615)	0	(1,781)	0
Comprehensive (loss) income	(485)	0	748	0
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0		0
Costs and expenses:
Cost of products sold	0		0
Research and development expense	0		0
Selling, general, and administrative expense	3		3
Restructuring charges, net	0		0
Certain litigation charges	0		0
Acquisition-related items	0		0
Amortization of intangible assets	0		0
Other (income) expense, net	11		11
Operating profit	(14)		(14)
Interest income	(175)		(533)
Interest expense	3		6
Interest expense, net	(172)		(527)
Equity in net (income) loss of subsidiaries	(972)		(2,016)
Income from operations before income taxes	1,130		2,529
Provision (benefit) for income taxes	0		0
Net income	1,130		2,529
Other comprehensive income (loss), net of tax	(1,494)		(1,781)
Comprehensive (loss) income	(364)		748
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	6,934	4,318	21,266	12,957
Costs and expenses:
Cost of products sold	2,261	1,216	7,089	3,628
Research and development expense	480	304	1,301	809
Selling, general, and administrative expense	2,207	1,309	6,788	3,839
Special (gains) charges, net		(40)		(40)
Restructuring charges, net	19		155	30
Certain litigation charges	0		26
Acquisition-related items	27	4	92	2
Amortization of intangible assets	481	86	1,439	256
Other (income) expense, net	289	394	986	1,041
Operating profit	1,170	1,045	3,390	3,392
Interest income	(99)	(96)	(328)	(275)
Interest expense	88	11	297	30
Interest expense, net	(11)	(85)	(31)	(245)
Equity in net (income) loss of subsidiaries	0	0	0	0
Income from operations before income taxes	1,181	1,130	3,421	3,637
Provision (benefit) for income taxes	101	156	870	631
Net income	1,080	974	2,551	3,006
Other comprehensive income (loss), net of tax	(1,212)	34	(1,414)	1
Comprehensive (loss) income	(132)	$ 1,008	1,137	$ 3,007
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	6,934		21,266
Costs and expenses:
Cost of products sold	2,141		6,779
Research and development expense	546		1,649
Selling, general, and administrative expense	2,283		7,013
Restructuring charges, net	19		159
Certain litigation charges	0		26
Acquisition-related items	63		183
Amortization of intangible assets	484		1,448
Other (income) expense, net	(2)		115
Operating profit	1,400		3,894
Interest income	(100)		(330)
Interest expense	512		1,751
Interest expense, net	412		1,421
Equity in net (income) loss of subsidiaries	0		0
Income from operations before income taxes	988		2,473
Provision (benefit) for income taxes	87		778
Net income	901		1,695
Other comprehensive income (loss), net of tax	(1,391)		(1,678)
Comprehensive (loss) income	$ (490)		$ 17

Guarantor Financial Informati71

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015	Jan. 23, 2015	Apr. 25, 2014
Current assets:
Cash and cash equivalents	$ 2,721	$ 4,843	$ 17,231	$ 1,403
Investments	14,565	14,637
Accounts receivable, net	4,863	5,112
Inventories	3,536	3,463
Intercompany receivable	0	0
Tax assets	502	1,335
Prepaid expenses and other current assets	1,382	1,454
Total current assets	27,569	30,844
Property, plant, and equipment, net	4,636	4,699
Goodwill	40,376	40,530
Other intangible assets, net	27,316	28,101
Long-term tax assets	1,060	774
Investment in subsidiaries	0	0
Intercompany loans receivable	0	0
Other assets	1,749	1,737
Total assets	102,706	106,685
Current liabilities:
Short-term borrowings	2,153	2,434
Accounts payable	1,437	1,610
Intercompany payable	0	0
Accrued compensation	1,481	1,611
Accrued income taxes	454	935
Deferred tax liabilities	0	119
Other accrued expenses	2,616	2,464
Total current liabilities	8,141	9,173
Long-term debt	33,681	33,752
Long-term accrued compensation and retirement benefits	1,585	1,535
Long-term accrued income taxes	2,822	2,476
Long-term intercompany loans payable	0	0
Long-term deferred tax liabilities	3,802	4,700
Other long-term liabilities	1,859	1,819
Total liabilities	51,890	53,455
Shareholders’ equity	50,816	53,230
Total liabilities and shareholders’ equity	102,706	106,685
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	(221)	(199)
Intercompany receivable	(327,563)	(291,839)
Tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(327,784)	(292,038)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	(173,251)	(175,547)
Intercompany loans receivable	(33,793)	(29,734)
Other assets	0	0
Total assets	(534,828)	(497,319)
Current liabilities:
Short-term borrowings	0	0
Accounts payable	0	0
Intercompany payable	(327,563)	(291,839)
Accrued compensation	0	0
Accrued income taxes	0	0
Deferred tax liabilities	0	0
Other accrued expenses	0	0
Total current liabilities	(327,563)	(291,839)
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	(33,793)	(29,734)
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	(361,356)	(321,573)
Shareholders’ equity	(173,472)	(175,746)
Total liabilities and shareholders’ equity	(534,828)	(497,319)
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	(20,813)	(21,035)
Tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(20,813)	(21,035)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	(168,348)	(152,838)
Intercompany loans receivable	(35,099)	(38,786)
Other assets	0	0
Total assets	(224,260)	(212,659)
Current liabilities:
Short-term borrowings	0	0
Accounts payable	0	0
Intercompany payable	(20,813)	(21,035)
Accrued compensation	0	0
Accrued income taxes	0	0
Deferred tax liabilities	0	0
Other accrued expenses	0	0
Total current liabilities	(20,813)	(21,035)
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	(35,099)	(38,786)
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	(55,912)	(59,821)
Shareholders’ equity	(168,348)	(152,838)
Total liabilities and shareholders’ equity	(224,260)	(212,659)
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	0	263	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	249	259
Tax assets	0	0
Prepaid expenses and other current assets	4	4
Total current assets	253	526
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	71,188	70,233
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	74,441	73,759
Current liabilities:
Short-term borrowings	0	0
Accounts payable	0	0
Intercompany payable	20,490	20,506
Accrued compensation	6	1
Accrued income taxes	8	19
Deferred tax liabilities	0	3
Other accrued expenses	1	0
Total current liabilities	20,505	20,529
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	10	0
Long-term intercompany loans payable	3,110	0
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	23,625	20,529
Shareholders’ equity	50,816	53,230
Total liabilities and shareholders’ equity	74,441	73,759
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	0	263
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	249	259
Tax assets	0	0
Prepaid expenses and other current assets	4	4
Total current assets	253	526
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	71,188	70,233
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	74,441	73,759
Current liabilities:
Short-term borrowings	0	0
Accounts payable	0	0
Intercompany payable	20,490	20,506
Accrued compensation	6	1
Accrued income taxes	8	19
Deferred tax liabilities	0	3
Other accrued expenses	1	0
Total current liabilities	20,505	20,529
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	10	0
Long-term intercompany loans payable	3,110	0
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	23,625	20,529
Shareholders’ equity	50,816	53,230
Total liabilities and shareholders’ equity	74,441	73,759
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	29	1,071	15,910	264
Investments	0	0
Accounts receivable, net	0	0
Inventories	164	165
Intercompany receivable	162,357	146,942
Tax assets	237	295
Prepaid expenses and other current assets	128	128
Total current assets	162,915	148,601
Property, plant, and equipment, net	1,058	976
Goodwill	1,672	1,607
Other intangible assets, net	34	39
Long-term tax assets	550	294
Investment in subsidiaries	37,072	42,250
Intercompany loans receivable	7,491	6,516
Other assets	750	678
Total assets	211,542	200,961
Current liabilities:
Short-term borrowings	501	1,110
Accounts payable	266	261
Intercompany payable	151,745	135,660
Accrued compensation	516	490
Accrued income taxes	0	0
Deferred tax liabilities	0	0
Other accrued expenses	666	628
Total current liabilities	153,694	138,149
Long-term debt	29,017	29,004
Long-term accrued compensation and retirement benefits	1,016	965
Long-term accrued income taxes	1,369	1,048
Long-term intercompany loans payable	10,122	10,218
Long-term deferred tax liabilities	0	0
Other long-term liabilities	200	207
Total liabilities	195,418	179,591
Shareholders’ equity	16,124	21,370
Total liabilities and shareholders’ equity	211,542	200,961
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	36	728
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	0	0
Tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	36	728
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	33,441	20,836
Intercompany loans receivable	2,810	7,401
Other assets	0	0
Total assets	36,287	28,965
Current liabilities:
Short-term borrowings	0	1,002
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	0	0
Deferred tax liabilities	0	0
Other accrued expenses	45	40
Total current liabilities	45	1,042
Long-term debt	4,519	4,581
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	8,696	8,385
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	13,260	14,008
Shareholders’ equity	23,027	14,957
Total liabilities and shareholders’ equity	36,287	28,965
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	1	170	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	0	0
Tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	1	170
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	64,991	63,064
Intercompany loans receivable	10,539	10,000
Other assets	0	0
Total assets	75,531	73,234
Current liabilities:
Short-term borrowings	1,292	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	2	0
Deferred tax liabilities	0	0
Other accrued expenses	0	0
Total current liabilities	1,294	0
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	10,053	10,000
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	11,347	10,000
Shareholders’ equity	64,184	63,234
Total liabilities and shareholders’ equity	75,531	73,234
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	1	170
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	60	269
Tax assets	0	0
Prepaid expenses and other current assets	5	6
Total current assets	66	445
Property, plant, and equipment, net	0	1
Goodwill	0	0
Other intangible assets, net	0	0
Long-term tax assets	0	0
Investment in subsidiaries	63,719	61,769
Intercompany loans receivable	12,025	11,303
Other assets	0	0
Total assets	75,810	73,518
Current liabilities:
Short-term borrowings	1,292	0
Accounts payable	0	2
Intercompany payable	277	279
Accrued compensation	0	0
Accrued income taxes	2	0
Deferred tax liabilities	0	0
Other accrued expenses	0	1
Total current liabilities	1,571	282
Long-term debt	0	0
Long-term accrued compensation and retirement benefits	0	0
Long-term accrued income taxes	0	0
Long-term intercompany loans payable	10,054	10,002
Long-term deferred tax liabilities	0	0
Other long-term liabilities	0	0
Total liabilities	11,625	10,284
Shareholders’ equity	64,185	63,234
Total liabilities and shareholders’ equity	75,810	73,518
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	2,691	3,339	$ 1,321	$ 1,139
Investments	14,565	14,637
Accounts receivable, net	4,863	5,112
Inventories	3,593	3,497
Intercompany receivable	164,957	144,638
Tax assets	265	1,040
Prepaid expenses and other current assets	1,250	1,322
Total current assets	192,184	173,585
Property, plant, and equipment, net	3,578	3,723
Goodwill	38,704	38,923
Other intangible assets, net	27,282	28,062
Long-term tax assets	510	480
Investment in subsidiaries	0	0
Intercompany loans receivable	12,763	10,218
Other assets	999	1,059
Total assets	276,020	256,050
Current liabilities:
Short-term borrowings	360	1,324
Accounts payable	1,171	1,349
Intercompany payable	155,328	135,673
Accrued compensation	959	1,120
Accrued income taxes	444	916
Deferred tax liabilities	0	116
Other accrued expenses	1,949	1,836
Total current liabilities	160,211	142,334
Long-term debt	4,664	4,748
Long-term accrued compensation and retirement benefits	569	570
Long-term accrued income taxes	1,443	1,428
Long-term intercompany loans payable	10,508	9,516
Long-term deferred tax liabilities	3,802	4,700
Other long-term liabilities	1,659	1,612
Total liabilities	182,856	164,908
Shareholders’ equity	93,164	91,142
Total liabilities and shareholders’ equity	276,020	256,050
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	2,684	3,682
Investments	14,565	14,637
Accounts receivable, net	4,863	5,112
Inventories	3,536	3,463
Intercompany receivable	20,504	20,507
Tax assets	502	1,335
Prepaid expenses and other current assets	1,373	1,444
Total current assets	48,027	50,180
Property, plant, and equipment, net	4,636	4,698
Goodwill	40,376	40,530
Other intangible assets, net	27,316	28,101
Long-term tax assets	1,060	774
Investment in subsidiaries	0	0
Intercompany loans receivable	17,264	17,082
Other assets	1,749	1,737
Total assets	140,428	143,102
Current liabilities:
Short-term borrowings	861	1,432
Accounts payable	1,437	1,608
Intercompany payable	46	250
Accrued compensation	1,475	1,610
Accrued income taxes	444	916
Deferred tax liabilities	0	116
Other accrued expenses	2,570	2,423
Total current liabilities	6,833	8,355
Long-term debt	29,162	29,171
Long-term accrued compensation and retirement benefits	1,585	1,535
Long-term accrued income taxes	2,812	2,476
Long-term intercompany loans payable	13,239	20,399
Long-term deferred tax liabilities	3,802	4,700
Other long-term liabilities	1,859	1,819
Total liabilities	59,292	68,455
Shareholders’ equity	81,136	74,647
Total liabilities and shareholders’ equity	$ 140,428	$ 143,102

Guarantor Financial Informati72

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 29, 2016	Jan. 23, 2015
Operating Activities:
Net cash provided by (used in) operating activities	$ 3,892	$ 2,990
Investing Activities:
Acquisitions, net of cash acquired	(1,132)	(611)
Additions to property, plant, and equipment	(693)	(316)
Purchases of marketable securities	(4,509)	(5,327)
Sales and maturities of marketable securities	4,017	4,351
Net increase (decrease) in intercompany loans	0	0
Increase in investment in subsidiary	0
Other investing activities, net	(11)	60
Net cash used in investing activities	(2,328)	(1,843)
Financing Activities:
Acquisition-related contingent consideration	(21)	(5)
Change in short-term borrowings, net	1,223	7
Repayment of short-term borrowings (maturities greater than 90 days)	(48)	(150)
Proceeds from short-term borrowings (maturities greater than 90 days)	139	150
Issuance of long-term debt	0	16,918
Payments on long-term debt	(1,612)	(13)
Dividends to shareholders	(1,608)	(902)
Issuance of ordinary shares	360	477
Repurchase of ordinary shares	(2,170)	(1,620)
Net intercompany loan borrowings (repayments)	0	0
Intercompany dividend paid	0	0
Capital contribution	0
Other financing activities, net	60	(64)
Net cash used in financing activities	(3,677)	14,798
Effect of exchange rate changes on cash and cash equivalents	(9)	(117)
Net change in cash and cash equivalents	(2,122)	15,828
Cash and cash equivalents at beginning of period	4,843	1,403
Cash and cash equivalents at end of period	2,721	17,231
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(1,508)	(26)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of marketable securities	0	0
Sales and maturities of marketable securities	0	0
Net increase (decrease) in intercompany loans	4,058	(42)
Increase in investment in subsidiary	0
Other investing activities, net	0	0
Net cash used in investing activities	4,058	(42)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in short-term borrowings, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt		0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(4,058)	42
Intercompany dividend paid	8	26
Capital contribution	1,500
Other financing activities, net	0	0
Net cash used in financing activities	(2,550)	68
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(12,461)
Investing Activities:
Acquisitions, net of cash acquired	0
Additions to property, plant, and equipment	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net increase (decrease) in intercompany loans	(3,689)
Other investing activities, net	0
Net cash used in investing activities	(3,689)
Financing Activities:
Acquisition-related contingent consideration	0
Change in short-term borrowings, net	0
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Payments on long-term debt	0
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	3,689
Intercompany dividend paid	3,050
Capital contribution	9,411
Other financing activities, net	0
Net cash used in financing activities	16,150
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	0
Cash and cash equivalents at beginning of period	0
Cash and cash equivalents at end of period	0
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(15)	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of marketable securities	0	0
Sales and maturities of marketable securities	0	0
Net increase (decrease) in intercompany loans	0	0
Increase in investment in subsidiary	0
Other investing activities, net	0	0
Net cash used in investing activities	0	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in short-term borrowings, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt		0
Payments on long-term debt	0	0
Dividends to shareholders	(1,608)	0
Issuance of ordinary shares	360	0
Repurchase of ordinary shares	(2,170)	0
Net intercompany loan borrowings (repayments)	3,110	0
Intercompany dividend paid	0	0
Capital contribution	0
Other financing activities, net	60	0
Net cash used in financing activities	(248)	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(263)	0
Cash and cash equivalents at beginning of period	263	0
Cash and cash equivalents at end of period	0	0
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(15)
Investing Activities:
Acquisitions, net of cash acquired	0
Additions to property, plant, and equipment	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net increase (decrease) in intercompany loans	0
Other investing activities, net	0
Net cash used in investing activities	0
Financing Activities:
Acquisition-related contingent consideration	0
Change in short-term borrowings, net	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Payments on long-term debt	0
Dividends to shareholders	(1,608)
Issuance of ordinary shares	360
Repurchase of ordinary shares	(2,170)
Net intercompany loan borrowings (repayments)	3,110
Intercompany dividend paid	0
Capital contribution	0
Other financing activities, net	60
Net cash used in financing activities	(248)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	(263)
Cash and cash equivalents at beginning of period	263
Cash and cash equivalents at end of period	0
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	839	995
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	(210)	(116)
Purchases of marketable securities	0	0
Sales and maturities of marketable securities	0	0
Net increase (decrease) in intercompany loans	(975)	3
Increase in investment in subsidiary	0
Other investing activities, net	0	0
Net cash used in investing activities	(1,185)	(113)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in short-term borrowings, net	0	7
Repayment of short-term borrowings (maturities greater than 90 days)	0	(150)
Proceeds from short-term borrowings (maturities greater than 90 days)	0	150
Issuance of long-term debt		16,918
Payments on long-term debt	(600)	(13)
Dividends to shareholders	0	(902)
Issuance of ordinary shares	0	477
Repurchase of ordinary shares	0	(1,620)
Net intercompany loan borrowings (repayments)	(96)	(39)
Intercompany dividend paid	0	0
Capital contribution	0
Other financing activities, net	0	(64)
Net cash used in financing activities	(696)	14,764
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(1,042)	15,646
Cash and cash equivalents at beginning of period	1,071	264
Cash and cash equivalents at end of period	29	15,910
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	3,316
Investing Activities:
Acquisitions, net of cash acquired	0
Additions to property, plant, and equipment	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net increase (decrease) in intercompany loans	4,592
Other investing activities, net	0
Net cash used in investing activities	4,592
Financing Activities:
Acquisition-related contingent consideration	0
Change in short-term borrowings, net	0
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Payments on long-term debt	(1,000)
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	311
Intercompany dividend paid	0
Capital contribution	(7,911)
Other financing activities, net	0
Net cash used in financing activities	(8,600)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	(692)
Cash and cash equivalents at beginning of period	728
Cash and cash equivalents at end of period	36
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	525	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of marketable securities	0	0
Sales and maturities of marketable securities	0	0
Net increase (decrease) in intercompany loans	(539)	0
Increase in investment in subsidiary	0
Other investing activities, net	0	0
Net cash used in investing activities	(539)	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in short-term borrowings, net	1,201	0
Repayment of short-term borrowings (maturities greater than 90 days)	(48)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	139	0
Issuance of long-term debt		0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	53	0
Intercompany dividend paid	0	0
Capital contribution	(1,500)
Other financing activities, net	0	0
Net cash used in financing activities	(155)	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(169)	0
Cash and cash equivalents at beginning of period	170	0
Cash and cash equivalents at end of period	1	0
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	709
Investing Activities:
Acquisitions, net of cash acquired	0
Additions to property, plant, and equipment	0
Purchases of marketable securities	0
Sales and maturities of marketable securities	0
Net increase (decrease) in intercompany loans	(722)
Other investing activities, net	0
Net cash used in investing activities	(722)
Financing Activities:
Acquisition-related contingent consideration	0
Change in short-term borrowings, net	1,201
Repayment of short-term borrowings (maturities greater than 90 days)	(48)
Proceeds from short-term borrowings (maturities greater than 90 days)	139
Payments on long-term debt	0
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	52
Intercompany dividend paid	0
Capital contribution	(1,500)
Other financing activities, net	0
Net cash used in financing activities	(156)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	(169)
Cash and cash equivalents at beginning of period	170
Cash and cash equivalents at end of period	1
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	4,051	2,021
Investing Activities:
Acquisitions, net of cash acquired	(1,132)	(611)
Additions to property, plant, and equipment	(483)	(200)
Purchases of marketable securities	(4,509)	(5,327)
Sales and maturities of marketable securities	4,017	4,351
Net increase (decrease) in intercompany loans	(2,544)	39
Increase in investment in subsidiary	0
Other investing activities, net	(11)	60
Net cash used in investing activities	(4,662)	(1,688)
Financing Activities:
Acquisition-related contingent consideration	(21)	(5)
Change in short-term borrowings, net	22	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt		0
Payments on long-term debt	(1,012)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	991	(3)
Intercompany dividend paid	(8)	(26)
Capital contribution	0
Other financing activities, net	0	0
Net cash used in financing activities	(28)	(34)
Effect of exchange rate changes on cash and cash equivalents	(9)	(117)
Net change in cash and cash equivalents	(648)	182
Cash and cash equivalents at beginning of period	3,339	1,139
Cash and cash equivalents at end of period	2,691	$ 1,321
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	12,343
Investing Activities:
Acquisitions, net of cash acquired	(1,132)
Additions to property, plant, and equipment	(693)
Purchases of marketable securities	(4,509)
Sales and maturities of marketable securities	4,017
Net increase (decrease) in intercompany loans	(181)
Other investing activities, net	(11)
Net cash used in investing activities	(2,509)
Financing Activities:
Acquisition-related contingent consideration	(21)
Change in short-term borrowings, net	22
Repayment of short-term borrowings (maturities greater than 90 days)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0
Payments on long-term debt	(612)
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	(7,162)
Intercompany dividend paid	(3,050)
Capital contribution	0
Other financing activities, net	0
Net cash used in financing activities	(10,823)
Effect of exchange rate changes on cash and cash equivalents	(9)
Net change in cash and cash equivalents	(998)
Cash and cash equivalents at beginning of period	3,682
Cash and cash equivalents at end of period	$ 2,684

Guarantor Financial Informati73

Guarantor Financial Information - Narrative (Details) - USD ($) $ in Millions	Jan. 29, 2016	Apr. 24, 2015
Condensed Financial Statements, Captions [Line Items]
Increase in shareholders' equity	$ 50,816	$ 53,230
Increase in investment in subsidiaries	0	0
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Increase in shareholders' equity	23,027	14,957
Increase in investment in subsidiaries	$ 33,441	20,836
Subsidiary Issuer [Member] | CIFSA Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Increase in shareholders' equity		14,700
Increase in investment in subsidiaries		$ 14,700